WO2021242776A2 - Methods of treating inflammatory diseases by blocking galectin-3 - Google Patents

Methods of treating inflammatory diseases by blocking galectin-3 Download PDF

Info

Publication number
WO2021242776A2
WO2021242776A2 PCT/US2021/034096 US2021034096W WO2021242776A2 WO 2021242776 A2 WO2021242776 A2 WO 2021242776A2 US 2021034096 W US2021034096 W US 2021034096W WO 2021242776 A2 WO2021242776 A2 WO 2021242776A2
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
seq
sequence
gal3
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2021/034096
Other languages
English (en)
French (fr)
Other versions
WO2021242776A3 (en
Inventor
Dongxu Sun
Catherine A. GORDON
Ksenya SHCHORS
Yan Wang
Tsung-Huang TSAI
Yew Ann LEONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Truebinding Inc
Original Assignee
Truebinding Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Truebinding Inc filed Critical Truebinding Inc
Priority to EP21812182.0A priority Critical patent/EP4157338A4/en
Priority to CA3185040A priority patent/CA3185040A1/en
Priority to CN202180059397.XA priority patent/CN116157151A/zh
Priority to JP2022572799A priority patent/JP2023528797A/ja
Priority to AU2021278935A priority patent/AU2021278935A1/en
Priority to MX2022014786A priority patent/MX2022014786A/es
Priority to KR1020227042763A priority patent/KR20230016186A/ko
Publication of WO2021242776A2 publication Critical patent/WO2021242776A2/en
Publication of WO2021242776A3 publication Critical patent/WO2021242776A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Definitions

  • Galectin-3 (Gal3). Some aspects bind Gal-3 and block its interaction with viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral- associated host proteins. Aspects of the present disclosure relate generally to antibodies or binding fragments thereof that reduce inflammation, for example, by reducing activation of immune cells by Gal3.
  • BACKGROUND [0004] Galectin-3 (Gal3, GAL3) is a lectin, or a carbohydrate-binding protein, with specificity towards beta-galactosides.
  • Gal3 In human cells, Gal3 is expressed and can be found in the nucleus, cytoplasm, cell surface, and in the extracellular space.
  • Galectin-3 (Gal3) has been implicated to have immunomodulatory activity.
  • An example of this is the interaction between Gal3 and T-cell immunoglobulin and mucin-domain containing-3 (TIM-3), which causes suppression of immune responses such as T cell activation and may enable cancer cells to evade immune clearance.
  • TIM-3 mucin-domain containing-3
  • Galectin-3 Gal3
  • viral proteins such as proteins of the SARS-CoV-2 virus or other coronaviruses, such as the coronavirus spike protein, or viral-associated host proteins, including ACE2 or CD147.
  • methods of treating a viral infection This viral infection may be associated with inflammatory symptoms.
  • the methods are directed to preventing and/or reducing a viral spread, or reducing a risk that a virus can invade a cell (e.g. either in vitro or in vivo).
  • an anti-Gal3 antibody or binding fragment thereof for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, which may, for example, develop as a sequela of a viral infection, or an inflammatory disease, such as chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • Also disclosed herein are the methods and uses of an anti-Gal3 antibodies or binding fragment thereof for the treatment of cytokine release syndrome (CRS, cytokine storm) or sepsis caused, for example, by a bacterial, viral, fungal, or protozoal infection.
  • CRS cytokine release syndrome
  • sepsis caused, for example, by a bacterial, viral, fungal, or protozoal infection.
  • the CRS may be a result of the sepsis. In some embodiments, the CRS is a result of a coronavirus infection, such as a SARS-CoV-2 infection.
  • a coronavirus infection such as a SARS-CoV-2 infection.
  • Also disclosed herein are methods, medicaments, and compositions involving an anti-Gal3 antibody or binding fragment thereof for the treatment of an inflammatory disease, or for decreasing or inhibiting inflammation in a subject. In some embodiments, this inflammation may be associated with activation and/or migration of immune cells such as neutrophils. In some embodiments, administration of the anti-Gal3 antibody or binding fragment thereof decreases or inhibits neutrophil activation and/or migration in the subject.
  • administration of the anti-Gal3 antibody or binding fragment thereof decreases or inhibits cleavage of CD62L expressed by neutrophils and/or decreases or inhibits IL-8 production in the subject. In some embodiments, administration of the anti-Gal3 antibody or binding fragment thereof decreases the number of neutrophils in the subject.
  • administration of the anti-Gal3 antibody or binding fragment thereof modulates expression of Gal3, myeloperoxidase (MPO), growth-related oncogene ⁇ (GRO ⁇ )/keratinocytes-derived chemokine (KC), Ly6c1, INOS, IL-6, TNF ⁇ , IL-1B, Col1A1, aSMA, TGF ⁇ , VEGFA, VEGFB, or any combination thereof, in the subject.
  • MPO myeloperoxidase
  • GRO ⁇ growth-related oncogene ⁇
  • KC growth-related oncogene ⁇
  • KC keratinocytes-derived chemokine
  • the inflammation may be lung inflammation and associated with diseases including but not limited to COPD, pneumonitis, asthma, sarcoidosis, pulmonary fibrosis, histiocytosis, bronchiolitis obliterans, or any combination thereof.
  • the inflammation may be associated with an autoimmune disease, including but not limited to systemic lupus erythematosus (SLE), Graves’ disease, rheumatoid arthritis, multiple sclerosis, Sjogren’s syndrome, celiac disease, or any combination thereof.
  • SLE systemic lupus erythematosus
  • Graves’ disease rheumatoid arthritis
  • multiple sclerosis multiple sclerosis
  • Sjogren’s syndrome celiac disease, or any combination thereof.
  • the methods comprise contacting the cell with an anti-Gal3 antibody or binding fragment thereof.
  • pharmaceutical antibody formulations comprising a therapeutically effective amount of any one or more of the antibodies disclosed herein.
  • the pharmaceutical antibody formulations further comprise histidine, methionine, NaCl, and polysorbate. In some embodiments, the pharmaceutical antibody formulation is at a pH between 5.3 and 6.3.
  • sterile vials comprising any one of the pharmaceutical antibody formulations disclosed herein. In some embodiments, the sterile vials comprise a concentrated form of any one of the pharmaceutical antibody formulations disclosed herein, such that the concentrated form is intended to be diluted prior to administration of the pharmaceutical antibody formulation.
  • the pharmaceutical antibody formulations and sterile vial embodiments disclosed herein may be used in a method of treatment in a subject in need thereof.
  • the pharmaceutical antibody formulations and sterile vial embodiments disclosed herein are used in a method of treating a coronavirus infection in a subject in need thereof.
  • the coronavirus infection is a SARS-related coronavirus infection.
  • the coronavirus infection is a SARS-CoV-2 infection.
  • the pharmaceutical antibody formulations and sterile vial embodiments disclosed herein are used in a method of decreasing or inhibiting inflammation in a subject in need thereof.
  • the inflammation may be associated with an inflammatory disease, including but not limited to lung inflammation, such as COPD, pneumonitis, asthma, sarcoidosis, pulmonary fibrosis, histiocytosis, bronchiolitis obliterans, or any combination thereof, or an autoimmune disease, such as systemic lupus erythematosus (SLE), Graves’ disease, rheumatoid arthritis, multiple sclerosis, Sjogren’s syndrome, celiac disease, or any combination thereof.
  • lung inflammation such as COPD, pneumonitis, asthma, sarcoidosis, pulmonary fibrosis, histiocytosis, bronchiolitis obliterans, or any combination thereof
  • an autoimmune disease such as systemic lupus erythematosus (SLE), Graves’ disease, rheumatoid arthritis, multiple sclerosis, Sjogren’s syndrome, celiac disease, or any combination thereof.
  • FIG. 1 depicts a graphical representation of relative Gal3 mRNA expression in normal individuals and COVID-19 patients.
  • FIG. 2 depicts a graphical representation of the assessment of relative binding affinity of hACE2 protein to Gal3 obtained from different vendors as measured by ELISA.
  • FIG. 3 depicts a graphical representation of the assessment of relative binding affinity of hCD147 protein to Gal3 obtained from different vendors as measured by ELISA.
  • FIG. 4 depicts a graphical representation of the assessment of relative binding affinity of spike (S) protein of SARS-CoV-2 protein to Gal3 as measured by ELISA.
  • FIG. 1 depicts a graphical representation of relative Gal3 mRNA expression in normal individuals and COVID-19 patients.
  • FIG. 2 depicts a graphical representation of the assessment of relative binding affinity of hACE2 protein to Gal3 obtained from different vendors as measured by ELISA.
  • FIG. 3 depicts a graphical representation of the assessment of relative binding affinity of hCD147 protein to Gal3 obtained from different vendors as measured by
  • FIG. 5A depicts a graphical representation of the assessment of relative binding affinity of hACE2 to Gal3 following blockade by anti-Gal3 antibodies as measured by ELISA.
  • FIG. 5B depicts a graphical representation of the assessment of relative binding affinity of spike (S) protein of SARS-CoV-2 protein to Gal3 following blockade by anti-Gal3 antibodies as measured by ELISA.
  • FIG. 6 depicts various embodiments of sequences of human Gal3 (isoform 1 and 3), ACE2, CD147, and SARS-CoV-2 S protein.
  • FIG. 7 depicts Gal3 peptides used for generating anti-Gal3 antibodies and binning. [0025] FIG.
  • FIG. 8 depicts variable heavy chain CDR1 sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the method or compositions provided herein can include one or more of the CDRs provided herein.
  • FIG. 9 depicts variable heavy chain CDR2 sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the method or compositions provided herein can include one or more of the CDRs provided herein.
  • FIG. 10 depicts variable heavy chain CDR3 sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the method or compositions provided herein can include one or more of the CDRs provided herein.
  • FIG. 11 depicts variable light chain CDR1 sequences of exemplary anti-Gal3 antibodies.
  • any of the method or compositions provided herein can include one or more of the CDRs provided herein.
  • FIG. 12 depicts variable light chain CDR2 sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the method or compositions provided herein can include one or more of the CDRs provided herein.
  • FIG. 13 depicts variable light chain CDR3 sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the method or compositions provided herein can include one or more of the CDRs provided herein.
  • FIG. 14 depicts heavy and light chain CDR combinations of various exemplary anti-Gal3 antibodies.
  • any of the method or compositions provided herein can include one or more of the heavy and light chain CDR combinations provided herein.
  • FIG. 15 depicts heavy chain variable region sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the methods or compositions provided herein can include any one of these VH regions.
  • FIG. 16 depicts light chain variable region sequences of exemplary anti-Gal3 antibodies. In some embodiments, any of the methods or compositions provided herein can include any one of these VL regions.
  • FIG. 17 depicts heavy chain variable region and light chain variable region sequences of exemplary anti-Gal3 antibodies.
  • any one or more of the VH/VL and/or CDRs provided in the other figures can be paired with any one or more of the relevant sequences provided herein.
  • FIG. 18 depicts heavy chain and light chain sequences of exemplary anti-Gal3 antibodies. In some embodiments, any one or more of the VH/VL and/or CDRs provided in the other figures can be paired with any one or more of the relevant sequences provided herein.
  • FIG. 19 depicts an alignment of hinge and constant heavy chain domain 2 (C H 2) domain amino acid sequences of wild-type human immunoglobulin G1 (IgG1), IgG2 and IgG4 as well as their sigma variants. The alignment above uses EU numbering.
  • Residues identical to wild- type IgG1 are indicated as dots; gaps are indicated with hyphens. Sequence is given explicitly if it differs from wild-type IgG1 or from the parental subtype for ⁇ variants. Open boxes beneath the alignment correspond to International Immunogenetics Information System (IMGT) strand definitions. Boxes beneath the alignment correspond to the strand and helix secondary structure assignment for wild-type IgG1. Residues 267-273 form the BC loop and 322-332 form the FG loop.
  • IMGT International Immunogenetics Information System
  • FIG. 20 depicts antibody affinities (K D ) of anti-Gal3 humanized antibodies IMT001 and IMT006a for human, cynomolgus, and mouse Gal3.
  • FIG. 20 depicts antibody affinities (K D ) of anti-Gal3 humanized antibodies IMT001 and IMT006a for human, cynomolgus, and mouse Gal3.
  • FIG. 21 depicts a graphical representation of body temperature of LPS-treated mice when further treated with either PBS control or the anti-Gal3 antibody IMT001. Mice treated with IMT001 experienced amelioration of LPS-induced hypothermia.
  • FIG.22A-B depict the impact of Gal3 constructs (full length wild-type, truncated, and P64H mutant Gal3) on neutrophil shedding of CD62L (FIG. 22A) and secretion of IL-8 (FIG. 22B).
  • FIG. 22A-B depict the impact of Gal3 constructs (full length wild-type, truncated, and P64H mutant Gal3) on neutrophil shedding of CD62L (FIG. 22A) and secretion of IL-8 (FIG. 22B).
  • FIG. 23A-B depict the effects of the exemplary anti-Gal3 antibody TB001 on reversing Gal3-induced shedding of CD62L (FIG.23A) and IL-8 secretion (FIG.23B) by activated neutrophils.
  • FIG. 24A-D depict the reduction of inflammation in a mouse model of inflammatory lung disease by anti-Gal3 antibodies.
  • FIG. 24A depicts elevated expression of Gal3 in bronchoalveolar fluid samples of a chronic obstructive pulmonary disease (COPD) mouse model.
  • COPD chronic obstructive pulmonary disease
  • FIG. 24B depicts elevated transcript levels of Gal3 and genes associated with neutrophil number and function (Ly6c1, Kc, Inos), inflammatory cytokines (Il6, Tnfa, Il1b), and fibrosis (Col1A1, aSma, Tgfb, Vegfa, Vegfb) in lung tissue from a COPD mouse model compared to healthy tissue.
  • Treatment with the exemplary anti-Gal3 antibodies 2D10.2B2 and mTB001 resulted in a reduction of these transcript levels in the COPD model.
  • FIG. 24C depicts increases in % and total neutrophil count in lung tissue of a COPD model compared to healthy tissue, and treatment with the exemplary anti-Gal3 antibodies results in a reduction in the neutrophil count.
  • FIG.24D depicts an increased expression of myeloperoxidase (MPO) and keratinocytes-derived chemokine (KC) in bronchoalveolar fluid samples of a COPD mouse model compared to healthy mice.
  • MPO myeloperoxidase
  • KC keratinocytes-derived chemokine
  • FIG. 25 depicts a reduction in anti-DNA autoantibody generation by treatment of the exemplary anti-Gal3 antibody mbTB001 in a graft versus host disease mouse model.
  • FIG.26 depicts reduction of TNF ⁇ production by activated neutrophils under pro- inflammatory conditions by treatment with the exemplary anti-Gal3 antibodies TB001 and TB006 compared to the control antibody MOPC21.
  • FIG. 27 depicts reduction of IL-6 production by activated neutrophils under pro- inflammatory conditions by treatment with the exemplary anti-Gal3 antibodies TB001 and TB006 compared to the control antibody MOPC21.
  • FIG. 28 depicts antibody names used throughout the present disclosure refer to the same antibody (with exemplary peptide and nucleic acid sequences provided elsewhere in the disclosure and appropriately attributed to at least one of the depicted names) and may be used interchangeably. The names shown in a column correspond to the same antibody.
  • FIG. 29 depicts nucleic acid sequences that encode for exemplary heavy chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the heavy chain variable regions encoded by the nucleic acids provided herein.
  • FIG. 30 depicts nucleic acid sequences that encode for exemplary light chain variable regions of anti-Gal3 antibodies disclosed herein. In some embodiments, any of the compositions or methods provided herein can include one or more of the light chain variable regions encoded by the nucleic acids provided herein.
  • FIG. 31 depicts nucleic acid sequences that encode for exemplary heavy chains of anti-Gal3 antibodies disclosed herein.
  • any of the compositions or methods provided herein can include one or more of the heavy chains encoded by the nucleic acids provided herein.
  • FIG. 32 depicts nucleic acid sequences that encode for exemplary light chains of anti-Gal3 antibodies disclosed herein.
  • any of the compositions or methods provided herein can include one or more of the light chains encoded by the nucleic acids provided herein.
  • FIG. 33A-B depicts an exemplary alignment for the heavy chain CDRs (FIG. 33A) and light chain CDRs (FIG. 33B) for the exemplary anti-Gal3 antibodies disclosed herein.
  • Galectin-3 (Gal3, GAL3) is known to play an important role in cell proliferation, adhesion, differentiation, angiogenesis, and apoptosis. This activity is, at least in part, due to immunomodulatory properties and binding affinity towards other immune regulatory proteins, signaling proteins, and other cell surface markers.
  • Gal3 functions by distinct N-terminal and C- terminal domains.
  • the N-terminal domain (isoform 1: amino acids 1-111, isoform 3: amino acids 1-125) comprise a tandem repeat domain (TRD, isoform 1: amino acids 36-109, isoform 3: amino acids 50-123) and is largely responsible for oligomerization of Gal3.
  • the C-terminal domain (isoform 1: amino acids 112-250, isoform 3: amino acids 126-264) comprise a carbohydrate- recognition-binding domain (CRD), which binds to ⁇ -galactosides.
  • An exemplary sequence for isoform 1 of human Gal3 (NCBI Reference No. NP_002297.2) is shown in SEQ ID NO: 1.
  • An exemplary sequence for isoform 3 of human Gal3 (NCBI Reference No. NP_001344607.1) is shown in SEQ ID NO: 2.
  • Gal3 plays an important role in promoting leukocyte recruitment to sites infected by a pathogen, such as a virus.
  • CRS cytokine release syndrome
  • SARS-CoV-2 SARS-CoV-2 and other coronaviruses.
  • Inhibition of Gal3 activity hinders leukocyte recruitment and reduces levels of harmful cytokine production.
  • anti-Gal3 antibodies or binding fragments thereof or compositions comprising anti-Gal3 antibodies or binding fragments thereof are provided.
  • the anti-Gal3 antibodies or binding fragments thereof bind to the N-terminal domain, the N-terminus and/or the TRD of Gal3.
  • the anti-Gal3 antibodies or binding fragments thereof bind to the C-terminal domain, the C-terminus and/or the CRD of Gal3. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof do not bind to the N-terminal domain, the N-terminus and/or the TRD of Gal3. In some embodiments, the anti- Gal3 antibodies or binding fragments thereof do not bind to the C-terminal domain, the C-terminus and/or the CRD of Gal3.
  • Some embodiments disclosed herein are antibodies and binding fragments thereof that are specific for Galectin-3 (Gal3), and methods of use thereof for the treatment or prevention of a viral infection, such as a SARS-CoV-2 infection, a SARS-related coronavirus infection, or other coronavirus infection.
  • a viral infection such as a SARS-CoV-2 infection, a SARS-related coronavirus infection, or other coronavirus infection.
  • the anti-Gal3 antibodies and binding fragments thereof disclosed herein disrupt the interaction between Gal3 and the SARS-CoV-2 spike (S) protein.
  • the anti-Gal3 antibodies and binding fragments thereof disclosed herein also disrupt the interaction between Gal3 and host cell receptors that viruses use to enter a host cell, such as ACE2 and/or CD147.
  • a respiratory viral infection such as a SARS-CoV-2 infection
  • CRS cytokine release syndrome
  • the viral infection is a coronavirus infection.
  • the viral infection is a SARS-CoV-2 viral infection. In other embodiments, this disruption is used to treat a sequela of a prior viral infection.
  • the methods involve an antibody that binds to Gal3 and disrupts an interaction between Gal3 and another protein, such as a viral protein or a host receptor protein. This can be a direct obstruction of the interaction zone between Gal3 and the other protein, or an indirect alteration, such as a binding that results in a conformational change of Gal3, so that it no longer binds or is active with the other protein. It can also result by binding to a first section of Gal3, where some other part of the antibody obstructs or alters the interaction between Gal3 and the other protein.
  • the first section of Gal3 is the N-terminal domain of Gal3, the tandem repeat domain (TRD) of Gal3, or the C-terminal domain of Gal3.
  • the antibody that binds to Gal3 does not bind to the C-terminal domain of Gal3.
  • a method is provided of disrupting an interaction between Gal3 and a viral protein or a host receptor protein.
  • the method comprises contacting an interaction site between Gal3 and the viral protein or host receptor protein with an antibody or binding fragment thereof that selectively binds to Gal3 and disrupts the interaction between Gal3 and the viral protein or host receptor protein.
  • methods of using the anti-Gal3 antibodies or binding fragments thereof or compositions comprising anti-Gal3 antibodies or binding fragments thereof to block or disrupt an interaction between Gal3 and another protein either in vitro or in vivo are provided.
  • the interaction is between Gal3 and a viral protein.
  • the viral protein is a coronavirus protein.
  • the viral protein is a SARS-CoV-2 protein.
  • the viral protein is a SARS-CoV-2 S, E, M, or HE protein.
  • the viral protein is a SARS-CoV-2 S protein.
  • the interaction is between Gal3 and a host receptor protein that a virus uses to enter the host cell.
  • the host receptor protein is a protein used by a coronavirus to enter the host cell.
  • the host receptor protein is a protein used by a SARS- CoV-2 virus to enter the host cell.
  • the host receptor protein is ACE2 and/or CD147.
  • the methods of using the anti-Gal3 antibodies or binding fragments thereof or compositions comprising anti-Gal3 antibodies or binding fragments thereof to block or disrupt an interaction between Gal3 and another protein is used to treat, cure, or prevent a disease or disorder in a subject.
  • the disease or disorder is a viral infection, such as a SARS-CoV-2 infection or other coronavirus infection.
  • the disease or disorder is a sequela of a prior viral (e.g. SARS-CoV-2 or other coronavirus) infection.
  • the sequela comprises fibrosis such as lung fibrosis.
  • the anti- Gal3 antibodies or binding fragments thereof are administered in conjunction with another antiviral or anti-inflammatory therapy.
  • the disease or disorder is CRS.
  • the CRS is a result of a viral infection.
  • the CRS is a result of a SARS-CoV-2 infection or other coronavirus infection.
  • the disease or disorder is sepsis. In some embodiments, the disease or disorder is viral sepsis. In some embodiments, the CRS is a result of sepsis caused by a viral infection. In some embodiments, the CRS is a result of sepsis caused by a SARS-CoV-2 infection or other coronavirus infection. [0059] Also disclosed herein are methods of decreasing or inhibiting inflammation in a subject in need thereof. In some embodiments, the methods comprise administering to the subject an effective amount of an anti-Gal3 antibody or binding fragment thereof. The inflammation may or may not be associated with a viral infection, such as a coronavirus infection.
  • inflammation may be associated with a disease, such as an inflammatory disease or an autoimmune disease.
  • the inflammatory disease may comprise lung inflammation, COPD, pneumonitis, asthma, sarcoidosis, pulmonary fibrosis, histiocytosis, bronchiolitis obliterans, or any combination thereof, or an autoimmune disease such as systemic lupus erythematosus, Graves’ disease, rheumatoid arthritis, multiple sclerosis, Sjogren’s syndrome, celiac disease, or any combination thereof.
  • the inflammation may be associated with neutrophil activation and/or migration, where administration of the anti-Gal3 antibody or binding fragment thereof reduces or inhibits neutrophil activation and/or migration.
  • Additional aspects of the present disclosure relate generally to pharmaceutical antibody formulations comprising antibodies that bind to Gal3 and one or more excipients, diluents, carriers, salts, buffers, and the like. These pharmaceutical antibody formulations are used to treat a disease such as an infection by a pathogen such as a virus, and/or inflammation associated with the aforementioned or herein disclosed disease(s).
  • the pharmaceutical antibody formulations comprise any one of the anti-Gal3 antibodies disclosed herein, histidine, methionine, NaCl, and polysorbate, and is at a pH of between 5.3 and 6.3.
  • sterile vials comprising any one of the pharmaceutical antibody formulations disclosed herein, including concentrated forms of the pharmaceutical antibody formulations intended to be diluted for administration.
  • methods of treating a coronavirus infection comprising administering any one of the pharmaceutical antibody formulations disclosed herein to a subject in need of treatment for a coronavirus infection.
  • the subject is a mammal.
  • the subject is a human. Definitions [0062] In the following detailed description, reference is made to the accompanying drawings, which form a part hereof. In the drawings, similar symbols typically identify similar components, unless context dictates otherwise.
  • the articles “a” and “an” are used herein to refer to one or to more than one (for example, at least one) of the grammatical object of the article.
  • an element means one element or more than one element.
  • “about” is meant a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much as 30, 25, 20, 15, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1% to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.
  • coronavirus refers to the family of enveloped, positive- sense, single stranded RNA viruses that infect mammals and birds. In humans, coronavirus infections can cause mild symptoms as a common cold, or more severe respiratory conditions such as severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), coughing, congestion, sore throat, shortness of breath, pneumonia, bronchitis, and hypoxia.
  • SARS severe acute respiratory syndrome
  • ARDS acute respiratory distress syndrome
  • hypoxia hypoxia
  • the viral envelope comprises spike (“S”), envelope (“E”), membrane (“M”), and hemagglutinin esterase (“HE”) transmembrane structural proteins.
  • S protein comprises a receptor binding domain (“RBD”), a highly immunogenic region that determines the host receptor specificity of the virus strain.
  • RBD receptor binding domain
  • NP nucleocapsid
  • RNA genome is translated by the host ribosome to produce new structural proteins and RNA-dependent RNA polymerases, which replicate the viral genome.
  • Viral particles are assembled in the host endoplasmic reticulum and are shed by Golgi-mediated exocytosis. More information about the structure and infection cycle of coronaviruses can be found in Fehr AR & Perlman S. “Coronaviruses: An Overview of Their Replication and Pathogenesis” Methods Mol. Biol. (2015); 1282:1-23, hereby expressly incorporated by reference in its entirety.
  • SARS-CoV-2 and “2019-nCoV” as used herein refers to the coronavirus strain responsible for the human coronavirus disease 2019 (“COVID-19”) pandemic.
  • COVID-19 human coronavirus disease 2019
  • COVID-19 human coronavirus disease 2019
  • ACE2 angiotensin- converting enzyme 2
  • the SARS-CoV-2 virus may also enter host cells using the CD147 (basigin, EMMPRIN) host cell receptor.
  • CD147 basic, EMMPRIN
  • the embodiments disclosed herein can be applied to other coronaviruses, including but not limited to HCoV-229E, HCoV-OC43, SARS-CoV-1, HCoV NL63, HKU1, and MERS-CoV.
  • S SARS-CoV-2 spike (S) protein
  • ACE2 human angiotensin-converting enzyme 2
  • An exemplary sequence for human CD147 (basigin, EMMPRIN) NCBI Reference No.
  • SARS-CoV-2 are respiratory viruses
  • complications involving the lungs are common sequelae of a coronavirus infection. This includes pulmonary fibrosis and/or pulmonary edema.
  • Other sequelae observed in patients afflicted with COVID-19 include but are not limited to other fibroses, cardiovascular disease, thrombosis, neurological disease, kidney disease, or liver disease.
  • CRS cytokine release syndrome
  • cytokine storm refers to an uncontrolled release of proinflammatory cytokines by immune cells, including T cells, natural killer cells, macrophages, dendritic cells, B cells, monocytes, neutrophils, leukocytes, lymphocytes, in response to a disease, infection, or immunotherapy.
  • CRS is caused by an infectious stimuli, non-infectious stimuli, condition, or syndrome, or any combination thereof.
  • CRS Chronic Infantile Neurological Cutaneous and Articular
  • CRS Chronic Infantile Neurological Cutaneous and Articular
  • Immunotherapies that can cause CRS include but are not limited to rituximab, obinutuzumab, alemtuzumab, brentuximab, dacetuzumab, nivolumab, theralizumab, oxaliplatin, lenalidomide, T-cell engager molecules, bi-specific T-cell engager (BiTE) molecules, or CAR T therapy.
  • CRS can be treated using anti-inflammatory therapies, including but not limited to anti-cytokine antibodies, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, corticosteroids, free radical scavengers, or TNF- ⁇ blockers.
  • cytokine refers to small proteins, polypeptides, or peptides that are involved in inflammatory signaling or proteins released by one cell population that act on another cell as intercellular mediators or have an autocrine effect on the cells producing the proteins.
  • Cytokines include but are not limited to chemokines, interferons, interleukins, lymphokines, monokines, tumor necrosis factors, CCL1, CCl2, CCL3, CCL4, CCL5, CCL6, CCL7, CCL8, CCL9, CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, CCL28, CXCL1, CXCL2, CXCL3, CXCL4, CXCL5, CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14, CXCL15, CXCL16, CXCL17, CX3CL1, XCL1, XCL2, INF ⁇ , INF ⁇ , INF ⁇ , IL-1, IL-1a,
  • the terms “individual(s)”, “subject(s)” and “patient(s)” mean any mammal. In some embodiments, the mammal is a human. In some embodiments, the mammal is a non-human. None of the terms require or are limited to situations characterized by the supervision (e.g. constant or intermittent) of a health care worker (e.g. a doctor, a registered nurse, a nurse practitioner, a physician’s assistant, an orderly or a hospice worker).
  • a health care worker e.g. a doctor, a registered nurse, a nurse practitioner, a physician’s assistant, an orderly or a hospice worker.
  • the terms “polypeptide”, “peptide”, and “protein” are used interchangeably herein to refer to polymers of amino acids of any length.
  • the polymer may be linear, cyclic, or branched, it may comprise modified amino acids, and it may be interrupted by non-amino acids.
  • the terms also encompass amino acid polymers that have been modified, for example, via sulfation, glycosylation, lipidation, acetylation, phosphorylation, iodination, methylation, oxidation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, ubiquitination, or any other manipulation, such as conjugation with a labeling component.
  • amino acid refers to either natural and/or unnatural or synthetic amino acids, including glycine and both the D or L optical isomers, and amino acid analogs and peptidomimetics.
  • a polypeptide or amino acid sequence “derived from” a designated protein refers to the origin of the polypeptide.
  • the polypeptide has an amino acid sequence that is essentially identical to that of a polypeptide encoded in the sequence, or a portion thereof wherein the portion consists of at least 10-20 amino acids, or at least 20-30 amino acids, or at least 30-50 amino acids, or which is immunologically identifiable with a polypeptide encoded in the sequence.
  • antibody is intended to include any polypeptide chain- containing molecular structure with a specific shape that fits to and recognizes an epitope, where one or more non-covalent binding interactions stabilize the complex between the molecular structure and the epitope.
  • Antibodies utilized in the present invention may be polyclonal antibodies, although monoclonal antibodies are preferred because they may be reproduced by cell culture or recombinantly and can be modified to reduce their antigenicity.
  • immunoglobulin fragments or “binding fragments” comprising the epitope binding site (e.g., Fab', F(ab')2, single-chain variable fragment (scFv), diabody, minibody, nanobody, single-domain antibody (sdAb), or other fragments) are useful as antibody moieties in the present invention.
  • Such antibody fragments may be generated from whole immunoglobulins by ricin, pepsin, papain, or other protease cleavage.
  • Minimal immunoglobulins may be designed utilizing recombinant immunoglobulin techniques.
  • Fv immunoglobulins for use in the present invention may be produced by linking a variable light chain region to a variable heavy chain region via a peptide linker (e.g., poly-glycine or another sequence which does not form an alpha helix or beta sheet motif).
  • a peptide linker e.g., poly-glycine or another sequence which does not form an alpha helix or beta sheet motif.
  • Nanobodies or single-domain antibodies can also be derived from alternative organisms, such as dromedaries, camels, llamas, alpacas, or sharks.
  • antibodies can be conjugates, e.g. pegylated antibodies, drug, radioisotope, or toxin conjugates.
  • Monoclonal antibodies directed against a specific epitope, or combination of epitopes will allow for the targeting and/or depletion of cellular populations expressing the marker.
  • Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (e.g. U.S. Pat. No. 5,985,660, hereby expressly incorporated by reference in its entirety).
  • the term "Fc region” is used to define a C-terminal region of an immunoglobulin heavy chain.
  • the "Fc region” may be a native sequence Fc region or a variant Fc region.
  • the human IgG heavy chain Fc region is usually defined to stretch from an amino acid residue at position Cys226, or from Pro230, to the carboxyl-terminus thereof.
  • the numbering of the residues in the Fc region is that of the EU index as in Kabat. Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md., 1991.
  • the Fc region of an immunoglobulin generally comprises two constant domains, CH2 and CH3.
  • an Fc region can be present in dimer or monomeric form.
  • a "constant region” of an antibody refers to the constant region of the antibody light chain or the constant region of the antibody heavy chain, either alone or in combination.
  • a “variable region” of an antibody refers to the variable region of the antibody light chain or the variable region of the antibody heavy chain, either alone or in combination.
  • the variable regions of the heavy and light chains each consist of four framework regions (FRs) connected by three complementarity determining regions (CDRs) also known as hypervariable regions, and contribute to the formation of the antigen binding site of antibodies.
  • variants of a subject variable region are desired, particularly with substitution in amino acid residues outside of a CDR region (i.e., in the framework region), appropriate amino acid substitution, preferably, conservative amino acid substitution, can be identified by comparing the subject variable region to the variable regions of other antibodies which contain CDR1 and CDR2 sequences in the same canonical class as the subject variable region (Chothia and Lesk, J Mol Biol 196(4): 901-917, 1987).
  • definitive delineation of a CDR and identification of residues comprising the binding site of an antibody is accomplished by solving the structure of the antibody and/or solving the structure of the antibody-ligand complex.
  • various methods of analysis can be employed to identify or approximate the CDR regions.
  • various methods of analysis can be employed to identify or approximate the CDR regions. Examples of such methods include, but are not limited to, the Kabat definition, the Chothia definition, the IMGT approach (Lefranc et al., 2003) Dev Comp Immunol. 27:55-77), computational programs such as Paratome (Kunik et al., 2012, Nucl Acids Res. W521-4), the AbM definition, and the conformational definition.
  • the Kabat definition is a standard for numbering the residues in an antibody and is typically used to identify CDR regions. See, e.g., Johnson & Wu, 2000, Nucleic Acids Res., 28: 214-8.
  • the Chothia definition is similar to the Kabat definition, but the Chothia definition takes into account positions of certain structural loop regions. See, e.g., Chothia et al., 1986, J. Mol. Biol., 196: 901-17; Chothia et al., 1989, Nature, 342: 877-83.
  • the AbM definition uses an integrated suite of computer programs produced by Oxford Molecular Group that model antibody structure.
  • the AbM definition models the tertiary structure of an antibody from primary sequence using a combination of knowledge databases and ab initio methods, such as those described by Samudrala et al., 1999, "Ab Initio Protein Structure Prediction Using a Combined Hierarchical Approach,” in PROTEINS, Structure, Function and Genetics Suppl., 3:194-198.
  • the contact definition is based on an analysis of the available complex crystal structures.
  • CDRs In another approach, referred to herein as the "conformational definition" of CDRs, the positions of the CDRs may be identified as the residues that make enthalpic contributions to antigen binding. See, e.g., Makabe et al., 2008, Journal of Biological Chemistry, 283:1156-1166. Still other CDR boundary definitions may not strictly follow one of the above approaches, but will nonetheless overlap with at least a portion of the Kabat CDRs, although they may be shortened or lengthened in light of prediction or experimental findings that particular residues or groups of residues do not significantly impact antigen binding.
  • a CDR may refer to CDRs defined by any approach known in the art, including combinations of approaches. The methods used herein may utilize CDRs defined according to any of these approaches. For any given embodiment containing more than one CDR, the CDRs may be defined in accordance with any of Kabat, Chothia, extended, IMGT, Paratome, AbM, and/or conformational definitions, or a combination of any of the foregoing. [0083] As disclosed herein, sequences having a % identity to any of the sequences disclosed herein are envisioned and may be used. The terms “% identity” refer to the percentage of units (i.e. amino acids or nucleotides) that are the same between two or more sequences relative to the length of the sequence.
  • sequences may include peptide sequences, nucleic acid sequences, CDR sequences, variable region sequences, or heavy or light chain sequences.
  • any sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any of the sequences disclosed herein may be used.
  • any sequence having at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 substitutions, deletions, or additions relative to any of the sequences disclosed herein may be used.
  • the changes in sequences may apply to, for example, single amino acids, single nucleic acid bases, or nucleic acid codons; however, differences in longer stretches of sequences are also envisioned.
  • sequences having a % homology to any of the sequences disclosed herein are envisioned and may be used.
  • the term “% homology” refers to the degree of conservation between two sequences when considering their three-dimensional structure. For example, homology between two protein sequences may be dependent on structural motifs, such as beta strands, alpha helices, and other folds, as well as their distribution throughout the sequence. Homology may be determined through structural determination, either empirically or in silico.
  • any sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence homology to any of the sequences disclosed herein may be used.
  • any sequence having at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 substitutions, deletions, or additions relative to any of the sequences disclosed herein, which may or may not affect the overall % homology, may be used.
  • sequences having a certain % similarity to any of the sequence disclosed herein are envisioned and may be used.
  • these sequences may include peptide sequences, nucleic acid sequences, CDR sequences, variable region sequences, or heavy or light chain sequences.
  • similarity refers to the comparison of amino acids based on their properties, including but not limited to size, polarity, charge, pK, aromaticity, hydrogen bonding properties, or presence of functional groups (e.g. hydroxyl, thiol, amine, carboxyl, and the like).
  • % similarity refers to the percentage of units (i.e. amino acids) that are the same between two or more sequences relative to the length of the sequence.
  • the % similarity will be respective that length.
  • deletions and/or insertions may be introduced to obtain the best alignment.
  • the similarity of two amino acids may dictate whether a certain substitution is conservative or non-conservative. Methods of determining the conservativeness of an amino acid substitution are generally known in the art and may involve substitution matrices. Commonly used substitution matrices include BLOSUM45, BLOSUM62, BLOSUM80, PAM100, PAM120, PAM160, PAM200, PAM250, but other substitution matrices or approaches may be used as considered appropriate by the skilled person.
  • a certain substitution matrix may be preferential over the others when considering aspects such as stringency, conservation and/or divergence of related sequences (e.g. within the same species or broader), and length of the sequences in question.
  • a peptide sequence having a certain % similarity to another sequence will have up to that % of amino acids that are either identical or an acceptable substitution as governed by the method of similarity determination used.
  • a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any of the sequences disclosed herein may be used.
  • any sequence having at least 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50 similar substitutions relative to any of the sequences disclosed herein may be used.
  • these similar substitutions may apply to antigen-binding regions (i.e. CDRs) or regions that do not bind to antigens or are only secondary to antigen binding (i.e. framework regions).
  • consensus sequence refers to the generalized sequence representing all of the different combinations of permissible amino acids at each location of a group of sequences.
  • a consensus sequence may provide insight into the conserved regions of related sequences where the unit (e.g. amino acid or nucleotide) is the same in most or all of the sequences, and regions that exhibit divergence between sequences.
  • the consensus sequence of a CDR may indicate amino acids that are important or dispensable for antigen binding. It is envisioned that consensus sequences may be prepared with any of the sequences provided herein, and the resultant various sequences derived from the consensus sequence can be validated to have similar effects as the template sequences.
  • the term "compete,” as used herein with regard to an antibody, means that a first antibody, or an antigen-binding portion thereof, binds to an epitope in a manner sufficiently similar to the binding of a second antibody, or an antigen-binding portion thereof, such that the result of binding of the first antibody with its cognate epitope is detectably decreased in the presence of the second antibody compared to the binding of the first antibody in the absence of the second antibody.
  • the alternative, where the binding of the second antibody to its epitope is also detectably decreased in the presence of the first antibody can, but need not be the case. That is, a first antibody can inhibit the binding of a second antibody to its epitope without that second antibody inhibiting the binding of the first antibody to its respective epitope.
  • each antibody detectably inhibits the binding of the other antibody with its cognate epitope or ligand, whether to the same, greater, or lesser extent, the antibodies are said to "cross-compete" with each other for binding of their respective epitope(s).
  • Both competing and cross-competing antibodies are encompassed by the present invention. Regardless of the mechanism by which such competition or cross-competition occurs (e.g., steric hindrance, conformational change, or binding to a common epitope, or portion thereof), the skilled artisan would appreciate, based upon the teachings provided herein, that such competing and/or cross-competing antibodies are encompassed and can be useful for the methods disclosed herein.
  • An antibody that "preferentially binds" or “specifically binds” (used interchangeably herein) to an epitope is a term well understood in the art, and methods to determine such specific or preferential binding are also well known in the art.
  • a molecule is said to exhibit “specific binding” or “preferential binding” if it reacts or associates more frequently, and/or more rapidly, and/or with greater duration and/or with greater affinity with a particular cell or substance than it does with alternative cells or substances.
  • An antibody “specifically binds” or “preferentially binds” to a target if it binds with greater affinity, and/or avidity, and/or more readily, and/or with greater duration than it binds to other substances.
  • an antibody that specifically or preferentially binds to a CFD epitope is an antibody that binds this epitope with greater affinity, and/or avidity, and/or more readily, and/or with greater duration than it binds to other CFD epitopes or non-CFD epitopes. It is also understood by reading this definition that, for example, an antibody (or moiety or epitope) that specifically or preferentially binds to a first target may or may not specifically or preferentially bind to a second target. As such, “specific binding” or “preferential binding” does not necessarily require (although it can include) exclusive binding. Generally, but not necessarily, reference to binding means preferential binding.
  • the term “antigen binding molecule” refers to a molecule that comprises an antigen binding portion that binds to an antigen and, optionally, a scaffold or framework portion that allows the antigen binding portion to adopt a conformation that promotes binding of the antigen binding portion or provides some additional properties to the antigen binding molecule.
  • the antigen is Gal3.
  • the antigen binding portion comprises at least one CDR from an antibody that binds to the antigen.
  • the antigen binding portion comprises all three CDRs from a heavy chain of an antibody that binds to the antigen or from a light chain of an antibody that binds to the antigen.
  • the antigen binding portion comprises all six CDRs from an antibody that binds to the antigen (three from the heavy chain and three from the light chain). In some embodiments, the antigen binding portion is an antibody fragment.
  • antigen binding molecules include antibodies, antibody fragments (e.g., an antigen binding fragment of an antibody), antibody derivatives, and antibody analogs. Further specific examples include, but are not limited to, a single-chain variable fragment (scFv), a nanobody (e.g. VH domain of camelid heavy chain antibodies; VHH fragment, see Cortez-Retamozo et al., Cancer Research, Vol.
  • a Fab fragment a Fab' fragment, a F(ab')2 fragment, a Fv fragment, a Fd fragment, and a complementarity determining region (CDR) fragment.
  • CDR complementarity determining region
  • These molecules can be derived from any mammalian source, such as human, mouse, rat, rabbit, pig, dog, cat, horse, donkey, guinea pig, goat, or camelid.
  • Antibody fragments may compete for binding of a target antigen with an intact antibody and the fragments may be produced by the modification of intact antibodies (e.g. enzymatic or chemical cleavage) or synthesized de novo using recombinant DNA technologies or peptide synthesis.
  • the antigen binding molecule can comprise, for example, an alternative protein scaffold or artificial scaffold with grafted CDRs or CDR derivatives.
  • Such scaffolds include, but are not limited to, antibody- derived scaffolds comprising mutations introduced to, for example, stabilize the three-dimensional structure of the antigen binding molecule as well as wholly synthetic scaffolds comprising, for example, a biocompatible polymer. See, for example, Korndorfer et al., 2003, Proteins: Structure, Function, and Bioinformatics, Volume 53, Issue 1:121-129 (2003); Roque et al., Biotechnol. Prog. 20:639-654 (2004).
  • an antigen binding molecule can also include a protein comprising one or more antibody fragments incorporated into a single polypeptide chain or into multiple polypeptide chains.
  • antigen binding molecule can include, but are not limited to, a diabody (see, e.g., EP 404,097; WO 93/11161; and Hollinger et al., Proc. Natl. Acad. Sci. USA, Vol.
  • a peptibody one or more peptides attached to an Fc region, see WO 00/24782; a linear antibody (a pair of tandem Fd segments (VH-CH1-VH-CH1) which, together with complementary light chain polypeptides, form a pair of antigen binding regions, see Zapata et al., Protein Eng., Vol. 8:1057-1062, 1995); a small modular immunopharmaceutical (see U.S. Patent Publication No. 20030133939); and immunoglobulin fusion proteins (e.g.
  • an antigen binding molecule can have, for example, the structure of an immunoglobulin.
  • An “immunoglobulin” is a tetrameric molecule, with each tetramer comprising two identical pairs of polypeptide chains, each pair having one “light” (about 25 kDa) and one “heavy” chain (about 50-70 kDa).
  • each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition.
  • the carboxy-terminal portion of each chain defines a constant region primarily responsible for effector function.
  • the complementarity defining regions disclosed herein follow the IMGT definition.
  • the CDRs can instead by Kabat, Chothia, or other definitions accepted by those of skill in the art.
  • the term “humanized” as applies to a non-human (e.g. rodent or primate) antibodies are hybrid immunoglobulins, immunoglobulin chains or fragments thereof which contain minimal sequence derived from non-human immunoglobulin.
  • treating means an approach for obtaining beneficial or desired results in a subject's condition, including clinical results.
  • beneficial or desired clinical results can include, but are not limited to, alleviation or amelioration of one or more symptoms or conditions, diminishment of the extent of a disease, stabilizing (i.e., not worsening) the state of disease, prevention of a disease's transmission or spread, delaying or slowing of disease progression, amelioration or palliation of the disease state, diminishment of the reoccurrence of disease, and remission, whether partial or total and whether detectable or undetectable.
  • Treatment as used herein also include prophylactic treatment.
  • Treatment methods comprise administering to a subject a therapeutically effective amount of an active agent.
  • the administering step may consist of a single administration or may comprise a series of administrations.
  • the compositions are administered to the subject in an amount and for a duration sufficient to treat the patient.
  • the length of the treatment period depends on a variety of factors, such as the severity of the condition, the age and genetic profile of the patient, the concentration of active agent, the activity of the compositions used in the treatment, or a combination thereof.
  • the effective dosage of an agent used for the treatment or prophylaxis may increase or decrease over the course of a particular treatment or prophylaxis regime. Changes in dosage may result and become apparent by standard diagnostic assays known in the art. In some embodiments, chronic administration may be required.
  • an effective amount or “effective dose” as used herein have their plain and ordinary meaning as understood in light of the specification, and refer to that amount of a recited composition or compound that results in an observable designated effect.
  • Actual dosage levels of active ingredients in an active composition of the presently disclosed subject matter can be varied so as to administer an amount of the active composition or compound that is effective to achieve the designated response for a particular subject and/or application.
  • the selected dosage level can vary based upon a variety of factors including, but not limited to, the activity of the composition, formulation, route of administration, combination with other drugs or treatments, severity of the condition being treated, and the physical condition and prior medical history of the subject being treated.
  • an effective amount or effective dose of a composition or compound may relate to the amount or dose that provides a significant, measurable, or sufficient therapeutic effect towards the treatment of a coronavirus infection, such as a SARS- CoV-2 infection.
  • the effective amount or effective dose of a composition or compound may treat, ameliorate, or prevent the progression of inflammation, shortness of breath, fatigue, pulmonary damage, or other symptoms associated with a coronavirus infection, such as a SARS-CoV-2 infection.
  • the effective amount or effective dose of a composition or compound may treat, ameliorate, or prevent the progression of a pulmonary inflammatory disease, such as COPD, or an autoimmune disease, such as systemic lupus erythematosus.
  • the effective amount or effective dose of a composition or compound may treat, ameliorate, or prevent the progression of inflammation (which might not be associated with a viral or other pathogenic infection) and symptoms and/or causes thereof, including neutrophil activation and migration.
  • administering includes oral administration, topical contact, administration as a suppository, intravenous, intraperitoneal, intramuscular, intralesional, intrathecal, intranasal, or subcutaneous administration, or the implantation of a slow-release device, e.g., a mini-osmotic pump, to a subject.
  • Administration is by any route, including parenteral and transmucosal (e.g., buccal, sublingual, palatal, gingival, nasal, vaginal, rectal, or transdermal).
  • Parenteral administration includes, e.g., intravenous, intramuscular, intra-arteriole, intradermal, subcutaneous, intraperitoneal, intraventricular, and intracranial.
  • a first compound described herein is administered at the same time, just prior to, or just after the administration of a second compound described herein.
  • a therapeutic target refers to a gene or gene product that, upon modulation of its activity (e.g., by modulation of expression, biological activity, and the like), can provide for modulation of the disease phenotype.
  • modulation is meant to refer to an increase or a decrease in the indicated phenomenon (e.g., modulation of a biological activity refers to an increase in a biological activity or a decrease in a biological activity).
  • pharmaceutically acceptable has its plain and ordinary meaning as understood in light of the specification and refers to carriers, excipients, and/or stabilizers that are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed or that have an acceptable level of toxicity.
  • a “pharmaceutically acceptable” “diluent,” “excipient,” and/or “carrier” as used herein have their plain and ordinary meaning as understood in light of the specification and are intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with administration to humans, cats, dogs, or other vertebrate hosts.
  • a pharmaceutically acceptable diluent, excipient, and/or carrier is a diluent, excipient, and/or carrier approved by a regulatory agency of a Federal, a state government, or other regulatory agency, or listed in the U.S.
  • diluent, excipient, and/or carrier can refer to a diluent, adjuvant, excipient, or vehicle with which the pharmaceutical formulation is administered.
  • Such pharmaceutical diluent, excipient, and/or carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin. Water, saline solutions and aqueous dextrose and glycerol solutions can be employed as liquid diluents, excipients, and/or carriers, particularly for injectable solutions.
  • Suitable pharmaceutical diluents and/or excipients include sugars, starch, glucose, fructose, lactose, sucrose, maltose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, salts, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like.
  • a non-limiting example of a physiologically acceptable carrier is an aqueous pH buffered solution.
  • the physiologically acceptable carrier may also comprise one or more of the following: antioxidants, such as ascorbic acid, low molecular weight (less than about 10 residues) polypeptides, proteins, such as serum albumin, gelatin, immunoglobulins, hydrophilic polymers such as polyvinylpyrrolidone, amino acids, carbohydrates such as glucose, mannose, or dextrins, chelating agents such as EDTA, sugar alcohols such as glycerol, erythritol, threitol, arabitol, xylitol, ribitol, mannitol, sorbitol, galactitol, fucitol, iditol, inositol, isomalt, maltitol, or lactitol, salt-forming counterions such as sodium, and nonionic surfactants such as TWEEN®, polyethylene glycol (PEG), and PLURONICS®.
  • antioxidants such as ascorbic acid,
  • the formulation can also contain minor amounts of wetting, bulking, emulsifying agents, or pH buffering agents. These formulations can take the form of solutions, suspensions, emulsion, sustained release formulations and the like. The formulation should suit the mode of administration.
  • pharmaceutically acceptable salts has its plain and ordinary meaning as understood in light of the specification and includes relatively non-toxic, inorganic and organic acid, or base addition salts of compositions or excipients, including without limitation, analgesic agents, therapeutic agents, other materials, and the like.
  • Examples of pharmaceutically acceptable salts include those derived from mineral acids, such as hydrochloric acid and sulfuric acid, and those derived from organic acids, such as ethanesulfonic acid, benzenesulfonic acid, p- toluenesulfonic acid, and the like.
  • suitable inorganic bases for the formation of salts include the hydroxides, carbonates, and bicarbonates of ammonia, sodium, lithium, potassium, calcium, magnesium, aluminum, zinc, and the like. Salts may also be formed with suitable organic bases, including those that are non-toxic and strong enough to form such salts.
  • the class of such organic bases may include but are not limited to mono-, di-, and trialkylamines, including methylamine, dimethylamine, and triethylamine; mono-, di-, or trihydroxyalkylamines including mono-, di-, and triethanolamine; amino acids, including glycine, arginine and lysine; guanidine; N-methylglucosamine; N-methylglucamine; L-glutamine; N-methylpiperazine; morpholine; ethylenediamine; N-benzylphenethylamine; trihydroxymethyl aminoethane.
  • a “carrier” refers to a compound, particle, solid, semi-solid, liquid, or diluent that facilitates the passage, delivery and/or incorporation of a compound to cells, tissues and/or bodily organs.
  • a lipid nanoparticle LNP
  • a “diluent” refers to an ingredient in a pharmaceutical composition that lacks pharmacological activity but may be pharmaceutically necessary or desirable.
  • a diluent may be used to increase the bulk of a potent drug whose mass is too small for manufacture and/or administration. It may also be a liquid for the dissolution of a drug to be administered by injection, ingestion or inhalation.
  • a common form of diluent in the art is a buffered aqueous solution such as, without limitation, phosphate buffered saline that mimics the composition of human blood.
  • excipient has its ordinary meaning as understood in light of the specification, and refers to inert substances, compounds, or materials added to a pharmaceutical composition to provide, without limitation, bulk, consistency, stability, binding ability, lubrication, disintegrating ability etc., to the composition.
  • Excipients with desirable properties include but are not limited to preservatives, adjuvants, stabilizers, solvents, buffers, diluents, solubilizing agents, detergents, surfactants, chelating agents, antioxidants, alcohols, ketones, aldehydes, ethylenediaminetetraacetic acid (EDTA), citric acid, salts, sodium chloride, sodium bicarbonate, sodium phosphate, sodium borate, sodium citrate, potassium chloride, potassium phosphate, magnesium sulfate sugars, dextrose, dextran, fructose, mannose, lactose, galactose, sucrose, sorbitol, cellulose, methyl cellulose, hydroxypropyl methyl cellulose (hypromellose), glycerin, polyvinyl alcohol, povidone, propylene glycol, serum, amino acids, polyethylene glycol, polysorbate 20, polysorbate 80, sodium deoxycholate, sodium taurodeoxycholate, magnesium stea
  • the amount of the excipient may be found in a pharmaceutical composition at a percentage of 0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% w/w or any percentage by weight in a range defined by any two of the aforementioned numbers.
  • Additional excipients with desirable properties include but are not limited to preservatives, adjuvants, stabilizers, solvents, buffers, diluents, solubilizing agents, detergents, surfactants, chelating agents, antioxidants, alcohols, ketones, aldehydes, ethylenediaminetetraacetic acid (EDTA), tris(hydroxymethyl)aminomethane (Tris), citric acid, ascorbic acid, acetic acid, salts, phosphates, citrates, acetates, succinates, chlorides, bicarbonates, borates, sulfates, sodium chloride, sodium bicarbonate, sodium phosphate, sodium borate, sodium citrate, potassium chloride, potassium phosphate, magnesium sulfate sugars, dextrose, dextran 40, fructose, mannose, lactose, trehalose, galactose, sucrose, sorbitol, mannitol, cellulose, serum, amino
  • excipients may be in residual amounts or contaminants from the process of manufacturing, including but not limited to serum, albumin, ovalbumin, antibiotics, inactivating agents, formaldehyde, glutaraldehyde, ⁇ - propiolactone, gelatin, cell debris, nucleic acids, peptides, amino acids, or growth medium components or any combination thereof.
  • the amount of the excipient may be found in the formulation at a percentage that is at least 0%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% w/w or any percentage by weight in a range defined by any two of the aforementioned numbers.
  • adjuvant refers to a substance, compound, or material that stimulates the immune response and increase the efficacy of protective immunity and is administered in conjunction with an immunogenic antigen, epitope, or composition.
  • Adjuvants serve to improve immune responses by enabling a continual release of antigen, up-regulation of cytokines and chemokines, cellular recruitment at the site of administration, increased antigen uptake and presentation in antigen presenting cells, or activation of antigen presenting cells and inflammasomes.
  • adjuvants include but are not limited to alum, aluminum salts, aluminum sulfate, aluminum hydroxide, aluminum phosphate, calcium phosphate hydroxide, potassium aluminum sulfate, oils, mineral oil, paraffin oil, oil-in-water emulsions, detergents, MF59®, squalene, AS03, ⁇ -tocopherol, polysorbate 80, AS04, monophosphoryl lipid A, virosomes, nucleic acids, polyinosinic:polycytidylic acid, saponins, QS-21, proteins, flagellin, cytokines, chemokines, IL-1, IL-2, IL-12, IL-15, IL-21, imidazoquinolines, CpG oligonucleotides, lipids, phospholipids, dioleoyl phosphatidylcholine (DOPC), trehalose dimycolate, peptidoglycans, bacterial extracts, lip
  • purity of any given substance, compound, or material as used herein refers to the actual abundance of the substance, compound, or material relative to the expected abundance.
  • the substance, compound, or material may be at least 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100% pure, including all decimals in between.
  • Purity may be affected by unwanted impurities, including but not limited to side products, isomers, enantiomers, degradation products, solvent, carrier, vehicle, or contaminants, or any combination thereof.
  • Immune cells refers to cells of hematopoietic origin that are involved in the specific recognition of antigens.
  • Immune cells include antigen presenting cells (APCs), such as dendritic cells or macrophages, B cells, T cells, natural killer cells, and myeloid cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes.
  • APCs antigen presenting cells
  • monocytes such as dendritic cells or macrophages, B cells, T cells, natural killer cells, and myeloid cells, such as monocytes, macrophages, eosinophils, mast cells, basophils, and granulocytes.
  • immune response refers to T cell-mediated and/or B cell-mediated immune responses.
  • Exemplary immune responses include B cell responses (e.g., antibody production) T cell responses (e.g., cytokine production, and cellular cytotoxicity) and activation of cytokine responsive cells, e.g., macrophages.
  • activating immune response refers to enhancing the level of T-cell-mediated and/or B cell-mediated immune response, using methods known to one of skilled in the art.
  • the level of enhancement is at least 20- 50%, alternatively at least 60%, at least 70%, at least 80%, at least 90%, at least 100%, at least 120%, at least 150%, or at least 200%.
  • standard of care refers to the treatment that is accepted by medical practitioners to be an appropriate, proper, effective, and/or widely used treatment for a certain disease.
  • the standard of care of a certain disease depends on many different factors, including the biological effect of treatment, region or location within the body, patient status (e.g. age, weight, gender, hereditary risks, other disabilities, secondary conditions), toxicity, metabolism, bioaccumulation, therapeutic index, dosage, and other factors known in the art.
  • Determining a standard of care for a disease is also dependent on establishing safety and efficacy in clinical trials as standardized by regulatory bodies such as the US Food and Drug Administration, International Council for Harmonisation, Health Canada, European Medicines Agency, Therapeutics Goods Administration, Central Drugs Standard Control Organization, National Medical Products Administration, Pharmaceuticals and Medical Devices Agency, Ministry of Food and Drug Safety, and the World Health Organization.
  • the standard of care for a disease may include but is not limited to surgery, radiation, chemotherapy, targeted therapy, or immunotherapy.
  • the term “% w/w” or “% wt/wt” means a percentage expressed in terms of the weight of the ingredient or agent over the total weight of the composition multiplied by 100.
  • antibodies or binding fragments thereof are provided.
  • the antibodies are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a V L -CDR1, a V L -CDR2, and a V L -CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3.
  • the VL-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 170-220.
  • the V L -CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 221-247.
  • the V L -CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 248-296.
  • the VH-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 27-70.
  • the VH-CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 71-111, 826.
  • the V H -CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 112-169, 827.
  • the antibodies comprise one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a VL sequence, a VH sequence, a VL/VH pairing, and/or V L -CDR1, V L -CDR2, V L -CDR3, V H -CDR1, V H -CDR2, V H -CDR3 (including 1, 2, 3, 4, or 5 amino acid substitutions of any one or more of these CDRs) set from the heavy chain and light chain sequences as depicted in FIG. 18.
  • antibodies or binding fragments thereof are provided.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a V L -CDR1, a V L -CDR2, and a V L - CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a V H -CDR1, a V H -CDR2, and a V H -CDR3.
  • the VL-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any amino acid sequence according to SEQ ID NOs: 170-220.
  • the VL-CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any amino acid sequence according to SEQ ID NOs: 221-247.
  • the V L -CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any amino acid sequence according to SEQ ID NOs: 248-296.
  • the V H - CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any amino acid sequence according to SEQ ID NOs: 27-70.
  • the VH-CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any amino acid sequence according to SEQ ID NOs: 71-111, 826.
  • the VH-CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to any amino acid sequence according to SEQ ID NOs: 112-169, 827.
  • the antibodies comprise one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% similar to a VL sequence, a VH sequence, a VL/VH pairing, and/or V L -CDR1, V L -CDR2, V L -CDR3, V H -CDR1, V H -CDR2, V H -CDR3 (including 1, 2, 3, 4, or 5 amino acid substitutions of any one or more of these CDRs) set from the heavy chain and light chain sequences as depicted in FIG. 18.
  • antibodies or binding fragments thereof are provided.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL- CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3.
  • the VL-CDR1 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any amino acid sequence according to SEQ ID NOs: 170-220.
  • the V L -CDR2 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any amino acid sequence according to SEQ ID NOs: 221-247.
  • the VL-CDR3 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any amino acid sequence according to SEQ ID NOs: 248-296.
  • the VH-CDR1 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any amino acid sequence according to SEQ ID NOs: 27-70.
  • the V H -CDR2 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any amino acid sequence according to SEQ ID NOs: 71-111, 826.
  • the VH-CDR3 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any amino acid sequence according to SEQ ID NOs: 112-169, 827.
  • the antibody or binding fragment thereof comprises a combination of a VL-CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 as illustrated in FIG. 14.
  • the antibody or binding fragment thereof comprises a combination of a VL-CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 where one or more of these CDRs is defined by a consensus sequence.
  • the consensus sequences provided herein have been derived from the alignments of CDRs depicted in FIG. 33A-B.
  • alternative alignments may be done (e.g. using global or local alignment, or with different algorithms, such as Hidden Markov Models, seeded guide trees, Needleman-Wunsch algorithm, or Smith-Waterman algorithm) and as such, alternative consensus sequences can be derived.
  • the V L -CDR1 is defined by the formula X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17, where X1 is no amino acid or R; X2 is no amino acid or S; X 3 is no amino acid, S, or T; X 4 is no amino acid, E, G, K, Q, or R; X 5 is no amino acid, A, D, G, I, N, or S; X6 is no amino acid, I, L, or V; X7 is no amino acid, F, L, S, or V; X8 is no amino acid, D, E, H, N, S, T, or Y; X9 is no amino acid, D, E, I, K, N, R, S, T, or V; X10 is no amino acid, D, H, N, R, S, or Y; X 11 is no amino acid, A, G, N, S, T,
  • the V L -CDR1 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the VL- CDR1 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the V L -CDR2 is defined by the formula X1X2X3X4X5X6X7X8, where X1 is no amino acid, K, L, N, Q, or R; X2 is no amino acid, A, L, M, or V; X3 is no amino acid, C, K, or S; X4 is no amino acid or T; X5 is no amino acid, A, E, F, G, H, K, Q, R, S, W, or Y; X 6 is no amino acid, A, G, or T; X 7 is no amino acid, I, K, N, S, or T; X 8 is no amino acid, N, or S.
  • the V L -CDR2 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the V L -CDR2 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the VL-CDR3 is defined by the formula X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 , where X 1 is no amino acid, A, E, F, H, L, M, Q, S, V, or W; X 2 is A, H, or Q; X3 is D, F, G, H, L, M, N, Q, S, T, W, or Y; X4 is no amino acid or W; X5 is A, D, I, K, L, N, Q, R, S, T, V, or Y; X6 is D, E, H, I, K, L, N, Q, S, or T; X7 is D, F, K, L, N, P, S, T, V, W, or Y; X 8 is H, P, or S; X 9 is F, L, P, Q, R, T, W, or Y; X 10 is no
  • the V L -CDR3 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the V L -CDR3 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the V H -CDR1 is defined by the formula X1X2X3X4X5X6X7X8X9X10, where X1 is E, G, or R; X2 is F, N, or Y; X3 is A, I, K, N, S, or T; X4 is F, I, or L; X5 is I, K, N, R, S, or T; X6 is D, G, I, N, S, or T; X7 is F, G, H, S, or Y; X8 is no amino acid, A, D, G, I, M, N, T, V, W, or Y; X 9 is no amino acid, M, or Y; X 10 is no amino acid or G; In some embodiments, the VH-CDR1 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 9
  • the V H -CDR1 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the VH-CDR2 is defined by the formula X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 , where X 1 is no amino acid, I, or L; X 2 is no amino acid or R; X 3 is no amino acid, F, I, L, or V; X 4 is A, D, F, H, K, L, N, S, W, or Y; X 5 is A, D, P, S, T, W, or Y; X 6 is D, E, G, H, K, N, S, V, or Y; X7 is D, E, G, N, S, or T; X8 is D, G, I, K, N, Q, R, S, V, or Y; X9 is A, D, E, G, I, K, I, K
  • the V H -CDR2 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the VH-CDR2 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the VH-CDR3 is defined by the formula X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25, where X1 is no amino acid or A; X 2 is no amino acid, A, R, or Y; X 3 is no amino acid, A, F, H, K, L, R, S, or V; X 4 is no amino acid, A, D, K, N, R, S, or T; X 5 is no amino acid, A, D, G, H, I, L, N, P, R, S, T, V, or Y; X6 is no amino acid, A, D, G, H, K, N, P, Q, R, S, or Y; X7 is no amino acid, D, F, G, H, P, R, S, W, or Y; X8 is no amino acid, A, D
  • the V H -CDR3 comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the VH-CDR3 comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the light chain variable region of the antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 374-447, 823-825.
  • the light chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence selected from SEQ ID NOs: 374-447, 823-825.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the heavy chain variable region of the antibody or binding fragment thereof comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the light chain variable region of the antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence selected from SEQ ID NOs: 374-447, 823-825.
  • the light chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence selected from SEQ ID NOs: 374-447, 823-825.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the antibodies comprise one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a VL sequence, a VH sequence, a VL/VH pairing, and/or V L -CDR1, V L -CDR2, V L -CDR3, V H -CDR1, V H -CDR2, V H -CDR3 (including 1, 2, 3, 4, or 5 amino acid substitutions of any one or more of these CDRs) set from the heavy chain and light chain sequences as depicted in FIG. 18.
  • antibodies or binding fragments thereof are provided.
  • the antibodies are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3.
  • the VL-CDR1 comprises one of the amino acid sequences of SEQ ID NOs: 170-220
  • the VL-CDR2 comprises one of the amino acid sequences of SEQ ID NOs: 211-247
  • the V L -CDR3 comprises one of the amino acid sequences of SEQ ID NOs: 248-296
  • the V H -CDR1 comprises one of the amino acid sequences of SEQ ID NOs: 27-70
  • the VH-CDR2 comprises one of the amino acid sequences of SEQ ID NOs: 71-111, 826
  • the VH-CDR3 comprises one of the amino acid sequences of SEQ ID NO: 112-169, 827
  • the light chain variable region has a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one of the amino acid sequences
  • the antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 495-538, 830.
  • the light chain comprises the sequence selected from SEQ ID NOs: 495-538, 830.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 448-494, 829.
  • the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence selected from SEQ ID NOs: 495-538, 830.
  • the light chain comprises the sequence selected from SEQ ID NOs: 495-538, 830.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence selected from SEQ ID NOs: 448-494, 829.
  • the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof. [0128] In some embodiments, antibodies or binding fragments thereof are provided.
  • the antibodies are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a V H -CDR1, a V H -CDR2, and a V H -CDR3.
  • the V L -CDR1 comprises one of the amino acid sequences of SEQ ID NOs: 170-220
  • the VL-CDR2 comprises one of the amino acid sequences of SEQ ID NOs: 211-247
  • the VL-CDR3 comprises one of the amino acid sequences of SEQ ID NOs: 248-296
  • the V H -CDR1 comprises one of the amino acid sequences of SEQ ID NOs: 27-70
  • the V H -CDR2 comprises one of the amino acid sequences of SEQ ID NOs: 71-111, 826
  • the VH-CDR3 comprises one of the amino acid sequences of SEQ ID NO: 112-169, 827
  • the light chain has a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one of the amino acid sequences of
  • antibodies or binding fragments thereof are provided.
  • the antibodies are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region and a heavy chain variable region.
  • the light chain variable region is paired with an IgG4 kappa chain constant domain.
  • the IgG4 kappa chain constant domain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 833.
  • the heavy chain variable region is paired with an IgG4 heavy chain constant domain or an IgG2 heavy chain constant domain.
  • the IgG4 heavy chain constant domain or IgG2 heavy chain constant domain are human or murine.
  • the IgG4 heavy chain constant domain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 832.
  • the IgG4 heavy chain constant domain is an S228P mutant.
  • the IgG2 heavy chain constant domain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 838 or SEQ ID NO: 839.
  • the IgG2 heavy chain constant domain is a LALAPG or a LALA mutant.
  • the light chain variable region and/or heavy chain variable region may be selected from those depicted in FIG. 15 and 16 and/or the combinations of light chain variable region and heavy chain variable region as depicted in FIG. 17.
  • the light chain variable region and/or heavy chain variable regions comprise one or more CDRs depicted in FIGs.8-13 and/or the combinations of CDRs depicted in FIG.14.
  • the antibody or binding fragment thereof is selected from the group consisting of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H
  • the antibody or binding fragment thereof comprises a sequence (e.g. CDR, VL, VH, LC, HC) having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to a sequence of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23
  • a sequence e.
  • the antibody or binding fragment thereof comprises a sequence (e.g. CDR, VL, VH, LC, HC) having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to a sequence of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5,
  • a sequence e.
  • antibodies or binding fragments thereof are provided.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL- CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3.
  • the VL-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 170.
  • the VL- CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 221.
  • the VL-CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 248.
  • the V H -CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 27.
  • the V H -CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 71.
  • the VH-CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity to SEQ ID NO: 112. [0134]
  • antibodies or binding fragments thereof are provided.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a V L -CDR1, a V L -CDR2, and a V L - CDR3. In some embodiments, the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3.
  • the V L -CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to SEQ ID NO: 170.
  • the V L -CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to SEQ ID NO: 221.
  • the V L -CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to SEQ ID NO: 248.
  • the VH-CDR1 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to SEQ ID NO: 27.
  • the VH-CDR2 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to SEQ ID NO: 71.
  • the VH-CDR3 comprises an amino acid sequence having at least 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence similarity to SEQ ID NO: 112. [0135] In some embodiments, antibodies or binding fragments thereof are provided.
  • the antibodies or binding fragments thereof are anti-Gal3 antibodies or binding fragments thereof.
  • the anti-Gal3 antibodies or binding fragments thereof comprise a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL- CDR3.
  • the anti-Gal3 antibodies or binding fragments thereof comprises a heavy chain variable region comprising a V H -CDR1, a V H -CDR2, and a V H -CDR3.
  • the VL-CDR1 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to SEQ ID NO: 170.
  • the VL-CDR2 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to SEQ ID NO: 221.
  • the VL-CDR3 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to SEQ ID NO: 248.
  • the VH-CDR1 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to SEQ ID NO: 27.
  • the V H -CDR2 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to SEQ ID NO: 71.
  • the VH- CDR3 comprises an amino acid sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to SEQ ID NO: 112.
  • the light chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 374.
  • the light chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence of SEQ ID NO: 374.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to SEQ ID NO: 297.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence of SEQ ID NO: 297.
  • the light chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to SEQ ID NO: 374.
  • the light chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence of SEQ ID NO: 374.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence of SEQ ID NO: 297.
  • the heavy chain variable region of the anti-Gal3 antibody or binding fragment thereof comprises the sequence of SEQ ID NO: 297.
  • the anti-Gal3 antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence of SEQ ID NO: 495.
  • the light chain comprises the sequence of SEQ ID NO: 495.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence of SEQ ID NO: 448.
  • the heavy chain comprises the sequence of SEQ ID NO: 448.
  • the anti-Gal3 antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence of SEQ ID NO: 495.
  • the light chain comprises the sequence of SEQ ID NO: 495.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% similarity to the sequence of SEQ ID NO: 448.
  • the heavy chain comprises the sequence of SEQ ID NO: 448.
  • the anti-Gal3 antibody or binding fragment thereof binds to specific epitopes within a Gal3 protein.
  • the anti-Gal3 antibody or binding fragment thereof binds to a specific epitope within a Gal3 protein having an amino acid sequence according to SEQ ID NO: 1-2, provided in FIG. 6.
  • the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within a peptide illustrated in FIG. 7 (SEQ ID NOs: 3-26).
  • the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 1-20 of SEQ ID NO: 1-2.
  • the anti- Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 31-50 of SEQ ID NO: 1-2. In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 51-70 of SEQ ID NO: 1-2. In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within amino acid residues 61-80 of SEQ ID NO: 1- 2.
  • the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid residues within Peptide 1 (SEQ ID NO: 3), Peptide 4 (SEQ ID NO: 6), Peptide 6 (SEQ ID NO: 8), or Peptide 7 (SEQ ID NO: 9). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20amino acid residues within Peptide 1 (SEQ ID NO: 3).
  • the anti-Gal3 antibody or binding fragment thereof may bind to at least 11, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20amino acid residues within Peptide 4 (SEQ ID NO: 6). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20amino acid residues within Peptide 6 (SEQ ID NO: 8). In some embodiments, the anti-Gal3 antibody or binding fragment thereof may bind to at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20amino acid residues within Peptide 7 (SEQ ID NO: 9).
  • the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within a region of Gal3 defined by Peptide 1 (SEQ ID NO: 3). In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within a region of Gal3 defined by Peptide 4 (SEQ ID NO: 6). In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to an epitope present within a region of Gal3 defined by Peptide 6 (SEQ ID NO: 8). In some embodiments, the anti- Gal3 antibody or binding fragment thereof binds to an epitope present within a region of Gal3 defined by Peptide 7 (SEQ ID NO: 9).
  • the antibody is one that binds to 1, 2, or all 3 of peptides 1, 6, and/or 7.
  • an anti-Gal3 antibody or binding fragment thereof as described herein may bind to the N-terminal domain of Gal3 or a portion thereof.
  • an anti-Gal3 antibody or binding fragment thereof as described herein may bind to an epitope of Gal3 that includes a motif of GxYPG, where x is the amino acids alanine (A), glycine (G), or valine (V).
  • an anti-Gal3 antibody or binding fragment thereof as described herein may bind to an epitope of Gal3 that includes two GxYPG motifs separated by three amino acids, where x is A, G, or V.
  • the anti-Gal3 antibody or binding fragment thereof binds to Gal3.
  • the anti-Gal3 antibody or binding fragment thereof binds to the N- terminus of Gal3, the N-terminal domain of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof does not bind to the N-terminus of Gal3, the N- terminal domain of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof binds to the C-terminus of Gal3, the C-terminal domain of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the C-terminus of Gal3, the C-terminal domain of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 isoform 1.
  • the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3 isoform 1, the N-terminal domain of Gal3 isoform 1, amino acids 1-111 of Gal3 isoform 1, the TRD of Gal3 isoform 1, or amino acids 36-109 of Gal3 isoform 1.
  • the anti- Gal3 antibody or binding fragment thereof does not bind to the N-terminus of Gal3 isoform 1, the N-terminal domain of Gal3 isoform 1, amino acids 1-111 of Gal3, the TRD of Gal3 isoform 1, or amino acids 36-109 of Gal3 isoform 1.
  • the anti-Gal3 antibody or binding fragment thereof binds to the C-terminus of Gal3 isoform 1, the C-terminal domain of Gal3 isoform 1, amino acids 112-250 of Gal3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the C-terminus of Gal3 isoform 1, the C-terminal domain of Gal3 isoform 1, amino acids 112-250 of Gal3 isoform 1, or the CRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3 isoform 3, the N-terminal domain of Gal3 isoform 3, amino acids 1-125 of Gal3, the TRD of Gal3 isoform 3, or amino acids 50-123 of Gal3 isoform 3.
  • the anti-Gal3 antibody or binding fragment thereof does not bind to the N-terminus of Gal3 isoform 3, the N-terminal domain of Gal3 isoform 3, amino acids 1-125 of Gal3 isoform 3, the TRD of Gal3, or amino acids 50-123 of Gal3 isoform 3.
  • the anti-Gal3 antibody or binding fragment thereof binds to the C-terminus of Gal3 isoform 3, the C-terminal domain of Gal3 isoform 3, amino acids 126-264 of Gal3 isoform 3, or the CRD of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof does not bind to the C-terminus of Gal3 isoform 3, the C- terminal domain of Gal3 isoform 3, amino acids 126-264 of Gal3 isoform 3, or the CRD of Gal3 isoform 3.
  • the interaction between Gal3 and a cell surface marker can be reduced to less than 80%, less than 75%, less than 70%, less than 60%, less than 59%, less than 50%, less than 40%, less than 34%, less than 30%, less than 20%, less than 14%, less than 10%, less than 7%, less than 5%, less than 4%, or less than 1%.
  • the interaction between Gal3 and the viral protein e.g.
  • SARS-CoV-2 S, E, M, or HE protein can be reduced to less than 80%, less than 75%, less than 70%, less than 60%, less than 59%, less than 50%, less than 40%, less than 34%, less than 30%, less than 20%, less than 14%, less than 10%, less than 7%, less than 5%, less than 4%, or less than 1%.
  • the interaction between Gal3 and the host receptor protein e.g.
  • ACE2 or CD147 can be reduced to less than 80%, less than 75%, less than 70%, less than 60%, less than 59%, less than 50%, less than 40%, less than 34%, less than 30%, less than 20%, less than 14%, less than 10%, less than 7%, less than 5%, less than 4%, or less than 1%.
  • the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a dissociation constant (KD) of less than 1 nM, less than 1.2 nM, less than 2 nM, less than 5 nM, less than 10 nM, less than 13.5 nM, less than 15 nM, less than 20 nM, less than 25 nM, or less than 30 nM.
  • KD dissociation constant
  • the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a K D of less than 1 nM.
  • the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 1.2 nM.
  • the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 2 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a K D of less than 5 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 10 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a K D of less than 13.5 nM. In some embodiments, the anti- Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 15 nM.
  • the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 20 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a K D of less than 25 nM. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to Gal3 with a KD of less than 30 nM. [0149] In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable heavy chain complementarity-determining region 1 (V H -CDR1) sequences illustrated in FIG. 8 (SEQ ID NOs: 27-70).
  • V H -CDR1 variable heavy chain complementarity-determining region 1
  • the anti-Gal3 antibody comprises a VH-CDR1 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 27-70.
  • the anti-Gal3 antibody comprises a V H -CDR1 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 27-70.
  • the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable heavy chain complementarity-determining region 2 (VH-CDR2) sequences illustrated in FIG.9 (SEQ ID NOs: 71-111, 826).
  • VH-CDR2 variable heavy chain complementarity-determining region 2
  • the anti-Gal3 antibody or binding fragment thereof comprises a VH-CDR2 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 71-111, 826.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VH-CDR2 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 71-111, 826.
  • the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable heavy chain complementarity-determining region 3 (VH-CDR3) sequences illustrated in FIG. 10 (SEQ ID NOs: 112-169, 827).
  • the anti- Gal3 antibody or binding fragment thereof comprises a V H -CDR3 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 112-169, 827.
  • the anti-Gal3 antibody or binding fragment thereof comprises a V H -CDR3 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 112-169, 827.
  • the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity-determining region 1 (VL-CDR1) sequences illustrated in FIG. 11 (SEQ ID NOs: 170-220).
  • VL-CDR1 variable light chain complementarity-determining region 1
  • the anti-Gal3 antibody or binding fragment thereof comprises a V L -CDR1 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 170-220.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VL-CDR1 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 170-220.
  • the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity-determining region 2 (V L -CDR2) sequences illustrated in FIG.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VL-CDR2 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 221-247.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VL-CDR2 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 221-247.
  • the anti-Gal3 antibody or binding fragment thereof comprises any one of the variable light chain complementarity-determining region 3 (VL-CDR3) sequences illustrated in FIG.
  • the anti-Gal3 antibody or binding fragment thereof comprises a V L -CDR3 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 248-296.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VL-CDR3 sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 248-296.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region (V H ) and a light chain variable region (V L ).
  • the VH may comprise a VH-CDR1, a VH-CDR2, and/or a VH-CDR3 selected from any of FIG. 8-10.
  • the VL may comprise a VL-CDR1, a VL-CDR2, and/or a V L -CDR3 selected from any of FIG. 11-13.
  • the anti-Gal3 antibody or binding fragment thereof comprises CDRs within the VH and VL sequences as illustrated in FIG. 14. It is understood that an antibody with an antibody name described herein can be referred using a shortened version of the antibody name, as long as there are no conflicts with another antibody described herein.
  • F846C.1B2 can also be referred to as 846C.1B2, or 846.1B2.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region (VH) sequence selected from FIG. 15 (SEQ ID NOs: 297-373, 822, 828).
  • the anti-Gal3 antibody or binding fragment thereof comprises a VH- sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 297-373, 822, 828.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VH- sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 297-373, 822, 828.
  • the anti-Gal3 antibody or binding fragment thereof comprises a light chain variable region (V L ) sequence selected from FIG.
  • the anti-Gal3 antibody or binding fragment thereof comprises a VL sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to any one of SEQ ID NOs: 374-447, 823-825.
  • the anti-Gal3 antibody or binding fragment thereof comprises a V L sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 86%, at least 87%, at least 88%, at least 89%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence similarity to any one of SEQ ID NOs: 374-447, 823-825.
  • the anti-Gal3 antibody or binding fragment thereof comprises a combination of heavy chain variable region and light chain variable region as illustrated in FIG. 17.
  • the anti-Gal3 antibody or binding fragment thereof comprises heavy chain and light chain sequences as illustrated in FIG. 18 (SEQ ID NOs: 448- 538, 830. [0160] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is selected from the group of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C
  • the anti-Gal3 antibody or binding fragment thereof comprises, consists essentially of, or consists of TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5,
  • the anti-Gal3 antibody or binding fragment thereof comprises one or more heavy chain variable region CDRs depicted in FIG. 8-10. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises one or more light chain variable region CDRs depicted in FIG.11-13. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain variable region depicted in FIG.15. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a light chain variable region depicted in FIG. 16. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a combination of heavy chain variable region and light chain variable region depicted in FIG. 17.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain and/or light chain depicted in FIG. 18.
  • the anti- Gal3 antibody or binding fragment thereof can comprise or include any one or more of the sequences provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • the anti-Gal3 antibody or binding fragment thereof can comprise or include any one or more of the sequences provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17 or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater similar thereto.
  • the anti-Gal3 antibody or binding fragment thereof comprises a humanized antibody or binding fragment thereof. In other instances, the anti-Gal3 antibody or binding fragment thereof comprises a chimeric antibody or binding fragment thereof.
  • the anti-Gal3 antibody comprises a full-length antibody or a binding fragment thereof. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a bispecific antibody or a binding fragment thereof. In some embodiments, the anti- Gal3 antibody or binding fragment thereof comprises a monovalent Fab’, a divalent Fab2, a single- chain variable fragment (scFv), a diabody, a minibody, a nanobody, a single-domain antibody (sdAb), or a camelid antibody or binding fragment thereof. [0164] In some embodiments, the anti-Gal3 antibody or binding fragment thereof is a bispecific antibody or binding fragment thereof.
  • bispecific antibody formats include, but are not limited to, Knobs-into-Holes (KiH), Asymmetric Re-engineering Technology- immunoglobulin (ART-Ig), Triomab quadroma, bispecific monoclonal antibody (BiMAb, BsmAb, BsAb, bsMab, BS-Mab, or Bi-MAb), Azymetric, Biclonics, Fab-scFv-Fc, Two-in-one/Dual Action Fab (DAF), FinomAb, scFv-Fc-(Fab)-fusion, Dock-aNd-Lock (DNL), Tandem diAbody (TandAb), Dual-affinity-ReTargeting (DART), nanobody, triplebody, tandems scFv (taFv), triple heads, tandem dAb/VHH, triple dAb/VHH, or tetravalent dAb/VHH.
  • KH Knobs-into-Holes
  • the anti-Gal3 antibody or binding fragment thereof is a bispecific antibody or binding fragment thereof comprising a bispecific antibody format illustrated in FIG.2 of Brinkmann and Kontermann, “The making of bispecific antibodies,” MABS 9(2): 182-212 (2017).
  • the anti-Gal3 antibody or binding fragment thereof can comprise an IgM, IgG (e.g., IgG1, IgG2, IgG3, or IgG4), IgA, or IgE framework.
  • the IgG framework can be IgG1, IgG2, IgG3 or IgG4.
  • the anti-Gal3 antibody or binding fragment thereof comprises an IgG1 framework.
  • the anti-Gal3 antibody or binding fragment thereof comprises an IgG2 framework. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises an IgG4 framework.
  • the anti-Gal3 antibody or binding fragment thereof can further comprise a Fc mutation. [0166] In some embodiments, the Fc region comprises one or more mutations that modulate Fc receptor interactions, e.g., to enhance effector functions such as ADCC and/or CDC.
  • exemplary residues when mutated modulate effector functions include S239, K326, A330, I332, or E333, in which the residue position correspond to IgG1 and the residue numbering is in accordance to Kabat numbering (EU index of Kabat et al 1991 Sequences of Proteins of Immunological Interest) (FIG.19).
  • the one or more mutations comprise S239D, K326W, A330L, I332E, E333A, E333S, or a combination thereof.
  • the one or more mutations comprise S239D, I332E, or a combination thereof.
  • the one or more mutations comprise S239D, A330L, I332E, or a combination thereof. In some embodiments, the one or more mutations comprise K326W, E333S, or a combination thereof. In some embodiments, the mutation comprises E333A.
  • an anti-Gal3 antibody or binding fragment thereof comprises a humanization score of above 70, above 80, above 81, above 82, above 83, above 84, above 85, above 86, above 87, above 88, above 89, above 90, or above 95. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score of above 80.
  • the anti-Gal3 antibody or binding fragment thereof comprises a humanization score of above 83. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score of above 85. In some embodiments, the anti- Gal3 antibody or binding fragment thereof comprises a humanization score of above 87. In some embodiments, the anti-Gal3 antibody or binding fragment thereof comprises a humanization score of above 90.
  • the anti-Gal3 antibody or binding fragment thereof comprises a humanization score of the heavy chain of above 70, above 80, above 81, above 82, above 83, above 84, above 85, above 86, above 87, above 88, above 89, above 90, or above 95, optionally above 80, above 85, or above 87.
  • the anti-Gal3 antibody or binding fragment thereof comprises a humanization score of the light chain of above 70, above 80, above 81, above 82, above 83, above 84, above 85, above 86, above 87, above 88, above 89, above 90, or above 95, optionally above 80, above 83, or above 85.
  • the proteins comprise one or more of SEQ ID NOs: 170-533. In some embodiments, the proteins comprise a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to one or more of SEQ ID NOs: 170-533. In some embodiments, the proteins comprise a sequence having at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to any one or more sequences of SEQ ID NOs: 170-533.
  • the proteins comprise six sequences selected from each of SEQ ID NOs: 170-220; SEQ ID NOs: 221-247; SEQ ID NOs: 248-296; SEQ ID NOs: 27-70; SEQ ID NOs: 71-111, 826; and SEQ ID NOs: 112-169, 827. In some embodiments, the proteins comprise two sequences selected from each of SEQ ID NOs: 374-447, 823-825 and SEQ ID NOs: 297-373, 822, 828. In some embodiments, the proteins comprise two sequences selected from each of SEQ ID NOs: 495-538, 830 and SEQ ID NOs: 448-494, 829.
  • the proteins comprise any one or more sequences selected from the groups of SEQ ID NOs: 170-220; SEQ ID NOs: 221- 247; SEQ ID NOs: 248-296; SEQ ID NOs: 27-70; SEQ ID NOs: 71-111, 826; SEQ ID NOs: 112-169, 827; SEQ ID NOs: 374-447, 823-825; SEQ ID NOs: 297-373, 822, 828; SEQ ID NOs: 495-538, 830; SEQ ID NOs: 448-494, 829.
  • the proteins comprise any one or more of the sequences depicted in FIGs. 8-18.
  • the protein comprises one or more sequences defined by a consensus sequence.
  • the consensus sequences provided herein have been derived from the alignments of CDRs depicted in FIG.33A-B. However, it is envisioned that alternative alignments may be done (e.g. using global or local alignment, or with different algorithms, such as Hidden Markov Models, seeded guide trees, Needleman-Wunsch algorithm, or Smith-Waterman algorithm) and as such, alternative consensus sequences can be derived.
  • the protein comprises a sequence defined by the formula X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 X 17 , where X 1 is no amino acid or R; X 2 is no amino acid or S; X3 is no amino acid, S, or T; X4 is no amino acid, E, G, K, Q, or R; X5 is no amino acid, A, D, G, I, N, or S; X 6 is no amino acid, I, L, or V; X 7 is no amino acid, F, L, S, or V; X 8 is no amino acid, D, E, H, N, S, T, or Y; X9 is no amino acid, D, E, I, K, N, R, S, T, or V; X10 is no amino acid, D, H, N, R, S, or Y; X11 is
  • the protein comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the protein comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the protein comprises a sequence defined by the formula X1X2X3X4X5X6X7X8, where X1 is no amino acid, K, L, N, Q, or R; X2 is no amino acid, A, L, M, or V; X3 is no amino acid, C, K, or S; X4 is no amino acid or T; X5 is no amino acid, A, E, F, G, H, K, Q, R, S, W, or Y; X 6 is no amino acid, A, G, or T; X 7 is no amino acid, I, K, N, S, or T; X 8 is no amino acid, N, or S.
  • the protein comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the protein comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the protein comprises a sequence defined by the formula X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 , where X 1 is no amino acid, A, E, F, H, L, M, Q, S, V, or W; X 2 is A, H, or Q; X 3 is D, F, G, H, L, M, N, Q, S, T, W, or Y; X 4 is no amino acid or W; X 5 is A, D, I, K, L, N, Q, R, S, T, V, or Y; X6 is D, E, H, I, K, L, N, Q, S, or T; X7 is D, F, K, L, N, P, S, T, V, W, or Y; X8 is H, P, or S; X9 is F, L, P, Q, R, T, W, or Y; X10 is no amino acid
  • the protein comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the protein comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the protein comprises a sequence defined by the formula X1X2X3X4X5X6X7X8X9X10, where X1 is E, G, or R; X2 is F, N, or Y; X3 is A, I, K, N, S, or T; X4 is F, I, or L; X 5 is I, K, N, R, S, or T; X 6 is D, G, I, N, S, or T; X 7 is F, G, H, S, or Y; X 8 is no amino acid, A, D, G, I, M, N, T, V, W, or Y; X 9 is no amino acid, M, or Y; X 10 is no amino acid or G; In some embodiments, the protein comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,
  • the protein comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the protein comprises a sequence defined by the formula X 1 X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 , where X 1 is no amino acid, I, or L; X 2 is no amino acid or R; X 3 is no amino acid, F, I, L, or V; X4 is A, D, F, H, K, L, N, S, W, or Y; X5 is A, D, P, S, T, W, or Y; X6 is D, E, G, H, K, N, S, V, or Y; X7 is D, E, G, N, S, or T; X8 is D, G, I, K, N, Q, R, S, V, or Y; X9 is A, D, E, G, I, K, N, P, S, T
  • the protein comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence. In some embodiments, the protein comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • the protein comprises a sequence defined by the formula X1X2X3X4X5X6X7X8X9X10X11X12X13X14X15X16X17X18X19X20X21X22X23X24X25, where X1 is no amino acid or A; X2 is no amino acid, A, R, or Y; X3 is no amino acid, A, F, H, K, L, R, S, or V; X 4 is no amino acid, A, D, K, N, R, S, or T; X 5 is no amino acid, A, D, G, H, I, L, N, P, R, S, T, V, or Y; X6 is no amino acid, A, D, G, H, K, N, P, Q, R, S, or Y; X7 is no amino acid, D, F, G, H, P, R, S, W, or Y; X8 is no amino acid, A, D, E
  • the protein comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to this consensus sequence.
  • the protein comprises a sequence having 0, 1, 2, 3, 4, 5, or 6 substitutions from this consensus sequence.
  • Exemplary Pharmaceutical Formulations [0176]
  • a pharmaceutical formulation for treating a disease as described herein can comprise an anti-Gal3 antibody or binding fragment thereof described supra.
  • the anti-Gal3 antibody or binding fragment thereof can be formulated for systemic administration.
  • the anti-Gal3 antibody or binding fragment thereof can be formulated for parenteral administration.
  • an anti-Gal3 antibody or binding fragment thereof is formulated as a pharmaceutical composition for administration to a subject by, but not limited to, parenteral (e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular), oral, intranasal, buccal, rectal, or transdermal administration routes.
  • parenteral e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular
  • parenteral e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular
  • the pharmaceutical composition describe herein is formulated for systemic administration. In other instances, the pharmaceutical composition describe herein is formulated for oral administration. In still other instances, the pharmaceutical composition describe herein is formulated for intranasal administration. [0178] In some embodiments, the pharmaceutical compositions further include pH adjusting agents or buffering agents which include acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
  • bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-hydroxymethylaminomethane
  • buffers such as citrate/dextrose, sodium bicarbonate
  • the pharmaceutical compositions include one or more salts in an amount required to bring osmolality of the composition into an acceptable range.
  • salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
  • the pharmaceutical compositions further include diluent which are used to stabilize compounds because they can provide a more stable environment.
  • Salts dissolved in buffered solutions are utilized as diluents in the art, including, but not limited to a phosphate buffered saline solution.
  • diluents increase bulk of the composition to facilitate compression or create sufficient bulk for homogenous blend for capsule filling.
  • Such compounds can include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel ® ; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac ® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose- based diluents, confectioner’s sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine, kaolin; mannitol, sodium chloride; inositol, bentonite, and the like.
  • the pharmaceutical formulations include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multiparticulate formulations (e.g., nanoparticle formulations), and mixed immediate and controlled release formulations.
  • the pharmaceutical formulation can further comprise an additional therapeutic agent.
  • Non-limiting examples of additional therapeutic agents include alpha-glucosidase inhibitors, including acarbose (Precose ® ) and miglitol (Glyset ® ); biguanides, including metformin-alogliptin (Kazano ® ), metformin-canagliflozin (Invokamet ® ), metformin- dapagliflozin (Xigduo ® XR), metformin-empagliflozin (Synjardy ® ), metformin-glipizide, metformin-glyburide (Glucovance ® ), metformin-linagliptin (Jentadueto ® ), metformin- pioglitazone (Actoplus ® ), metformin-repaglinide (PrandiMet ® ), metformin-rosiglitazone (Avandamet ® ), metformin-saxagliptin
  • the pharmaceutical antibody formulations can be used for therapeutic applications.
  • the pharmaceutical antibody formulations comprise a therapeutically effective amount of an antibody, such as an anti-Gal3 antibody.
  • the antibody is any of the anti-Gal3 antibodies disclosed herein or otherwise known in the art, such as those described in WO 2020/160156.
  • the pharmaceutical antibody formulations may also comprise one or more excipients, diluents, salts, buffers, and the like, which confer desirable properties to the formulation, such as improved stability, reduction in aggregation, and modulation of isotonicity and pH.
  • excipients, diluents, salts, buffers, and the like generally known in the art can be used in the pharmaceutical antibody formulations disclosed herein and/or can be used as an acceptable substitute for any of the excipients, diluents, salts, buffers, and the like used in the pharmaceutical antibody formulations disclosed herein, and determining an optimal formulation of excipients, diluents, salts, buffers, and the like is within the ability of one skilled in the art.
  • excipients may be adjusted for the treatment of a certain disease, such as a coronavirus infection, or inflammation associated with said disease, and/or optimized to improve the stability of the pharmaceutical antibody formulations under storage.
  • a certain disease such as a coronavirus infection, or inflammation associated with said disease
  • pharmaceutical antibody formulations comprising an antibody and one or more excipients.
  • the one or more excipients may be used to improve stability of the anti-Gal3 antibody under storage conditions and/or improve biocompatibility when administered to a subject.
  • the one or more excipients may comprise small molecules, amino acids, peptides, proteins, nucleic acids, DNA, RNA, lipids, ionic compounds, salts, carbohydrates, sugars, sugar alcohols, acids, bases, surfactants, detergents, or other excipients known in the art.
  • the pharmaceutical antibody formulations are at a specific pH that improves stability of the anti-Gal3 antibody under storage conditions and/or improve biocompatibility when administered to a subject.
  • the one or more excipients are used to adjust the pH to the desired level.
  • the pH of the pharmaceutical antibody formulations are adjusted after addition of the one or more excipients to the desired pH (e.g.
  • the pharmaceutical antibody formulations may be acidic, basic, or neutral.
  • the antibody is an anti-Gal3 antibody.
  • the one or more excipients comprise one or more amino acids, one or more salts, one or more surfactants, or any combination thereof.
  • the one or more amino acids may comprise alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, valine, or any combination thereof.
  • the one or more amino acids used as excipients may be L-stereoisomers or D-stereoisomers.
  • the one or more amino acids may be in the form of small peptides, such as dipeptides, tripeptides, tetrapeptides, or more.
  • the pharmaceutical antibody formulations comprise histidine or methionine, or both.
  • the histidine or methionine, or both are L-stereoisomers or D-stereoisomers.
  • Other amino acids either as substitutes of histidine or methionine, or both, or in addition to histidine or methionine, or both, are also envisioned in some embodiments, depending on the desired properties conferred to the formulations, such as improved stability, pH adjustment, and compatibility to the intended subject.
  • Some non-limiting embodiments of pharmaceutical antibody formulations may comprise 1) histidine and methionine, 2) histidine and any one or more other amino acids, 3) methionine and any one or more other amino acids, 4) one or more amino acids other than histidine and methionine (e.g. one or more of arginine, glycine, or glutamate), or 5) histidine, methionine, and one or more other amino acids (e.g. one or more of arginine, glycine, or glutamate).
  • the antibody is an anti-Gal3 antibody.
  • the one or more excipients comprise one or more salts.
  • the one or more salts may comprise salts conventionally used as excipients.
  • the one or more salts may comprise chloride salts, phosphate salts, carbonate salts, bicarbonate salts, citrate salts, ascorbate salts, acetate salts, succinate salts, Tris salts, borate salts, sulfate salts, ammonia salts, metal salts, sodium salts, potassium salts, calcium salts, magnesium salts, organic salts, amino acid salts, nucleic acid salts, aromatic salts, low solubility salts, and the like, including any disclosed throughout the present disclosure.
  • salts as an excipient includes but is not limited to improving stability and reducing aggregation of an antibody, equalizing ionic charges for other components in the formulation, adjusting solubility of other components in the formulation, adjusting pH and isotonicity, and improving biocompatibility for administration to a subject.
  • Exemplary pharmaceutical antibody formulations disclosed herein comprise NaCl.
  • alternative salts may also be used, either instead of NaCl or in addition to NaCl, including but not limited to those provided herein, such as other chloride salts, other sodium salts, ascorbate salts, acetate salts, phosphate salts, citrate salts, Tris salts, or succinate salts, or those otherwise known in the art.
  • the antibody is an anti-Gal3 antibody.
  • the one or more excipients comprise one or more surfactants.
  • the one or more surfactants may comprise surfactants conventionally used as excipients.
  • the one or more surfactants may include polysorbate, polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, oils, poloxamers, poloxamer 188, polyglycosides, cetyl alcohol, cocamides, stearates, laurates, nonoxynols, octoxynols, or other surfactants generally known in the art and used as excipients, including any disclosed throughout the present disclosure.
  • the surfactants may also act as wetting agents, detergents, or emulsifying agents, depending on the specific surfactant and the intended purpose.
  • exemplary pharmaceutical antibody formulations disclosed herein comprise a polysorbate.
  • the polysorbate may be polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80, or any combination thereof.
  • the polysorbate is polysorbate 80.
  • alternative surfactants may also be used, either instead of the polysorbate, or in addition to the polysorbate, including but not limited to those provided herein, such as poloxamer 188, or those otherwise known in the art.
  • the antibody is an anti-Gal3 antibody.
  • the one or more excipients may also comprise one or more sugars or sugar alcohols.
  • the one or more sugars or sugar alcohols include those conventionally used as excipients.
  • the sugars include but are not limited to erythrose, arabinose, ribose, deoxyribose, xylose, galactose, glucose (dextrose), fructose, isomaltose, lactose, maltose, sucrose, trehalose, maltodextrin, chitosan, dextrin, dextran, dextran 40, cellulose, or starch, or other sugars generally known in the art and used as excipients, including any disclosed throughout the present disclosure.
  • the sugar alcohols include but are not limited to glycerol, erythritol, arabitol, xylitol, ribitol, deoxyribitol, mannitol, sorbitol, galactitol, isomalt, maltitol, or lactitol, or other sugar alcohols generally known in the art and used as excipients, including any disclosed throughout the present disclosure.
  • the purpose of these sugars and sugar alcohols in the pharmaceutical antibody formulations may include but are not limited to improving the stability and preventing aggregation of the antibody.
  • Exemplary pharmaceutical antibody formulations disclosed herein may comprise a sugar or a sugar alcohol, or both.
  • exemplary pharmaceutical antibody formulations comprise sucrose and/or mannitol.
  • alternative sugars and sugar alcohols may be used, either instead of the sucrose and/or mannitol, or in addition to the sucrose and/or mannitol, including but not limited to those provided herein, such as sorbitol, trehalose, dextrose, dextran, or dextran 40.
  • formulations that are intended for subcutaneous use comprise any one or more of the sugars or sugar alcohols disclosed herein, including sucrose and/or mannitol.
  • formulations that are intended for intravenous use might not comprise any one or more of the sugars or sugar alcohols disclosed herein, including sucrose and/or mannitol.
  • the antibody is an anti- Gal3 antibody.
  • the pharmaceutical antibody formulations comprise an antibody.
  • the antibody is an anti-Gal3 antibody.
  • the anti-Gal3 antibody is any one of the anti-Gal3 antibodies disclosed herein, or otherwise known in the art, such as those disclosed in WO 2020/160156.
  • the anti-Gal3 antibody may be a full length antibody, an Fab fragment, an F(ab’) 2 fragment, an scFv, an sdAb, a monovalent fragment, or any other modified antibody known in the art, including bispecific, trispecific, and other multi-specific variants.
  • the anti-Gal3 antibody will generally comprise complementarity-determining regions (CDRs).
  • the anti-Gal3 antibody may comprise a heavy chain CDR1 (V H - CDR1), heavy chain CDR2 (VH-CDR2), heavy chain CDR3 (VH-CDR3) and/or light chain CDR1 (VL-CDR1), light chain CDR2 (VL-CDR2), or light chain CDR3 (VL-CDR3), or any combination thereof.
  • V H - CDR1 heavy chain CDR1
  • VH-CDR2 heavy chain CDR2
  • VH-CDR3 VH-CDR3
  • VL-CDR1 light chain CDR1
  • VL-CDR2 light chain CDR2
  • VL-CDR3 VL-CDR3
  • the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249.
  • exemplary CDR sequences are depicted in FIGs.8-13.
  • each CDR can have up to 1, 2, 3, 4, or 5 amino acids changed from the recited sequence.
  • each CDR can have a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to those depicted in FIGs. 8-13. In some embodiments, each CDR can have a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to those depicted in FIGs. 8-13.
  • the anti-Gal3 antibody comprises a VH having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298. In some embodiments, the anti-Gal3 antibody comprises a VH having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 298.
  • the anti-Gal3 antibody comprises a VL having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375. In some embodiments, the anti-Gal3 antibody comprises a VL having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 375.
  • the pharmaceutical antibody formulations may comprise one or more excipients. In some embodiments, the one or more excipients are present in amounts that are optimized for a certain disease or disorder, to improve stability and/or biocompatibility when administered to a subject.
  • the one or more excipients may be present in a concentration that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111
  • the one or more excipient may also be present in a concentration that is at least 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%, or any combination within a range within any two of the aforementioned concentrations.
  • the pharmaceutical antibody formulations further comprise one or more amino acids, one or more salts, or one or more surfactants (which may make up the one or more excipients).
  • the one or more amino acids, one or more salts, and one or more surfactants may be any one of the amino acids, salts, and surfactants disclosed herein.
  • the one or more amino acids are present at 10 to 50 mM or about 10 to about 50 mM.
  • the one or more amino acids are present at 20 mM or about 20 mM.
  • the one or more salts are present at 50 to 150 mM or about 50 to about 150 mM.
  • the one or more salts are present at 100 mM or about 100 mM.
  • the one or more surfactants are present at 0.01% to 0.04% or about 0.01% to about 0.04%.
  • the one or more surfactants are present at 0.02% or about 0.02%.
  • the formulation is at a pH between 5.3 and 6.3. In some embodiments, the formulation is at a pH of 5.8 or about 5.8.
  • the antibodies comprise one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a VL sequence, a VH sequence, a VL/VH pairing, and/or V L -CDR1, V L -CDR2, V L -CDR3, V H -CDR1, V H -CDR2, V H - CDR3 (including 1, 2, 3, 4, or 5 amino acid substitutions of any one or more of these CDRs) set from the heavy chain and light chain sequences as depicted in FIG. 18.
  • the pharmaceutical antibody formulations comprise an antibody.
  • the antibody is an anti-Gal3 antibody.
  • the anti-Gal3 antibody is any one of the anti-Gal3 antibodies disclosed herein, or otherwise known in the art, such as those disclosed in WO 2020/160156.
  • the antibody comprises V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249.
  • exemplary CDR sequences are depicted in FIGs. 8-13.
  • each CDR can have up to 1, 2, 3, 4, or 5 amino acids changed from the recited sequence.
  • the anti-Gal3 antibody comprises a VH having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298. In some embodiments, the anti-Gal3 antibody comprises a VH having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 298. In some embodiments, the anti-Gal3 antibody comprises having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375.
  • the anti-Gal3 antibody comprises having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 375.
  • the pharmaceutical antibody formulations further comprise one or more amino acids, one or more salts, or one or more surfactants.
  • the one or more amino acids comprise histidine and/or methionine
  • the one or more salts comprise sodium chloride (NaCl)
  • the one or more surfactants comprise a polysorbate, or any combination thereof.
  • the pharmaceutical antibody formulations comprise histidine, methionine, NaCl, or polysorbate, or any combination thereof, including all of histidine, methionine, NaCl, and polysorbate.
  • the histidine may be L-histidine.
  • the L-histidine is present at 10 to 50 mM or about 10 to about 50 mM, or any amount or concentration envisioned herein.
  • the L-histidine is present at 20 mM or about 20 mM.
  • the methionine is present at 2 to 10 mM or about 2 to about 10 mM, or any amount or concentration envisioned herein.
  • the methionine is present at 5 mM or about 5 mM.
  • the NaCl is present at 50 to 150 mM or about 50 to about 150 mM, or any amount or concentration envisioned herein.
  • the NaCl is present at 100 mM or about 100 mM.
  • the polysorbate comprises polysorbate-20, polysorbate-40, polysorbate-60, polysorbate-80, or any combination thereof.
  • the polysorbate is or comprises polysorbate-80.
  • the polysorbate-80 is present at 0.01% to 0.04% or about 0.01% to about 0.04%, or any amount or concentration envisioned herein.
  • the polysorbate- 80 is present at 0.02% or about 0.02%.
  • the formulation is at a pH between 5.3 and 6.3. In some embodiments, the formulation is at a pH of 5.8 or about 5.8.
  • the antibodies comprise one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a VL sequence, a VH sequence, a VL/VH pairing, and/or VL-CDR1, VL-CDR2, V L -CDR3, V H -CDR1, V H -CDR2, V H -CDR3 (including 1, 2, 3, 4, or 5 amino acid substitutions of any one or more of these CDRs) set from the heavy chain and light chain sequences as depicted in FIG.18.
  • the formulation includes one or more of: Polysorbate 80, Polysorbate 20, Poloxamer 188, Mannitol, Sorbitol, Sucrose, Trehalose, Dextrose, Dextran 40, NaCl, Arginine, Glycine, Methionine, Ascorbic acid, NaOAc, Phosphate, Citrate, Acetate, Tris, Succinate, Histidine.
  • pharmaceutical antibody formulations are provided.
  • the formulations can include a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, histidine, methionine, NaCl, and polysorbate.
  • the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID
  • the formulation can be at a pH between 5.3 and 6.3, which may or may not be accomplished by the addition of the histidine, methionine, NaCl, and/or polysorbate.
  • the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298.
  • the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 298.
  • the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375. In some embodiments, the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 375.
  • the formulation can also include additional ingredients and/or excipients to those listed, or exclude one or more of the positively recited options. In some embodiments, the ingredients and/or excipients can be replaced or used additionally with one or more alternatives that function to achieve the same result.
  • the histidine can be replaced with an alternative buffer with an appropriate pKa. In some embodiments, the histidine can be replaced with an alternative that has the same buffer capacity. In some embodiments, the histidine can be replaced with another amino acid. In some embodiments, the histidine can be replaced with an alternative that exhibits the same or similar antibody protective effects. In some embodiments, the histidine can be replaced with an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the histidine can be replaced with an alternative that has the same or similar cryoprotective capabilities. In some embodiments, the methionine can be replaced with an alternative buffer with an appropriate pKa.
  • the methionine can be replaced with an alternative that has the same buffer capacity. In some embodiments, the methionine can be replaced with another amino acid. In some embodiments, the methionine can be replaced with an alternative that has the same or similar antioxidant effects. In some embodiments, the methionine can be replaced with an alternative that has the same antibody protective effects. In some embodiments, the methionine can be replaced by an alternative that has the same or similar protein stabilization effects. In some embodiments, the methionine can be replaced by an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternatives for histidine and/or methionine may be any of those provided herein, such as arginine or glycine, or otherwise known in the art.
  • the NaCl can be replaced with another salt.
  • the NaCl can be replaced with an alternative that has the same or similar aqueous solubility.
  • the NaCl can be replaced with an alternative that has the same or similar effect on formulation isotonicity.
  • the NaCl can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternative for NaCl may be any of those provided herein, such as other chloride salts, other sodium salts, ascorbate salts, acetate salts, phosphate salts, citrate salts, Tris salts, or succinate salts, or otherwise known in the art.
  • the polysorbate can be replaced with another surfactant and/or detergent.
  • the polysorbate can be replaced with an alternative that has the same or similar surfactant ability/effect.
  • the polysorbate can be replaced with an alternative that has the same or similar capability for solubilizing antibodies and/or other excipients.
  • the polysorbate can be replaced with an alternative that has the same or similar capacity to reduce aggregation of the antibody.
  • the polysorbate can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternative for polysorbate may be any of those provided herein, such as poloxamer 188, or otherwise known in the art.
  • the pH can be acidic, basic, or neutral.
  • the pH can be basic.
  • the pH can be varied.
  • the pH can be increased or decreased in line with the ingredients, excipients, and/or buffers used in the formulation and the particulars of the antibody species used and/or the amount of antibody, ingredients, or excipients used.
  • the pH can be increased or decreased to a desired pH after adding the antibody, ingredients, or excipients.
  • the alternatives contemplated herein may be any one or more of the excipients, diluents, salts, buffers, and the like, provided throughout the disclosure.
  • the histidine is L-histidine, D-histidine, or racemic histidine.
  • the histidine is racemic histidine.
  • the histidine is D-histidine.
  • the histidine can be replaced with an alternative buffer with an appropriate pKa. In some embodiments, the histidine can be replaced with an alternative that has the same buffer capacity. In some embodiments, the histidine can be replaced with another amino acid. In some embodiments, the histidine can be replaced with an alternative that exhibits the same or similar antibody protective effects. In some embodiments, the histidine can be replaced with an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the histidine can be replaced with an alternative that has the same or similar cryoprotective capabilities, including alternatives that may exhibit any one or more of the properties provided herein.
  • histidine may be any of those provided herein, such as arginine or glycine, or otherwise known in the art.
  • the histidine may be present in a concentration that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94,
  • the histidine is present at 10 to 50 mM, e.g.10, 15, 20, 25, 30, 35, 40, 45, or 50 mM. In some embodiments, the histidine is present at 20 mM or about 20 mM. In some embodiments, where the histidine is L-histidine, the L-histidine is present at 10 to 50 mM, e.g.10, 15, 20, 25, 30, 35, 40, 45, or 50 mM. In some embodiments, where the histidine is L-histidine, the L-histidine is present at 20 mM or about 20 mM.
  • the methionine is L-methionine, D-methionine, or racemic methionine.
  • the methionine is racemic methionine.
  • the methionine is D-methionine.
  • the methionine can be replaced with an alternative buffer with an appropriate pKa.
  • the methionine can be replaced with an alternative that has the same buffer capacity.
  • the methionine can be replaced with another amino acid.
  • the methionine can be replaced with an alternative that has the same or similar antioxidant effects. In some embodiments, the methionine can be replaced with an alternative that has the same antibody protective effects. In some embodiments, the methionine can be replaced by an alternative that has the same or similar protein stabilization effects. In some embodiments, the methionine can be replaced by an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternatives for methionine may be any of those provided herein, such as arginine or glycine, or otherwise known in the art.
  • the methionine may be present in a concentration that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106,
  • the methionine is present at 2 to 10 mM, e.g.2, 3, 4, 5, 6, 7, 8, 9, or 10 mM. In some embodiments, the methionine is present at 5 mM or about 5 mM.
  • the NaCl may be present in a concentration that is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84
  • the NaCl is present at 50 to 150 mM, e.g. 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 mM. In some embodiments, the NaCl is present at 100 mM. In some embodiments, the NaCl can be replaced with another salt. In some embodiments, the NaCl can be replaced with an alternative that has the same or similar aqueous solubility. In some embodiments, the NaCl can be replaced with an alternative that has the same or similar effect on formulation isotonicity. In some embodiments, the NaCl can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit any one or more of the properties provided herein.
  • the polysorbate comprises polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or any combination thereof. In some embodiments, the polysorbate comprises, consists essentially of, or consists of polysorbate 80.
  • the polysorbate may be present in a concentration that is at least 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%, or any combination within a range within any two of the aforementioned concentrations.
  • the polysorbate is present at 0.01% to 0.04%, e.g.0.01%, 0.02%, 0.03%, or 0.04%. In some embodiments, the polysorbate is present at about 0.01% to about 0.04%, e.g. about 0.01%, about 0.02%, about 0.03%, or about 0.04%. In some embodiments, the polysorbate is present at 0.02% or about 0.02%. In some embodiments, where the polysorbate is polysorbate 80, the polysorbate 80 is present at 0.01% to 0.04%, e.g. 0.01%, 0.02%, 0.03%, or 0.04%.
  • the polysorbate 80 is present at about 0.01% to about 0.04%, e.g. about 0.01%, about 0.02%, about 0.03%, or about 0.04%. In some embodiments, the polysorbate 80 is present at 0.02% or about 0.02%. In some embodiments, the polysorbate can be replaced with another surfactant and/or detergent. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar surfactant ability/effect. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar capability for solubilizing antibodies and/or other excipients.
  • the polysorbate can be replaced with an alternative that has the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternative for polysorbate may be any of those provided herein, such as poloxamer 188, or otherwise known in the art.
  • the pH is about 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, or 6.3. In some embodiments, the pH is about 5.8. In some embodiments, the pH is 5.8.
  • the pH can be acidic, basic, or neutral. In some embodiments, the pH can be varied. In some embodiments, the pH can be increased or decreased in line with the ingredients, excipients, and/or buffers used in the formulation and the particulars of the antibody species used and/or the amount of antibody, ingredients, or excipients used. In some embodiments, the pH can be increased or decreased to a desired pH after adding the antibody, ingredients, or excipients.
  • the formulations further comprise one or more sugars or one or more sugar alcohols, or both, such as the sugars or sugar alcohols disclosed herein or otherwise known in the art. In some embodiments, the one or more sugars comprises sucrose.
  • the one or more sugar alcohols comprise mannitol.
  • the formulations comprise sucrose or mannitol, or both.
  • the formulations comprise sucrose and mannitol.
  • the sucrose and/or mannitol can be replaced with another sugar and/or sugar alcohol.
  • the sucrose and/or mannitol can be replaced with an alternative that has the same or similar antibody protective effects.
  • the sucrose and/or mannitol can be replaced with an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody.
  • the sucrose and/or mannitol can be replaced with an alternative that has the same or similar cryoprotective capabilities.
  • sucrose and/or mannitol can be replaced with an alternative that have the same effect on isotonicity, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternative for sucrose and/or mannitol may be any of those provided herein, such as sorbitol, trehalose, dextrose, dextran, or dextran 40, or otherwise known in the art.
  • the one or more sugars or one or more sugar alcohols may be present in a concentration that is at least 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, or 20%, or any combination within a range within any two of the aforementioned concentrations.
  • the one or more sugars or one or more sugar alcohols are present at 2% to 5%, e.g. 2%, 3%, 4%, or 5%. In some embodiments, the one or more sugars or one or more sugar alcohols are present at about 2% to about 5%, e.g. about 2%, about 3%, about 4%, or about 5%. In some embodiments where the sugar is sucrose, the sucrose is present at 2% to 5% or about 2% to 5%. In some embodiments where the sugar alcohol is mannitol, the mannitol is present at 2% to 5% or about 2% to 5%.
  • the formulation is configured for parenteral administration.
  • the formulation is configured for subcutaneous administration.
  • the formulation may comprise one or more sugars and/or one or more sugar alcohols.
  • the formulation configured for subcutaneous administration comprises sucrose or mannitol, or both.
  • the formulation is configured for intravenous administration.
  • the formulation may not comprise one or more sugars and/or one or more sugar alcohols.
  • the formulation configured for intravenous administration does not comprise sucrose or mannitol, or both.
  • the antibody may be present at an amount that is or is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, or 60 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts. In some embodiments, the antibody is present at an amount of 1 to 50 mg as a unit dose.
  • the antibody is present at an amount of one of: 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts. In some embodiments, the antibody is present at an amount of 1 mg. In some embodiments, the antibody is present at an amount of 5 mg. In some embodiments, the antibody is present at an amount of 10 mg. In some embodiments, the antibody is present at an amount of 20 mg. In some embodiments, the antibody is present at an amount of 40 mg. In some embodiments, the antibody is present at an amount of 50 mg.
  • the antibody is present in the formulation at a concentration of one of: 1 mg/mL, 5 mg/mL, 10 mg/mL, 20 mg/mL, 40 mg/mL, or 50 mg/mL, or any concentration within a range defined by any two of the aforementioned concentrations. In some embodiments, the antibody is present at a concentration of 1 mg/mL. In some embodiments, the antibody is present at a concentration of 5 mg/mL. In some embodiments, the antibody is present at a concentration of 10 mg/mL. In some embodiments, the antibody is present at a concentration of 20 mg/mL. In some embodiments, the antibody is present at a concentration of 40 mg/mL.
  • the antibody is present at a concentration of 50 mg/mL.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is one of: 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is 1 mg as a unit dose.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is 5 mg as a unit dose.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is 10 mg as a unit dose.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is 20 mg as a unit dose.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is 40 mg as a unit dose.
  • L-histidine is present at about 20 mM
  • methionine is present at about 5 mM
  • NaCl is present at about 100 mM
  • polysorbate 80 is present at about 0.02%
  • sucrose is present at 2-5%
  • mannitol is present at 2-5%
  • the pH of the formulation is about 5.8, and the therapeutically effective amount of the antibody is 50 mg as a unit dose.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody.
  • the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249.
  • the antibody is present at an amount as a unit dose of: 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, or any amount as a unit dose within a range defined by any two of the aforementioned amounts.
  • the antibody is present at an amount of 1 mg. In some embodiments, the antibody is present at an amount of 5 mg. In some embodiments, the antibody is present at an amount of 10 mg. In some embodiments, the antibody is present at an amount of 20 mg. In some embodiments, the antibody is present at an amount of 40 mg. In some embodiments, the antibody is present at an amount of 50 mg.
  • the pharmaceutical antibody formulation further comprises L- histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02%. In some embodiments, the pH of the formulation is about 5.8. In some embodiments, the pharmaceutical antibody formulation further comprises sucrose and/or mannitol.
  • sucrose is present in the formulation at 2-5%. In some embodiments, mannitol is present in the formulation at 2-5%.
  • the formulation is configured for parenteral administration. In some embodiments, the formulation is configured for subcutaneous administration. In some embodiments, the formulation configured for subcutaneous administration comprises sucrose or mannitol, or both. In some embodiments, the formulation is configured for intravenous administration. In some embodiments, the formulation configured for intravenous administration does not comprise sucrose or mannitol, or both.
  • the pharmaceutical antibody formulation is prepared at a concentration of antibody that is or is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 mg/mL, or any concentration within a range defined by any
  • the pharmaceutical antibody formulation is prepared at a concentration of 0.3, 0.8, 2.8, 8.4, or 10 mg/mL, or about 0.3, about 0.8, about 2.8, about 8.4, or about 10 mg/mL. In some embodiments, the pharmaceutical antibody formulation is prepared at a concentration of 20 mg/mL or about 20 mg/mL. In some embodiments, the pharmaceutical antibody formulation is prepared at a concentration of 50 mg/mL or about 50 mg/mL. [0208] As applied to any of the embodiments disclosed herein, the pharmaceutical antibody formulation remains at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% stable over 3 months.
  • the pharmaceutical antibody formulation remains at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% stable over 3 months at either 5°C or 25°C/60% relative humidity (RH).
  • the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298.
  • the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 298.
  • the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375. In some embodiments, the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 375.
  • the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298, and wherein the antibody comprises a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375.
  • the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 298, and wherein the antibody comprises a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 375.
  • the antibody comprises a VH region having a sequence of SEQ ID NO: 298. In some embodiments, the antibody comprises a VL region having a sequence of SEQ ID NO: 375. In some embodiments, the antibody comprises a VH region having a sequence of SEQ ID NO: 298, and wherein the antibody comprises a VL region having a sequence of SEQ ID NO: 375. In some embodiments, the antibody comprises a heavy chain (HC) having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 449.
  • HC heavy chain
  • the antibody comprises a heavy chain (HC) having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 449.
  • the antibody comprises a light chain (LC) having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 496.
  • the antibody comprises a light chain (LC) having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 496.
  • the antibody comprises an HC having a sequence of SEQ ID NO: 449.
  • the antibody comprises an LC having a sequence of SEQ ID NO: 496.
  • the antibody is TB006 (4A11.H3L1, IMT006a, IMT006-5).
  • the % identity or % similarity of two sequences is well understood in the art and can be calculated by the number of conserved or similar amino acids or nucleotides relative to the length of the sequences.
  • the antibody or a component thereof is encoded by one or more nucleic acids.
  • the antibody comprises a VH that is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 540. In some embodiments, the antibody comprises a VL that is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 622. In some embodiments, the antibody comprises a VH that is encoded by a nucleic acid sequence of SEQ ID NO: 540. In some embodiments, the antibody comprises a VL that is encoded by a nucleic acid sequence of SEQ ID NO: 622.
  • the antibody comprises an HC that is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 704. In some embodiments, the antibody comprises an LC that is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 751. In some embodiments, the antibody comprises an HC that is encoded by a nucleic acid sequence of SEQ ID NO: 704. In some embodiments, the antibody comprises an LC that is encoded by a nucleic acid sequence of SEQ ID NO: 751.
  • the pharmaceutical formulations include, but are not limited to, aqueous liquid dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multi-particulate formulations (e.g., nanoparticle formulations), and mixed immediate and controlled release formulations.
  • aqueous liquid dispersions self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solid dosage forms, powders, immediate release formulations, controlled release formulations, fast melt formulations, tablets, capsules, pills, delayed release formulations, extended release formulations, pulsatile release formulations, multi-particulate formulations (e.g., nanoparticle formulations), and mixed immediate and controlled release formulations.
  • the pharmaceutical formulations further include pH adjusting agents or buffering agents which include acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids; bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-(hydroxymethyl)aminomethane; and buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • acids such as acetic, boric, citric, lactic, phosphoric and hydrochloric acids
  • bases such as sodium hydroxide, sodium phosphate, sodium borate, sodium citrate, sodium acetate, sodium lactate and tris-(hydroxymethyl)aminomethane
  • buffers such as citrate/dextrose, sodium bicarbonate and ammonium chloride.
  • Such acids, bases and buffers are included in an amount required to maintain pH of the formulation in an acceptable range.
  • the pharmaceutical formulations include one or more salts in an amount required to bring osmolality of the
  • Such salts include those having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions; suitable salts include sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
  • the pharmaceutical formulations further include diluents which are used to stabilize compounds because they can provide a more stable environment. Salts dissolved in buffered solutions (which also can provide pH control or maintenance) are utilized as diluents in the art, including, but not limited to a phosphate buffered saline solution.
  • diluents increase bulk of the formulation to facilitate compression or create sufficient bulk for homogenous blend for capsule filling.
  • Such compounds can include e.g., lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel ® ; dibasic calcium phosphate, dicalcium phosphate dihydrate; tricalcium phosphate, calcium phosphate; anhydrous lactose, spray-dried lactose; pregelatinized starch, compressible sugar, such as Di-Pac ® (Amstar); mannitol, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, sucrose- based diluents, confectioner’s sugar; monobasic calcium sulfate monohydrate, calcium sulfate dihydrate; calcium lactate trihydrate, dextrates; hydrolyzed cereal solids, amylose; powdered cellulose, calcium carbonate; glycine,
  • the pharmaceutical formulation is formulated for administration to a subject by one or more administration routes, including but not limited to, parenteral (e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular), oral, intranasal, buccal, rectal, or transdermal administration routes.
  • parenteral e.g., intravenous, subcutaneous, intramuscular, intraarterial, intradermal, intraperitoneal, intravitreal, intracerebral, or intracerebroventricular
  • the pharmaceutical antibody formulation is formulated for intravenous administration.
  • the pharmaceutical antibody formulation is formulated for subcutaneous administration. Proper formulation is dependent upon the route of administration chosen. Techniques for formulation and administration of the compounds described herein are known to those skilled in the art. [0216] In some embodiments, the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody. In some embodiments, the antibody is an anti- Gal3 antibody. [0217] In some embodiments, the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate. [0218] In some embodiments, the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3.
  • the histidine is L- histidine.
  • the polysorbate is polysorbate 80.
  • the histidine is L-histidine and the polysorbate is polysorbate 80.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the histidine is L-histidine.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the polysorbate is polysorbate 80.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the histidine is L- histidine and the polysorbate is polysorbate 80.
  • the antibody is an anti-Gal3 antibody.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the histidine is present at 10 to 50 mM. In some embodiments, the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the histidine is present at 20 mM.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the methionine is present at 2 to 10 mM. In some embodiments, the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the methionine is present at 5 mM.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the NaCl is present at 50 to 150 mM. In some embodiments, the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the NaCl is present at 100 mM.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the polysorbate is present at 0.01 to 0.04%.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3, where the polysorbate is present at 0.02%.
  • the histidine is L-histidine.
  • the polysorbate is polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.
  • the polysorbate is polysorbate 80.
  • the pH is 5.8.
  • the pharmaceutical antibody formulation further comprises sucrose. In some embodiments, the sucrose is present at 2% to 5%. In some embodiments, the pharmaceutical antibody formulation further comprises mannitol. In some embodiments, the mannitol is present at 2% to 5%. In some embodiments, the antibody is an anti-Gal3 antibody.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, histidine, methionine, NaCl, and polysorbate, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate present at 0.02%, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate present at 0.02%, where the formulation is at a pH of about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H - CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate 80 present at 0.02%, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate 80 present at 0.02%, where the formulation is at a pH of about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 40 mg, histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate present at 0.02%, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate present at 0.02%, where the formulation is at a pH of about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate 80 present at 0.02%, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount as a unit dose of 1 mg, 50 mg, 10 mg, 20 mg, 40 mg, or 50 mg, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate 80 present at 0.02%, where the formulation is at a pH of about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate present at 0.02%, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate present at 0.02%, where the formulation is at a pH of about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate 80 present at 0.02%, where the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount as a unit dose of 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, and polysorbate 80 present at 0.02%, where the formulation is at a pH of about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 1 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H - CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 5 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H - CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 10 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 20 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH- CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 40 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H - CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 50 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 1 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 5 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 10 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 20 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 40 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 50 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • kits and articles of manufacture for use with one or more of the compositions and methods described herein.
  • Such kits include a carrier, package, or container that is compartmentalized to receive one or more containers such as vials, tubes, and the like, each of the container(s) comprising one of the separate elements to be used in a method described herein.
  • Suitable containers include, for example, bottles, vials, syringes, and test tubes.
  • the containers are formed from a variety of materials such as glass or plastic.
  • the articles of manufacture provided herein contain packaging materials.
  • kits include an anti-Gal3 antibody or binding fragment thereof as disclosed herein, host cells for producing one or more antibodies described herein, and/or vectors comprising nucleic acid molecules that encode the antibodies described herein.
  • kits optionally include an identifying description or label or instructions relating to its use in the methods described herein.
  • a kit typically includes labels listing contents and/or instructions for use, and package inserts with instructions for use. A set of instructions will also typically be included.
  • a label is on or associated with the container.
  • a label is on a container when letters, numbers or other characters forming the label are attached, molded or etched into the container itself; a label is associated with a container when it is present within a receptacle or carrier that also holds the container, e.g., as a package insert.
  • a label is used to indicate that the contents are to be used for a specific therapeutic application.
  • the label also indicates directions for use of the contents, such as in the methods described herein.
  • the pharmaceutical compositions are presented in a pack or dispenser device which contains one or more unit dosage forms containing a compound provided herein.
  • the pack for example, contains metal or plastic foil, such as a blister pack.
  • the pack or dispenser device is accompanied by instructions for administration.
  • the pack or dispenser is also accompanied with a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.
  • a notice associated with the container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals which notice is reflective of approval by the agency of the form of the drug for human or veterinary administration.
  • Such notice for example, is the labeling approved by the U.S. Food and Drug Administration for prescription drugs, or the approved product insert.
  • compositions containing a compound provided herein formulated in a compatible pharmaceutical carrier are also prepared, placed in an appropriate container, and labeled for treatment of an indicated condition.
  • sterile vials comprising pharmaceutical antibody formulations are provided, where the formulations can include a therapeutically effective amount of an antibody.
  • the sterile vials comprise any one of the pharmaceutical antibody formulations disclosed herein.
  • the antibody comprises a VH- CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249.
  • the antibody comprises a V H -CDR1 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 31, a VH-CDR2 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.
  • V L -CDR2 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%. 95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 222; and a VL-CDR3 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.
  • the antibody comprises a V H -CDR1 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.95%, 96%, 97%, 98%, 99%, or 100% similar to the sequence of SEQ ID NO: 31, a VH-CDR2 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.95%, 96%, 97%, 98%, 99%, or 100% similar to the sequence of SEQ ID NO: 72, a VH-CDR3 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 91%, 91%, 91%, 92%, 93%, 94%.95%, 96%, 97%, 98%, 99%, or
  • the pharmaceutical antibody formulations can further comprise histidine, methionine, NaCl, and polysorbate. In some embodiments, the formulation can be at a pH between 5.3 and 6.3. In some embodiments, the antibody can be an anti-Gal3 antibody. In some embodiments, the antibody can be an anti-Gal3 antibody disclosed herein, or otherwise known in the art, such as those disclosed in WO 2020/160156. In some embodiments, the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298.
  • VH heavy chain variable domain
  • the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 298.
  • the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375.
  • the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% similar to that of SEQ ID NO: 375.
  • the formulation can also include additional ingredients and/or excipients to those listed, or exclude one or more of the positively recited options.
  • the ingredients and/or excipients can be replaced or used additionally with one or more alternatives that function to achieve the same result.
  • the histidine can be replaced with an alternative buffer with an appropriate pKa.
  • the histidine can be replaced with an alternative that has the same buffer capacity.
  • the histidine can be replaced with another amino acid.
  • the histidine can be replaced with an alternative that exhibits the same or similar antibody protective effects.
  • the histidine can be replaced with an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody.
  • the histidine can be replaced with an alternative that has the same or similar cryoprotective capabilities, including alternatives that may exhibit any one or more of the properties provided herein.
  • the methionine can be replaced with an alternative buffer with an appropriate pKa. In some embodiments, the methionine can be replaced with an alternative that has the same buffer capacity. In some embodiments, the methionine can be replaced with another amino acid. In some embodiments, the methionine can be replaced with an alternative that has the same or similar antioxidant effects. In some embodiments, the methionine can be replaced with an alternative that has the same antibody protective effects. In some embodiments, the methionine can be replaced by an alternative that has the same or similar protein stabilization effects.
  • the methionine can be replaced by an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody, including alternatives that may exhibit any one or more of the properties provided herein.
  • the alternatives for histidine and/or methionine may be any of those provided herein, such as arginine or glycine, or otherwise known in the art.
  • the NaCl can be replaced with another salt.
  • the NaCl can be replaced with an alternative that has the same or similar aqueous solubility.
  • the NaCl can be replaced with an alternative that has the same or similar effect on formulation isotonicity.
  • the NaCl can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit one or more of the properties provided herein.
  • the alternative for NaCl may be any of those provided herein, such as other chloride salts, other sodium salts, ascorbate salts, acetate salts, phosphate salts, citrate salts, Tris salts, or succinate salts, or otherwise known in the art.
  • the polysorbate can be replaced with another surfactant and/or detergent.
  • the polysorbate can be replaced with an alternative that has the same or similar surfactant ability/effect.
  • the polysorbate can be replaced with an alternative that has the same or similar capability for solubilizing antibodies and/or other excipients. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit one or more of the properties provided herein.
  • the alternative for polysorbate may be any of those provided herein, such as poloxamer 188, or otherwise known in the art.
  • the pH can be acidic. In some embodiments, the pH can be basic. In some embodiments, the pH can be varied.
  • the pH can be increased or decreased in line with the ingredients, excipients, and/or buffers used in the formulation and the particulars of the antibody species used and/or the amount of antibody, ingredients, or excipients used. In some embodiments, the pH can be increased or decreased to a desired pH after adding the antibody, ingredients, or excipients.
  • the alternatives contemplated herein may be any one or more of the excipients, diluents, salts, buffers, and the like, provided throughout the disclosure.
  • the antibodies comprise one or more sequences having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91% , 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to a VL sequence, a VH sequence, a VL/VH pairing, and/or VL-CDR1, VL-CDR2, V L -CDR3, V H -CDR1, V H -CDR2, V H -CDR3 (including 1, 2, 3, 4, or 5 amino acid substitutions of any one or more of these CDRs) set from the heavy chain and light chain sequences as depicted in FIG.18.
  • the histidine is L-histidine, D-histidine, or racemic histidine.
  • the histidine is racemic histidine.
  • the histidine is D-histidine.
  • the histidine can be replaced with an alternative buffer with an appropriate pKa.
  • the histidine can be replaced with an alternative that has the same buffer capacity.
  • the histidine can be replaced with another amino acid.
  • the histidine can be replaced with an alternative that exhibits the same or similar antibody protective effects. In some embodiments, the histidine can be replaced with an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the histidine can be replaced with an alternative that has the same or similar cryoprotective capabilities, including alternatives that may exhibit one or more of the properties provided herein.
  • the alternatives for histidine may be any of those provided herein, such as arginine or glycine, or otherwise known in the art.
  • the histidine is present at 10 to 50 mM, e.g.10, 15, 20, 25, 30, 35, 40, 45, or 50 mM. In some embodiments, the histidine is present at 20 mM or about 20 mM. In some embodiments, where the histidine is L-histidine, the L-histidine is present at 10 to 50 mM, e.g. 10, 15, 20, 25, 30, 35, 40, 45, or 50 mM. In some embodiments, where the histidine is L-histidine, the L-histidine is present at 20 mM or about 20 mM.
  • the methionine is L-methionine.
  • the methionine is racemic methionine.
  • the methionine is D-methionine.
  • the methionine can be replaced with an alternative buffer with an appropriate pKa.
  • the methionine can be replaced with an alternative that has the same buffer capacity.
  • the methionine can be replaced with another amino acid.
  • the methionine can be replaced with an alternative that has the same or similar antioxidant effects.
  • the methionine can be replaced with an alternative that has the same antibody protective effects. In some embodiments, the methionine can be replaced by an alternative that has the same or similar protein stabilization effects. In some embodiments, the methionine can be replaced by an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody, including alternatives that may exhibit one or more of the properties provided herein.
  • the alternatives for methionine may be any of those provided herein, such as arginine or glycine, or otherwise known in the art. [0256]
  • the methionine is present at 2 to 10 mM, e.g.
  • the methionine is present at 5 mM or about 5 mM.
  • the NaCl is present at 50 to 150 mM, e.g. 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 mM. In some embodiments, the NaCl is present at 100 mM. In some embodiments, the NaCl can be replaced with another salt. In some embodiments, the NaCl can be replaced with an alternative that has the same or similar aqueous solubility.
  • the NaCl can be replaced with an alternative that has the same or similar effect on formulation isotonicity. In some embodiments, the NaCl can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit one or more of the properties provided herein.
  • the alternative for NaCl may be any of those provided herein, such as other chloride salts, other sodium salts, ascorbate salts, acetate salts, phosphate salts, citrate salts, Tris salts, or succinate salts, or otherwise known in the art.
  • the polysorbate comprises polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or any combination thereof.
  • the polysorbate comprises, consists essentially of, or consists of polysorbate 80.
  • the polysorbate is present at 0.01% to 0.04%, e.g. 0.01%, 0.02%, 0.03%, or 0.04%.
  • the polysorbate is present at about 0.01% to about 0.04%, e.g. about 0.01%, about 0.02%, about 0.03%, or about 0.04%.
  • the polysorbate is present at 0.02% or about 0.02%. In some embodiments, where the polysorbate is polysorbate 80, the polysorbate 80 is present at 0.01% to 0.04%, e.g. 0.01%, 0.02%, 0.03%, or 0.04%. In some embodiments, where the polysorbate is polysorbate 80, the polysorbate 80 is present at about 0.01% to about 0.04%, e.g. about 0.01%, about 0.02%, about 0.03%, or about 0.04%. In some embodiments, the polysorbate 80 is present at 0.02% or about 0.02%. In some embodiments, the polysorbate can be replaced with another surfactant and/or detergent.
  • the polysorbate can be replaced with an alternative that has the same or similar surfactant ability/effect. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar capability for solubilizing antibodies and/or other excipients. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the polysorbate can be replaced with an alternative that has the same or similar protein stabilization effects, including alternatives that may exhibit one or more of the properties provided herein.
  • the alternative for polysorbate may be any of those provided herein, such as poloxamer 188, or otherwise known in the art.
  • the pH is about 5.8. In some embodiments, the pH is 5.8. In some embodiments, the pH can be acidic. In some embodiments, the pH can be basic. In some embodiments, the pH can be varied. In some embodiments, the pH can be increased or decreased in line with the ingredients, excipients, and/or buffers used in the formulation and the particulars of the antibody species used and/or the amount of antibody, ingredients, or excipients used. In some embodiments, the pH can be increased or decreased to a desired pH after adding the antibody, ingredients, or excipients.
  • the formulations further comprise one or more sugars or one or more sugar alcohols, or both, including any one of the sugars or sugar alcohols disclosed herein or otherwise known in the art.
  • the one or more sugars comprises sucrose.
  • the one or more sugar alcohols comprise mannitol.
  • the formulations comprise sucrose or mannitol, or both.
  • the formulations comprise sucrose and mannitol.
  • the sucrose and/or mannitol can be replaced with another sugar and/or sugar alcohol.
  • the sucrose and/or mannitol can be replaced with an alternative that has the same or similar antibody protective effects. In some embodiments, the sucrose and/or mannitol can be replaced with an alternative that exhibits the same or similar capacity to reduce aggregation of the antibody. In some embodiments, the sucrose and/or mannitol can be replaced with an alternative that has the same or similar cryoprotective capabilities. In some embodiments, the sucrose and/or mannitol can be replaced with an alternative that have the same effect on isotonicity, including alternatives that may exhibit one or more of the properties provided herein.
  • sucrose and/or mannitol may be any of those provided herein, such as sorbitol, trehalose, dextrose, dextran, or dextran 40, or otherwise known in the art.
  • the one or more sugars or one or more sugar alcohols are present at 2% to 5%, e.g. 2%, 3%, 4%, or 5%.
  • the one or more sugars or one or more sugar alcohols are present at about 2% to about 5%, e.g. about 2%, about 3%, about 4%, or about 5%.
  • the sucrose is present at 2% to 5% or about 2% to 5%.
  • the formulation is configured for parenteral administration.
  • the formulation is configured for subcutaneous administration.
  • the formulation configured for subcutaneous administration comprises one or more sugars and/or one or more sugar alcohols.
  • the formulation configured for subcutaneous administration comprises sucrose or mannitol, or both.
  • the formulation is configured for intravenous administration. In some embodiments, the formulation configured for intravenous administration does not comprise one or more sugars and/or one or more sugar alcohols.
  • the formulation configured for intravenous administration does not comprise sucrose or mannitol, or both.
  • sterile vials comprising a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody, such as an anti-Gal3 antibody.
  • the sterile vials comprise any of the pharmaceutical antibody formulations disclosed herein.
  • the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody.
  • the antibody is an anti-Gal3 antibody.
  • the antibody is any one of the anti-Gal3 antibodies disclosed herein or otherwise known in the art, such as those described in WO 2020/160156.
  • the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249.
  • the antibody comprises a V H -CDR1 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.
  • V H -CDR2 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.
  • the antibody comprises a VH-CDR1 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.95%, 96%, 97%, 98%, 99%, or 100% identical to the sequence of SEQ ID NO: 249.
  • the antibody comprises a VH-CDR1 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.
  • a V H -CDR2 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.95%, 96%, 97%, 98%, 99%, or 100% similar to the sequence of SEQ ID NO: 72, a VH-CDR3 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%.95%, 96%, 97%, 98%, 99%, or 100% similar to the sequence of SEQ ID NO: 113, a VL-CDR1 that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%
  • the antibody comprises a V H -CDR1 having a sequence that has at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to the sequence of SEQ ID NO: 31, a VH-CDR2 having a sequence that has at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to the sequence of SEQ ID NO: 72, a V H -CDR3 having a sequence that has at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to the sequence of SEQ ID NO: 113, a VL-CDR1 having a sequence that has at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to the sequence of SEQ ID NO: 171, a V L -CDR2 having a sequence that has at least 0, 1, 2, 3, 4, 5, or 6 substitutions relative to the sequence of SEQ ID NO: 222; and a V L -CDR3 having a sequence that has at least 0, 1, 2, 3, 4, 5,
  • the pharmaceutical antibody formulation in the sterile vial further comprises histidine, methionine, NaCl, and polysorbate.
  • the pharmaceutical antibody formulation in the sterile vial is at a pH between 5.3 and 6.3.
  • the sterile vial is a 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mL sterile vial.
  • the sterile vial is a 5 mL sterile vial.
  • the sterile vial is a 10 mL sterile vial.
  • the sterile vial contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mL of the pharmaceutical antibody formulation.
  • the sterile vial contains 2 mL or at least 2 mL of the pharmaceutical antibody formulation. In some embodiments, the sterile vial contains 8 mL or at least 8 mL of the pharmaceutical antibody formulation. In some embodiments, the pharmaceutical antibody formulation in the sterile vial is a concentrated form of any one of the pharmaceutical antibody formulations disclosed herein.
  • the concentrated form of the pharmaceutical antibody formulation in the sterile vial is at a concentration of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 mg/mL.
  • the concentrated form of the pharmaceutical antibody formation in the sterile vial is at a concentration of 20 mg/mL or about 20 mg/mL or at least 20 mg/mL. In some embodiments, the concentrated form of the pharmaceutical antibody formulation in the sterile vial is at a concentration of 50 mg/mL or about 50 mg/mL or at least 50 mg/mL.
  • the sterile vial contains 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mL of the concentrated form of the pharmaceutical antibody formulation, where the concentrated form of the pharmaceutical antibody formulation is at a concentration of 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100 mg/mL of antibody.
  • the sterile vial comprises 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910,
  • the concentrated form of the pharmaceutical antibody formulation in the sterile vial is intended to be diluted 1x, 2x, 3x, 4x, 5x, 6x, 7x, 8x, 9x, 10x, 11x, 12x, 13x, 14x, 15x, 16x, 17x, 18x, 19x, 20x, 30x, 40x, 50x, 60x, 70x, 80x, 90x, or 100x fold, or any fold within a range defined by any two of the aforementioned fold.
  • the concentrated form of the pharmaceutical antibody formulation in the sterile vial is intended to be diluted to 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 mg/mL or any concentration within a range defined by any two of the aforementioned concentrations.
  • the concentrated form of the pharmaceutical antibody formulation is intended to be diluted into a final volume of 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, or 600 mL.
  • the concentrated form of the pharmaceutical antibody formulation is intended to be diluted into a final volume of 250 mL or 500 mL.
  • the concentrated form of the pharmaceutical antibody formulation in the sterile vial is intended to be diluted with saline. In some embodiments, the saline is 0.9% saline. In some embodiments, the pharmaceutical antibody formulation in the sterile vial is configured for parenteral administration. In some embodiments, the pharmaceutical antibody formulation in the sterile vial is configured for subcutaneous administration. In some embodiments, the pharmaceutical antibody formulation in the sterile vial configured for subcutaneous administration comprises sucrose or mannitol, or both. In some embodiments, the pharmaceutical antibody formulation in the sterile vial is configured for intravenous administration. In some embodiments, the pharmaceutical antibody formulation in the sterile vial configured for intravenous administration does not comprise sucrose or mannitol, or both.
  • the pharmaceutical antibody formulation remains 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% stable over 3 months. In some embodiments, the pharmaceutical antibody formulation remains 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% stable over 3 months at either 5°C or 25°C/60% relative humidity (RH).
  • RH relative humidity
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249 (or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to the respective sequence), where the antibody is present at an amount of 1 mg as a unit dose
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249 (or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to the respective sequence), where the antibody is present at an amount of 5 mg as a unit dose, L
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249 (or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to the respective sequence), where the antibody is present at an amount of 10 mg as a unit
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249 (or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to the respective sequence), where the antibody is present at an amount of 20 mg as a unit dose
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249 (or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to the respective sequence), where the antibody is present at an amount of 40 mg as a
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249 (or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical or similar to the respective sequence), where the antibody is present at an amount of 50 mg as a unit dose, where the antibody is present at an amount
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 375, where the antibody is present at an amount of 1 mg as a unit dose, L- histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 375, where the antibody is present at an amount of 5 mg as a unit dose, L- histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 375, where the antibody is present at an amount of 10 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 375, where the antibody is present at an amount of 20 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 375, where the antibody is present at an amount of 40 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial comprises a pharmaceutical antibody formulation comprising a therapeutically effective amount of an antibody or a concentrated form of the pharmaceutical antibody formulation, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical or similar to that of SEQ ID NO: 375, where the antibody is present at an amount of 50 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is a concentrated form. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or about 20 mg/mL of antibody. In some embodiments, the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or about 50 mg/mL of antibody.
  • the sterile vial can be substituted with a suitable alternative container, such as a tube, bag, pack, syringe, or dispenser. In some embodiments, the vial or alternative container may be contained within a kit for use. In some embodiments, the kit may contain identifying description, label, or instructions relating to its use in the methods disclosed herein.
  • the kit also includes a notice prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, denoting approval of the form of the drug for human or veterinary administration.
  • exemplary Methods of Use and Therapeutic Regimens [0277]
  • the anti-Gal3 antibodies or binding fragments thereof disclosed herein are administered for therapeutic applications.
  • the anti-Gal3 antibody or binding fragment thereof is administered once per day, twice per day, three times per day or more.
  • the anti-Gal3 antibody or binding fragment thereof is administered daily, every day, every alternate day, five days a week, once a week, every other week, two weeks per month, three weeks per month, once a month, twice a month, three times per month, or more.
  • the anti-Gal3 antibody or binding fragment thereof is administered for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 18 months, 2 years, 3 years, or more.
  • the administration of the anti-Gal3 antibody or binding fragment thereof is given continuously; alternatively, the dose of the anti-Gal3 antibody or binding fragment thereof being administered is temporarily reduced or temporarily suspended for a certain length of time (i.e., a “drug holiday”).
  • the length of the drug holiday varies between 2 days and 1 year, including by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days.
  • the dose reduction during a drug holiday is from 10%-100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.
  • the amount of a given agent that correspond to such an amount varies depending upon factors such as the particular compound, the severity of the disease, the identity (e.g., weight) of the subject or host in need of treatment, but nevertheless is routinely determined in a manner known in the art according to the particular circumstances surrounding the case, including, e.g., the specific agent being administered, the route of administration, and the subject or host being treated.
  • the desired dose is conveniently presented in a single dose or as divided doses administered simultaneously (or over a short period of time) or at appropriate intervals, for example as two, three, four or more sub-doses per day.
  • the foregoing ranges are merely suggestive, as the number of variables in regard to an individual treatment regime is large, and considerable excursions from these recommended values are not uncommon. Such dosages is altered depending on a number of variables, not limited to the activity of the compound used, the disease or condition to be treated, the mode of administration, the requirements of the individual subject, the severity of the disease or condition being treated, and the judgment of the practitioner.
  • toxicity and therapeutic efficacy of such therapeutic regimens are determined by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, the determination of the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
  • the dose ratio between the toxic and therapeutic effects is the therapeutic index and it is expressed as the ratio between LD50 and ED50.
  • Compounds exhibiting high therapeutic indices are preferred.
  • the data obtained from cell culture assays and animal studies are used in formulating a range of dosage for use in human.
  • the dosage of such compounds lies preferably within a range of circulating concentrations that include the ED50 with minimal toxicity.
  • the methods and uses disclosed herein are directed to the treatment of a disease or disorder in a subject.
  • the methods and uses are directed to administering a protein to a subject having, suspected of having, or at risk of developing a disease or disorder.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the disease or disorder is a viral infection.
  • the disease or disorder is a coronavirus infection.
  • the disease or disorder is a SARS-CoV-2 viral infection.
  • the methods and uses are directed to treating a sequela that arises from a disease or disorder.
  • the sequela is lung fibrosis or other fibrosis or sequela caused by a SARS-CoV-2 viral infection.
  • the disease or disorder is an inflammatory disease, which may or may not be associated with a viral infection.
  • the inflammatory disease may be a lung inflammatory disease (e.g. COPD), or an autoimmune disease (e.g. systemic lupus erythematosus).
  • the inflammatory disease is associated with neutrophil activation and/or migration in the subject.
  • a method of treating lung fibrosis in a subject in need thereof is provided. The method comprises administering to the subject a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a TGF-b receptor.
  • the lung fibrosis is a sequela of a viral infection.
  • the subject can have any viral infection.
  • the viral infection is a respiratory viral infection.
  • any of the methods provided herein can be used in a subject that has a viral infection.
  • the viral infection is a coronavirus infection.
  • the viral infection is a SARS-related coronavirus infection. In some embodiments, the viral infection is a SARS-CoV-2 coronavirus infection.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of disrupting an interaction between Gal3 and a virus-associated host cell receptor comprises contacting the virus- associated host cell receptor with a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the virus-associated host cell receptor is a SARS-CoV-2 associated host cell receptor.
  • the virus-associated host cell receptor is ACE2 or CD147.
  • the method provided herein can be used in a subject that has a viral infection.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of disrupting an interaction between Gal3 and a virus protein is provided. The method comprises contacting the viral protein with a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the virus protein is a coronavirus protein. In some embodiments, the virus protein is a SARS-related coronavirus protein. In some embodiments, the virus protein is a SARS-CoV-2 coronavirus protein. In some embodiments, the virus protein is a SARS-CoV-2 spike (S) protein.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of treating a SARS-CoV-2 infection in a subject in need thereof is provided. The method comprises administering to the subject an effective amount of a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N- terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti- Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a SARS-CoV- 2-associated host cell receptor.
  • the SARS-CoV-2 associated host cell receptor is ACE2 or CD147.
  • the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a SARS-CoV-2 protein.
  • the SARS-CoV-2 protein is a SARS-CoV-2 S protein.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of treating a viral infection in a subject in need thereof comprises administering to the subject an effective amount of a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a viral protein.
  • the viral infection is a coronavirus infection and the viral protein is a coronavirus protein.
  • the viral infection is a SARS-related coronavirus infection and the viral protein is a SARS-related coronavirus protein.
  • the viral infection is a SARS-CoV-2 viral infection and the viral protein is a SARS-CoV-2 S protein.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of treating a SARS-CoV-2 infection comprises administering to a subject an effective amount of a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a SARS-CoV-2 S protein.
  • the anti-Gal3 antibody is capable of binding to Gal3 on a SARS-CoV-2 virus, or Gal3 associated with a cell.
  • the Gal3 associated with a cell is a Gal3 expressed by the cell.
  • the Gal3 associated with a cell is a Gal3 bound to the cell surface.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of preventing and/or reducing a viral spread comprises administering to a subject an effective amount of a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and ACE2 and/or Gal3 and CD147.
  • the method described herein can be applied to any subject that has a viral infection.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.
  • a method of reducing a risk that a virus can invade a cell comprises administering to a cell a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and ACE2 and/or Gal3 and CD147.
  • the method described herein can be applied to any cell and any virus.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • a method of decreasing or inhibiting toxicity in a subject experiencing cytokine release syndrome (cytokine storm) or vulnerable to CRS is provided. The method comprises administering to the subject an effective amount of a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment thereof is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the CRS is a result of a bacterial infection, viral infection, fungal infection, protozoan infection, graft-versus- host disease, cytomegalovirus, Epstein-Barr virus, hemophagocytic lymphohistiocystosis (HLH), Epstein-Barr virus-associated HLH, sporadic HLH, macrophage activation syndrome (MAS), chronic arthritis, systemic Juvenile idiopathic Arthritis (sJIA), Still’s Disease, Cryopyrin- associated Periodic Syndrome (CAPS), Familial Cold Auto-inflammatory Syndrome (FCAS), Familial Cold Urticaria (FCU), Muckle-Well Syndrome (MWS), Chronic Infantile Neurological Cutaneous and Articular
  • the CRS is a result of sepsis.
  • the sepsis is bacterial sepsis, viral sepsis, fungal sepsis, or protozoan sepsis.
  • the CRS is a result of a viral infection.
  • the CRS is a result of a coronavirus infection.
  • the CRS is a result of a SARS-related coronavirus infection.
  • the CRS is a result of a SARS-CoV-2 coronavirus infection.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.
  • a method of decreasing or inhibiting inflammation in a subject in need thereof comprises administering to the subject an effective amount of a protein.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment thereof is specific for the N-terminus of Gal3, the N-terminal domain of Gal3, or the TRD of Gal3.
  • the inflammation in the subject is associated with neutrophil activation and/or migration.
  • administration of the effective amount of the anti-Gal3 antibody or binding fragment thereof decreases or inhibits neutrophil activation and/or migration in the subject.
  • administration of the effective amount of the anti-Gal3 antibody or binding fragment thereof decreases or inhibits cleavage of CD62L expressed by neutrophils and/or decreases or inhibits IL-8 production in the subject.
  • the method further comprise detecting a decrease in neutrophil CD62L cleavage and/or a decrease in IL-8 production in the subject after the administering step.
  • administration of the effective amount of the anti-Gal3 antibody or binding fragment thereof decreases the number of neutrophils in the subject.
  • the method further comprises detecting a decrease in the number of neutrophils in the subject after the administering step.
  • administration of the effective amount of the anti-Gal3 antibody or binding fragment thereof modulates (e.g.
  • the method further comprises detecting a change (e.g.
  • the subject after the administrating step.
  • administration of the effective amount of the anti-Gal3 antibody or binding fragment thereof decreases production of autoantibodies in the subject.
  • the autoantibodies are anti-nucleic acid autoantibodies.
  • the inflammation comprises lung inflammation.
  • the inflammation comprises COPD, pneumonitis, asthma, sarcoidosis, pulmonary fibrosis, histiocytosis, bronchiolitis obliterans, or any combination thereof.
  • the inflammation comprises an autoimmune disease.
  • the autoimmune disease comprises systemic lupus erythematosus (SLE), Graves’ disease, rheumatoid arthritis, multiple sclerosis, Sjogren’s syndrome, celiac disease, or any combination thereof.
  • the method further comprises detecting an improvement in the inflammation in the subject after the administrating step.
  • a method of decreasing or inhibiting cleavage of CD62L, decreasing IL-8 production, and/or modulating (e.g. increasing or decreasing) expression of Gal3, MPO, GRO ⁇ /KC, Ly6c1, INOS, IL-6, TNF ⁇ , IL-1B, Col1A1, aSMA, TGF ⁇ , VEGFA, VEGFB, or any combination thereof, by a cell is disclosed.
  • the method comprises contacting the cell with an anti-Gal3 antibody or binding fragment thereof, thereby decreasing or inhibiting cleavage of CD62L, decreasing IL-8 production, and/or modulating expression of Gal3, MPO, GRO ⁇ /KC, Ly6c1, INOS, IL-6, TNF ⁇ , IL-1B, Col1A1, aSMA, TGF ⁇ , VEGFA, VEGFB, or any combination thereof, by the cell.
  • the cell is an immune cell.
  • the cell is a neutrophil.
  • cleavage of CD62L is decreased by at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100%
  • IL-8 production is decreased by at least 1%, 2%, 3%, 4%, 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%
  • TNF ⁇ expression is decreased by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%
  • IL-6 expression is decreased by at least 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%
  • IL-6 expression is decreased by at least 10%, 15%, 20%, 25%, 30%
  • the decrease or inhibition of cleavage of CD62L, decrease in IL-8 production, and/or change (e.g. increase or decrease) in expression of Gal3, MPO, GRO ⁇ /KC, Ly6c1, INOS, IL-6, TNF ⁇ , IL-1B, Col1A1, aSMA, TGF ⁇ , VEGFA, VEGFB, or any combination thereof is determined by ELISA.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.
  • a method of detecting Gal3 in a sample comprises contacting the sample with a protein and detecting the presence or absence of Gal3.
  • the protein is an anti-Gal3 antibody or binding fragment thereof.
  • the anti-Gal3 antibody or binding fragment comprises a detectable moiety.
  • the anti-Gal3 antibody or binding fragment is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG. 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3, the N-terminal domain of Gal3, or the tandem repeat domain (TRD) of Gal3, or any combination thereof.
  • the anti-Gal3 antibody or binding fragment thereof binds to Peptide 1 (ADNFSLHDALSGSGNPNPQG; SEQ ID NO: 3), Peptide 6 (GAYPGQAPPGAYPGAPGAYP; SEQ ID NO: 8), or Peptide 7 (AYPGAPGAYPGAPAPGVYPG; SEQ ID NO: 9), or any combination thereof.
  • the anti-Gal3 antibody or binding fragment comprises a combination of a VL-CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 as illustrated in FIG. 14.
  • the light chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 374-449.
  • the light chain variable region comprises the sequence selected from SEQ ID NOs: 374-449.
  • the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the heavy chain variable region comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the anti-Gal3 antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 495-538, 830.
  • the light chain comprises the sequence selected from SEQ ID NOs: 495-538, 830.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 448-494, 829.
  • the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829.
  • the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F
  • the anti-Gal3 antibody or binding fragment thereof is administered with one or more antiviral or anti-inflammatory therapeutics.
  • the one or more antiviral or anti-inflammatory therapeutics is selected from the group consisting of chloroquine, hydroxychloroquine, favipiravir, favilavir, remdesivir, tocilizumab, baricitinib, acalabrutinib, galidesivir, sarilumab, lopinavir, ritonavir, darunavir, ribavirin, dexamethasone, ciclesonide, convalescent plasma, interferon- ⁇ , pegylated interferon- ⁇ , and interferon alfa-2b, or any combination thereof.
  • a use of an anti-Gal3 antibody or binding fragment thereof for the treatment of a viral infection is provided.
  • a use of an anti-Gal3 antibody or binding fragment thereof for the treatment of lung fibrosis is provided, where the lung fibrosis is a sequela of a viral infection.
  • the use of an anti-Gal3 antibody or binding fragment thereof for the treatment of CRS is provided.
  • the CRS is a result of a viral infection.
  • the CRS is a result of sepsis.
  • the CRS is a result of bacterial sepsis, viral sepsis, fungal sepsis, or protozoan sepsis.
  • the viral infection is a coronavirus infection. In some embodiments, the viral infection is a SARS-related coronavirus infection. In some embodiments, the viral infection is a SARS-CoV-2 coronavirus infection. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the N-terminal domain of Gal3. In some embodiments, the anti-Gal3 antibody or binding fragment thereof binds to the tandem repeat domain of Gal3.
  • the anti-Gal3 antibody or binding fragment thereof binds to Peptide 1 (ADNFSLHDALSGSGNPNPQG; SEQ ID NO: 3), Peptide 6 (GAYPGQAPPGAYPGAPGAYP; SEQ ID NO: 8), or Peptide 7 (AYPGAPGAYPGAPAPGVYPG; SEQ ID NO: 9), or any combination thereof.
  • the anti-Gal3 antibody or binding fragment thereof comprises (1) a light chain variable region comprising a V L -CDR1, a V L -CDR2, and a V L -CDR3; and (2) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3, wherein the VL-CDR1 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 170-220, the V L -CDR2 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 221-247, the VL-CDR3 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 248-296, the V H -CDR
  • the anti-Gal3 antibody or binding fragment comprises a combination of a V L -CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 as illustrated in FIG. 14.
  • the light chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 374-449.
  • the light chain variable region comprises the sequence selected from SEQ ID NOs: 374-449.
  • the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the heavy chain variable region comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828.
  • the anti-Gal3 antibody or binding fragment thereof comprises a light chain, wherein the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 495-538, 830.
  • the light chain comprises the sequence selected from SEQ ID NOs: 495-538, 830.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain, wherein the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 448-494, 829.
  • the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829.
  • the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5, F846TC.7F
  • the anti-Gal3 antibody or binding fragment thereof comprises or includes any one or more of the sequences described herein or provided in any one or more of FIG.8, 9, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or any one or more of a sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or greater identical thereto.
  • any one or more of the antibodies or fragments thereof provided herein can be used for the treatment and/or prevention of any one or more of: a cytokine storm, influenza, bird flu, severe acute respiratory syndrome (SARS), Epstein-Barr virus- associated hemophagocytic lymphohistiocytosis (HLH), sepsis, gram-negative sepsis, malaria, an Ebola virus, a variola virus, a systemic Gram-negative bacterial infection, or Jarisch-Herxheimer syndrome, hemophagocytic lymphohistiocytosis (HLH), sporadic HLH, macrophage activation syndrome (MAS), chronic arthritis, systemic Juvenile idiopathic Arthritis (sJIA), Still's Disease, a Cryopyrin-associated Periodic Syndrome (CAPS), Familial Cold Auto-inflammatory Syndrome (FCAS), Familial Cold Urticaria (FCU), Muckle-Well Syndrome (MWS), Chronic Infantile Neurological
  • SARS severe acute respiratory syndrome
  • compositions that comprise, consist essentially of, or consist of an effective amount of an anti-Gal3 antibody or binding fragment described herein and a pharmaceutically acceptable carrier, excipient, or combination thereof.
  • a pharmaceutical composition described herein is suitable for human and/or veterinary applications.
  • any of the pharmaceutical antibody formulations disclosed herein are administered for therapeutic applications. In some embodiments, these can be used for the treatment of a disease such as a coronavirus infection or inflammation associated with said disease.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL- CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 1 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L - CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 5 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL- CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 10 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL- CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 20 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L - CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 40 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL- CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, where the antibody is present at an amount of 50 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 1 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 5 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 10 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 20 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 40 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation administered for therapeutic applications comprises a therapeutically effective amount of an antibody, where the antibody comprises a VH region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298 and a VL region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375, where the antibody is present at an amount of 50 mg as a unit dose, L-histidine present at 20 mM, methionine present at 5 mM, NaCl present at 100 mM, polysorbate 80 present at 0.02% and where the pH is about 5.8.
  • the pharmaceutical antibody formulation is administered once per day, twice per day, three times per day or more. In some embodiments, the pharmaceutical antibody formulation is administered daily, every day, every alternate day, every ten days, five days a week, once a week, every other week, two weeks per month, three weeks per month, once a month, twice a month, three times per month, or more. The pharmaceutical antibody formulation is administered for at least 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 2 years, 3 years, or more.
  • the pharmaceutical antibody formulation is administered enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously, or any combination thereof. In some embodiments, the pharmaceutical antibody formulation is administered intravenously or subcutaneously. In some embodiments, the subject is a mammal. In some embodiments, the subject is a human. [0316] In some embodiments, any of the pharmaceutical antibody compositions provided herein are used in a method for treating a coronavirus infection.
  • the methods comprise administering the pharmaceutical antibody formulation of any one of the preceding pharmaceutical antibody formulation claims or sterile vial claims to a subject in need of treatment for a coronavirus infection. In some embodiments, the methods further comprise detecting an improvement in the coronavirus infection in the subject after administration.
  • the pharmaceutical antibody formulation is administered daily, weekly, bi-weekly, or every 10 days.
  • the subject is administered 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg of antibody as a unit dose, or any amount of antibody as a unit dose within a range defined by any two of the aforementioned amounts. In some embodiments, the subject is administered 1 mg of antibody as a unit dose.
  • the subject is administered 5 mg of antibody as a unit dose. In some embodiments, the subject is administered 10 mg of antibody as a unit dose. In some embodiments, the subject is administered 20 mg of antibody as a unit dose. In some embodiments, the subject is administered 40 mg of antibody as a unit dose. In some embodiments, the subject is administered 50 mg of antibody as a unit dose. In some embodiments, the unit dose is administered over the course of 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 130, 140, 150, 160, 170, 180, 190, or 200 minutes, or any time within a range defined by any two of the aforementioned times. In some embodiments, the unit dose is administered over the course of 60 minutes.
  • the method further comprise identifying the subject in need of treatment for a coronavirus infection prior to administration, such as having the coronavirus infection or at risk of contracting the coronavirus infection.
  • the step of identifying the subject as in need of treatment for a coronavirus infection may be done according to the following inclusion criteria: [0317] 1) Willing and able to provide written informed consent prior to performing study or treatment procedures (or legally authorized representative able to provide consent on the patient’s behalf). [0318] 2) Age ⁇ 18 years. [0319] 3) A positive SARS-CoV-2 infection confirmed by PCR test or an equivalent test ⁇ 3 days before treatment.
  • High risk patients are defined as meeting at least one of the following criteria: have diabetes, have hypertension, have cancer, body mass index ⁇ 35, have chronic kidney disease, are ⁇ 65 years of age, are ⁇ 55 years of age and have cardiovascular disease such as hypertension or chronic obstructive pulmonary disease/other chronic respiratory disease.
  • the step of identifying the subject in need of treatment for a coronavirus infection comprises one or more of identifying a positive coronavirus infection by PCR test or equivalent test, identifying the subject as having symptoms of fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath with excursion, respiratory rate ⁇ 20 breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ⁇ 90 beats per minute, diabetes, hypertension, cancer, chronic kidney disease, body mass index (BMI) ⁇ 35, ⁇ 65 years of age, cardiovascular disease such as hypertension, chronic obstructive pulmonary disease or other chronic respiratory disease.
  • PCR test or equivalent test identifying the subject as having symptoms of fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath with excursion, respiratory rate ⁇ 20 breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ⁇ 90 beats per minute, diabetes, hypertension,
  • the treating step is to a patient that already has symptoms of a coronavirus infection.
  • the treating step is prophylactic.
  • the coronavirus infection is a SARS-CoV, MERS-CoV, or SARS-CoV-2 infection.
  • the antibody is administered for 10-18 months.
  • the antibody is administered intravenously.
  • the antibody is administered subcutaneously.
  • the methods comprise administering a pharmaceutical antibody formulation to a subject in need of treatment for a coronavirus infection, wherein the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, wherein the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • the methods comprise administering a pharmaceutical antibody formulation to the subject in need thereof, wherein the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, wherein the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • polynucleotides and vectors for antibody production [0328]
  • the present disclosure provides isolated nucleic acids encoding any of the anti-Gal3 antibodies or binding fragments thereof disclosed herein.
  • the present disclosure provides vectors comprising a nucleic acid sequence encoding any anti-Gal3 antibody or binding fragment thereof disclosed herein.
  • this disclosure provides isolated nucleic acids that encode a light-chain CDR and a heavy-chain CDR of an anti-Gal3 antibody or binding fragment thereof disclosed herein.
  • nucleic acid sequences encoding for heavy chain variable regions are depicted in FIG.29 (SEQ ID NOs: 539-620, 834).
  • nucleic acid sequences encoding for light chain variable regions are depicted in FIG. 30 (SEQ ID NOs: 621- 702, 835).
  • nucleic acid sequences encoding for heavy chains are depicted in FIG. 31 (SEQ ID NO: 703-749, 836).
  • nucleic acid sequences encoding for light chains are depicted in FIG. 32 (SEQ ID NO: 750-796, 837).
  • the subject anti-Gal3 antibodies or binding fragments thereof can be prepared by recombinant DNA technology, synthetic chemistry techniques, or a combination thereof.
  • sequences encoding the desired components of the anti-Gal3 antibodies are typically assembled cloned into an expression vector using standard molecular techniques know in the art. These sequences may be assembled from other vectors encoding the desired protein sequence, from PCR-generated fragments using respective template nucleic acids, or by assembly of synthetic oligonucleotides encoding the desired sequences.
  • Expression systems can be created by transfecting a suitable cell with an expressing vector which comprises an anti-Gal3 antibody of interest or binding fragment thereof.
  • Nucleotide sequences corresponding to various regions of light or heavy chains of an existing antibody can be readily obtained and sequenced using convention techniques including but not limited to hybridization, PCR, and DNA sequencing.
  • Hybridoma cells that produce monoclonal antibodies serve as a preferred source of antibody nucleotide sequences.
  • a vast number of hybridoma cells producing an array of monoclonal antibodies may be obtained from public or private repositories. The largest depository agent is American Type Culture Collection, which offers a diverse collection of well-characterized hybridoma cell lines.
  • antibody nucleotides can be obtained from immunized or non-immunized rodents or humans, and form organs such as spleen and peripheral blood lymphocytes.
  • Anti-Gal3 antibody production [0333] In some embodiments, anti-Gal3 antibodies or binding fragments thereof are raised by standard protocol by injecting a production animal with an antigenic composition. See, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory, 1988.
  • antibodies When utilizing an entire protein, or a larger section of the protein, antibodies may be raised by immunizing the production animal with the protein and a suitable adjuvant (e.g., Freund's, Freund's complete, oil-in-water emulsions, etc.).
  • a suitable adjuvant e.g., Freund's, Freund's complete, oil-in-water emulsions, etc.
  • BSA bovine serum albumin
  • KLH keyhole limpet hemocyanin
  • peptides derived from the full sequence may be utilized.
  • polypeptide in order to generate antibodies to relatively short peptide portions of the protein target, a superior immune response may be elicited if the polypeptide is joined to a carrier protein, such as ovalbumin, BSA or KLH.
  • a carrier protein such as ovalbumin, BSA or KLH.
  • Polyclonal or monoclonal anti-Gal3 antibodies or binding fragments thereof can be produced from animals which have been genetically altered to produce human immunoglobulins.
  • a transgenic animal can be produced by initially producing a “knock-out” animal which does not produce the animal's natural antibodies, and stably transforming the animal with a human antibody locus (e.g., by the use of a human artificial chromosome). In such cases, only human antibodies are then made by the animal.
  • anti-Gal3 antibodies or binding fragments thereof can be produced from phage libraries containing human variable regions. See U.S. Pat. No.6,174,708, incorporated fully herein by reference in its entirety.
  • an anti-Gal3 antibody or binding fragment thereof is produced by a hybridoma.
  • hybridomas may be formed by isolating the stimulated immune cells, such as those from the spleen of the inoculated animal. These cells can then be fused to immortalized cells, such as myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin- secreting cell line.
  • immortalized cells such as myeloma cells or transformed cells, which are capable of replicating indefinitely in cell culture, thereby producing an immortal, immunoglobulin- secreting cell line.
  • the immortal cell line utilized can be selected to be deficient in enzymes necessary for the utilization of certain nutrients.
  • Many such cell lines (such as myelomas) are known to those skilled in the art, and include, for example: thymidine kinase (TK) or hypoxanthine-guanine phosphoriboxyl transferase (HGPRT).
  • anti-Gal3 antibody or binding fragment thereof may be produced by genetic engineering.
  • Anti-Gal3 antibodies or binding fragments thereof disclosed herein can have a reduced propensity to induce an undesired immune response in humans, for example, anaphylactic shock, and can also exhibit a reduced propensity for priming an immune response which would prevent repeated dosage with an antibody therapeutic or imaging agent (e.g., the human-anti- murine-antibody “HAMA” response).
  • Such anti-Gal3 antibodies or binding fragments thereof include, but are not limited to, humanized, chimeric, or xenogenic human anti-Gal3 antibodies or binding fragments thereof.
  • Chimeric anti-Gal3 antibodies or binding fragments thereof can be made, for example, by recombinant means by combining the murine variable light and heavy chain regions (VK and VH), obtained from a murine (or other animal-derived) hybridoma clone, with the human constant light and heavy chain regions, in order to produce an antibody with predominantly human domains.
  • VK and VH murine variable light and heavy chain regions
  • the production of such chimeric antibodies is well known in the art and may be achieved by standard means (as described, e.g., in U.S. Pat. No.
  • humanized antibodies are hybrid immunoglobulins, immunoglobulin chains or fragments thereof which contain minimal sequence derived from non-human immunoglobulin.
  • humanized antibodies are human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat, rabbit or primate having the desired specificity, affinity and capacity.
  • donor antibody such as mouse, rat, rabbit or primate having the desired specificity, affinity and capacity.
  • Fv framework region (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues.
  • the humanized antibody may comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. These modifications are made to further refine and optimize antibody performance and minimize immunogenicity when introduced into a human body.
  • the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin sequence.
  • the humanized antibody may also comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.
  • Fc immunoglobulin constant region
  • Humanized antibodies can be engineered to contain human-like immunoglobulin domains and incorporate only the complementarity-determining regions of the animal-derived antibody. This can be accomplished by carefully examining the sequence of the hyper-variable loops of the variable regions of a monoclonal antigen binding unit or monoclonal antibody and fitting them to the structure of a human antigen binding unit or human antibody chains. See, e.g., U.S. Pat. No. 6,187,287, incorporated fully herein by reference.
  • Methods for humanizing non-human antibodies are well known in the art. “Humanized” antibodies are antibodies in which at least part of the sequence has been altered from its initial form to render it more like human immunoglobulins.
  • the heavy (H) chain and light (L) chain constant (C) regions are replaced with human sequence.
  • This can be a fusion polypeptide comprising a variable (V) region and a heterologous immunoglobulin C region.
  • the complementarity determining regions (CDRs) comprise non-human antibody sequences, while the V framework regions have also been converted to human sequences. See, for example, EP 0329400.
  • V regions are humanized by designing consensus sequences of human and mouse V regions and converting residues outside the CDRs that are different between the consensus sequences.
  • a framework sequence from a humanized antibody can serve as the template for CDR grafting; however, it has been demonstrated that straight CDR replacement into such a framework can lead to significant loss of binding affinity to the antigen.
  • the more homologous a human antibody (HuAb) is to the original murine antibody (muAb) the less likely that the human framework will introduce distortions into the murine CDRs that could reduce affinity.
  • the HuAb IC4 Based on a sequence homology search against an antibody sequence database, the HuAb IC4 provides good framework homology to muM4TS.22, although other highly homologous HuAbs would be suitable as well, especially kappa L chains from human subgroup I or H chains from human subgroup III. Kabat et al. (1987). Various computer programs such as ENCAD (Levitt et al. (1983) J. Mol. Biol. 168:595) are available to predict the ideal sequence for the V region. The disclosure thus encompasses HuAbs with different variable (V) regions. It is within the skill of one in the art to determine suitable V region sequences and to optimize these sequences. Methods for obtaining antibodies with reduced immunogenicity are also described in U.S. Pat.
  • Humanized antibodies can be prepared by a process of analysis of the parental sequences and various conceptual humanized products using three dimensional models of the parental and humanized sequences. Three dimensional immunoglobulin models are familiar to those skilled in the art. Computer programs are available which illustrate and display probable three-dimensional conformational structures of selected candidate immunoglobulin sequences. Inspection of these displays permits analysis of the likely role of the residues in the functioning of the candidate immunoglobulin sequence, i.e., the analysis of residues that influence the ability of the candidate immunoglobulin to bind its antigen.
  • a process for humanization of subject antigen binding units can be as follows. The best-fit germline acceptor heavy and light chain variable regions are selected based on homology, canonical structure and physical properties of the human antibody germlines for grafting. Computer modeling of mVH/VL versus grafted hVH/VL is performed and prototype humanized antibody sequence is generated. If modeling indicated a need for framework back- mutations, second variant with indicated FW changes is generated. DNA fragments encoding the selected germline frameworks and murine CDRs are synthesized.
  • the synthesized DNA fragments are subcloned into IgG expression vectors and sequences are confirmed by DNA sequencing.
  • the humanized antibodies are expressed in cells, such as 293F and the proteins are tested, for example in MDM phagocytosis assays and antigen binding assays.
  • the humanized antigen binding units are compared with parental antigen binding units in antigen binding affinity, for example, by FACS on cells expressing the target antigen. If the affinity is greater than 2-fold lower than parental antigen binding unit, a second round of humanized variants can be generated and tested as described above.
  • an anti-Gal3 antibody or binding fragment thereof can be either “monovalent” or “multivalent.” Whereas the former has one binding site per antigen-binding unit, the latter contains multiple binding sites capable of binding to more than one antigen of the same or different kind. Depending on the number of binding sites, antigen binding units may be bivalent (having two antigen-binding sites), trivalent (having three antigen-binding sites), tetravalent (having four antigen-binding sites), and so on. [0348] Multivalent anti-Gal3 antibodies or binding fragments thereof can be further classified on the basis of their binding specificities.
  • a “monospecific” anti-Gal3 antibody or binding fragment thereof is a molecule capable of binding to one or more antigens of the same kind.
  • a “multispecific” anti-Gal3 antibody or binding fragment thereof is a molecule having binding specificities for at least two different antigens. While such molecules normally will only bind two distinct antigens (i.e. bispecific anti-Gal3 antibodies), antibodies with additional specificities such as trispecific antibodies are encompassed by this expression when used herein.
  • This disclosure further provides multispecific anti-Gal3 antibodies.
  • Multispecific anti-Gal3 antibodies or binding fragments thereof are multivalent molecules capable of binding to at least two distinct antigens, e.g., bispecific and trispecific molecules exhibiting binding specificities to two and three distinct antigens, respectively.
  • the methods further provide for screening for or identifying antibodies capable of disrupting an interaction between Gal3 and a viral protein, such as a protein of the SARS-CoV-2 virus or other coronaviruses.
  • a viral protein such as a protein of the SARS-CoV-2 virus or other coronaviruses.
  • the viral protein is a SARS-CoV-2 S, E, M, or HE protein.
  • the method may comprise: (a) contacting Gal3 protein with an antibody that selectively binds to Gal3, thereby forming a Gal3-antibody complex; (b) contacting the Gal3-antibody complex with the viral protein; (c) removing unbound viral protein; and (d) detecting viral protein bound to the Gal3- antibody complex, wherein the antibody is capable of disrupting an interaction of Gal3 and the viral protein when the viral protein is not detected in (d).
  • the method comprises an immunoassay.
  • the immunoassay is an enzyme-linked immunosorbent assay (ELISA).
  • the methods further provide for screening for or identifying antibodies capable of disrupting an interaction between Gal3 and a host receptor protein that a virus uses to enter the host cell.
  • the virus is a SARS-CoV-2 virus or other coronavirus.
  • the host receptor protein is ACE2 or CD147.
  • the method may comprise: (a) contacting Gal3 protein with an antibody that selectively binds to Gal3, thereby forming a Gal3-antibody complex; (b) contacting the Gal3- antibody complex with the host receptor protein; (c) removing unbound host receptor protein; and (d) detecting host receptor protein bound to the Gal3-antibody complex, wherein the antibody is capable of disrupting an interaction of Gal3 and the host receptor protein when the host receptor protein is not detected in (d).
  • the method comprises an immunoassay.
  • the immunoassay is an enzyme-linked immunosorbent assay (ELISA).
  • the methods further provide for treating a disease or disorder in a subject in need thereof.
  • the disease or disorder is a viral infection. In some embodiments, the disease or disorder is a coronavirus infection. In some embodiments, the disease or disorder is a SARS-CoV-2 infection. In some embodiments, the disease or disorder is a sequela of a previous viral infection.
  • the methods may comprise: administering to the subject an anti-Gal3 antibody or binding fragment thereof, wherein the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a viral protein and/or a host receptor protein, thereby treating the infection. In some embodiments, the anti-Gal3 antibody or binding fragment thereof is specific for the N-terminal domain of Gal3, N-terminus of Gal3, or the TRD of Gal3.
  • the viral protein is a SARS-CoV-2 S, E, M, or HE protein.
  • the host receptor protein is ACE2 or CD147.
  • the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of: 6H6.2D6, 20H5.A3, 20D11.2C6, 4G2.2G6, 13H12.2F8, 19B5.2E6, 15G7.2A7, 23H9.2E4, 19D9.2E5, 2D10.2B2, 2D10-VH0-VL0, 4A11.2B5, 14H10.2C9, 3B11.2G2, 13A12.2E5, 7D8.2D8, 15F10.2D6, 23B10.2B12, 12G5.D7, 24D12.2H9, 6B3.2D3, 13G4.2F8, 9H2.2H10, IMT-001, IMT006, IMT006b, and IMT006c, or binding fragment thereof.
  • the sequelae include but are not limited to fibrosis, pulmonary fibrosis, pulmonary edema, cardiovascular disease, thrombosis, neurological disease, kidney disease, or liver disease.
  • the anti-Gal3 antibody or binding fragment thereof is administered in conjunction with another antiviral or anti-inflammatory therapy.
  • any anti-Gal3 antibody disclosed herein further comprises a payload.
  • the payload comprises a small molecule, a protein or functional fragment thereof, a peptide, or a nucleic acid polymer.
  • the number of payloads conjugated to the anti-Gal3 antibody e.g., the drug-to-antibody ratio or DAR
  • the ratio of the payloads to the anti-Gal3 antibody is about 2:1, 3:1, 4:1, 5:1, 6:1, 7:1, 8:1, 9:1, 10:1, 11:1, 12:1, 13:1, 14:1, 15:1, 16:1, 17:1, 18:1, 19:1, or 20:1.
  • the ratio of the payloads to the anti-Gal3 antibody is about 2:1. In some embodiments, the ratio of the payloads to the anti-Gal3 antibody is about 3:1. In some embodiments, the ratio of the payloads to the anti-Gal3 antibody is about 4:1. In some embodiments, the ratio of the payloads to the anti-Gal3 antibody is about 6:1. In some embodiments, the ratio of the payloads to the anti-Gal3 antibody is about 8:1. In some embodiments, the ratio of the payloads to the anti-Gal3 antibody is about 12:1. [0354] In some embodiment, the payload is a small molecule. In some embodiments, the small molecule is a cytotoxic payload.
  • Exemplary cytotoxic payloads include, but are not limited to, microtubule disrupting agents, DNA modifying agents, or Akt inhibitors.
  • the payload comprises a microtubule disrupting agent.
  • Exemplary microtubule disrupting agents include, but are not limited to, 2-methoxyestradiol, auristatin, chalcones, colchicine, combretastatin, cryptophycin, dictyostatin, discodermolide, dolastain, eleutherobin, epothilone, halichondrin, laulimalide, maytansine, noscapinoid, paclitaxel, peloruside, phomopsin, podophyllotoxin, rhizoxin, spongistatin, taxane, tubulysin, vinca alkaloid, vinorelbine, or derivatives or analogs thereof.
  • the maytansine is a maytansinoid.
  • the maytansinoid is DM1, DM4, or ansamitocin.
  • the maytansinoid is DM1.
  • the maytansinoid is DM4.
  • the maytansinoid is ansamitocin.
  • the maytansinoid is a maytansionid derivative or analog such as described in U.S. Patent Nos. 5208020, 5416064, 7276497, and 6716821 or U.S. Publication Nos. 2013029900 and US20130323268.
  • the payload is a dolastatin, or a derivative or analog thereof.
  • the dolastatin is dolastatin 10 or dolastatin 15, or derivatives or analogs thereof.
  • the dolastatin 10 analog is auristatin, soblidotin, symplostatin 1, or symplostatin 3.
  • the dolastatin 15 analog is cemadotin or tasidotin.
  • the dolastatin 10 analog is auristatin or an auristatin derivative.
  • the auristatin or auristatin derivative is auristatin E (AE), auristatin F (AF), auristatin E5-benzoylvaleric acid ester (AEVB), monomethyl auristatin E (MMAE), monomethyl auristatin F (MMAF), or monomethyl auristatin D (MMAD), auristatin PE, or auristatin PYE.
  • the auristatin derivative is monomethyl auristatin E (MMAE).
  • the auristatin derivative is monomethyl auristatin F (MMAF).
  • the auristatin is an auristatin derivative or analog such as described in U.S.
  • the payload comprises a DNA modifying agent.
  • the DNA modifying agent comprises DNA cleavers, DNA intercalators, DNA transcription inhibitors, or DNA cross-linkers.
  • the DNA cleaver comprises bleomycin A2, calicheamicin, or derivatives or analogs thereof.
  • the DNA intercalator comprises doxorubicin, epirubicin, PNU-159682, duocarmycin, pyrrolobenzodiazepine, oligomycin C, daunorubicin, valrubicin, topotecan, or derivatives or analogs thereof.
  • the DNA transcription inhibitor comprises dactinomycin.
  • the DNA cross-linker comprises mitomycin C.
  • the DNA modifying agent comprises amsacrine, anthracycline, camptothecin, doxorubicin, duocarmycin, enediyne, etoposide, indolinobenzodiazepine, netropsin, teniposide, or derivatives or analogs thereof.
  • the anthracycline is doxorubicin, daunorubicin, epirubicin, idarubicin, mitomycin-C, dactinomycin, mithramycin, nemorubicin, pixantrone, sabarubicin, or valrubicin.
  • the analog of camptothecin is topotecan, irinotecan, silatecan, cositecan, exatecan, lurtotecan, gimatecan, belotecan, rubitecan, or SN-38.
  • the duocarmycin is duocarmycin A, duocarmycin B1, duocarmycin B2, duocarmycin C1, duocarmycin C2, duocarmycin D, duocarmycin SA, or CC- 1065.
  • the enediyne is a calicheamicin, esperamicin, or dynemicin A.
  • the pyrrolobenzodiazepine is anthramycin, abbeymycin, chicamycin, DC-81, mazethramycin, neothramycins A, neothramycin B, porothramycin, prothracarcin, sibanomicin (DC-102), sibiromycin, or tomaymycin.
  • the pyrrolobenzodiazepine is a tomaymycin derivative, such as described in U.S. Patent Nos.8404678 and 8163736.
  • the pyrrolobenzodiazepine is such as described in U.S.
  • the pyrrolobenzodiazepine is a pyrrolobenzodiazepine dimer.
  • the PBD dimer is a symmetric dimer.
  • symmetric PBD dimers include, but are not limited to, SJG-136 (SG-2000), ZC-423 (SG2285), SJG-720, SJG-738, ZC-207 (SG2202), and DSB-120.
  • the PBD dimer is an unsymmetrical dimer.
  • unsymmetrical PBD dimers include, but are not limited to, SJG-136 derivatives such as described in U.S. Patent Nos. 8697688 and 9242013 and U.S. Publication No. 20140286970.
  • the payload comprises an Akt inhibitor.
  • the Akt inhibitor comprises ipatasertib (GDC-0068) or derivatives thereof.
  • the payload comprises a polymerase inhibitor, including, but not limited to polymerase II inhibitors such as a-amanitin, and poly(ADP-ribose) polymerase (PARP) inhibitors.
  • PARP inhibitors include, but are not limited to Iniparib (BSI 201), Talazoparib (BMN-673), Olaparib (AZD-2281), Olaparib, Rucaparib (AG014699, PF-01367338), Veliparib (ABT-888), CEP 9722, MK 4827, BGB-290, or 3-aminobenzamide.
  • the payload comprises a detectable moiety.
  • a “detectable moiety” may comprise an atom, molecule, or compound that is useful in diagnosing, detecting or visualizing a location and/or quantity of a target molecule, cell, tissue, organ, and the like.
  • Detectable moieties that can be used in accordance with the embodiments herein include, but are not limited to, radioactive substances (e.g. radioisotopes, radionuclides, radiolabels or radiotracers), dyes, contrast agents, fluorescent compounds or molecules, bioluminescent compounds or molecules, enzyme and enhancing agents (e.g. paramagnetic ions), or specific binding moieties such as streptavidin, avidin, or biotin.
  • radioactive substances that can be used as detectable moieties in accordance with the embodiments herein include, but are not limited to, 18 F, 18 F-FAC, 32 P, 33 P, 45 Ti, 47 Sc, 52 Fe, 59 Fe, 62 Cu, 64 Cu, 67 Cu, 67 Ga, 68 Ga, 75 Sc, 77 As, 86 Y, 90 Y, 89 Sr, 89 Zr, 94 Tc, 94 Tc, 99 mTc, 9 1 223 Ra and 225 Ac.
  • Exemplary paramagnetic ions substances that can be used as detectable markers include, but are not limited to ions of transition and lanthanide metals (e.g. metals having atomic numbers of 6 to 9, 21-29, 42, 43, 44, or 57-71). These metals include ions of Cr, V, Mn, Fe, Co, Ni, Cu, La, Ce, Pr, Nd, Pm, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb and Lu.
  • the detectable marker is a radioactive metal or paramagnetic ion
  • the marker can be reacted with a reagent having a long tail with one or more chelating groups attached to the long tail for binding these ions.
  • the long tail can be a polymer such as a polylysine, polysaccharide, or other derivatized or derivatizable chain having pendant groups to which may be bound to a chelating group for binding the ions.
  • chelating groups include, but are not limited to, ethylenediaminetetraacetic acid (EDTA), diethylenetriaminepentaacetic acid (DTPA), DOTA, NOTA, NOGADA, NETA, deferoxamine (DfO), porphyrins, polyamines, crown ethers, bis- thiosemicarbazones, polyoximes, and like groups.
  • the chelate can be linked to the antigen binding construct by a group which allows formation of a bond to the molecule with minimal loss of immunoreactivity and minimal aggregation and/or internal cross-linking.
  • the same chelates when complexed with non-radioactive metals, such as manganese, iron and gadolinium are useful for MRI, when used along with the antigen binding constructs and carriers described herein.
  • Macrocyclic chelates such as NOTA, NOGADA, DOTA, and TETA are of use with a variety of metals and radiometals including, but not limited to, radionuclides of gallium, yttrium and copper, respectively.
  • ring-type chelates such as macrocyclic polyethers, which are of interest for stably binding radionuclides, such as Radium-223 for RAIT may be used.
  • chelating moieties may be used to attach a PET imaging agent, such as an Aluminum-18F complex, to a targeting molecule for use in PET analysis.
  • Exemplary contrast agents that can be used as detectable moieties in accordance with the embodiments of the disclosure include, but are not limited to, barium, diatrizoate, ethiodized oil, gallium citrate, iocarmic acid, iocetamic acid, iodamide, iodipamide, iodoxamic acid, iogulamide, iohexyl, iopamidol, iopanoic acid, ioprocemic acid, iosefamic acid, ioseric acid, iosulamide meglumine, iosemetic acid, iotasul, iotetric acid, iothalamic acid, iotroxic acid, ioxaglic acid, ioxotrizoic acid, ipodate, meglumine, metrizamide, metrizoate, propyliodone, thallous chloride,
  • Bioluminescent and fluorescent compounds or molecules and dyes that can be used as detectable moieties in accordance with the embodiments of the disclosure include, but are not limited to, allophycocyanin (APC), phycoerythrin (PE), fluorescein, fluorescein isothiocyanate (FITC), OREGON GREENTM, rhodamine, Texas red, tetrarhodimine isothiocynate (TRITC), Cy3, Cy5, and the like), fluorescent markers (e.g., green fluorescent protein (GFP) and the like), autoquenched fluorescent compounds that are activated by tumor-associated proteases, enzymes (e.g., luciferase, horseradish peroxidase, alkaline phosphatase, and the like), nanoparticles, biotin, digoxigenin or combinations thereof.
  • APC allophycocyanin
  • PE phycoerythrin
  • FITC fluorescein, fluorescein iso
  • Enzymes that can be used as detectable moieties in accordance with the embodiments of the disclosure include, but are not limited to, horseradish peroxidase, alkaline phosphatase, acid phosphatase, glucose oxidase, ⁇ -galactosidase, ⁇ -glucoronidase or ⁇ -lactamase. Such enzymes may be used in combination with a chromogen, a fluorogenic compound or a luminogenic compound to generate a detectable signal.
  • the payload is a nanoparticle.
  • nanoparticle refers to a microscopic particle whose size is measured in nanometers, e.g., a particle with at least one dimension less than about 100 nm. Nanoparticles can be used as detectable substances because they are small enough to scatter visible light rather than absorb it. For example, gold nanoparticles possess significant visible light extinction properties and appear deep red to black in solution. As a result, compositions comprising antigen binding constructs conjugated to nanoparticles can be used for the in vivo imaging of T-cells in a subject. At the small end of the size range, nanoparticles are often referred to as clusters. Metal, dielectric, and semiconductor nanoparticles have been formed, as well as hybrid structures (e.g.
  • the payload is an antimicrobial agent, a therapeutic agent, a prodrug, a peptide, a protein, an enzyme, a lipid, a biological response modifier, a pharmaceutical agent, a lymphokine, a heterologous antibody or fragment thereof, a detectable label, a polyethylene glycol (PEG) molecule, or a combination of two or more of the agents.
  • the payload comprises a neuroactive polypeptide, for example, a neurotrophic factors, endocrine factors, growth factors, paracrine factors, hypothalamic release factors, neurotransmitter polypeptides, polypeptide agonists for a receptor expressed by a CNS cell, polypeptides involved in lysosomal storage disease or any combination thereof.
  • a neuroactive polypeptide for example, a neurotrophic factors, endocrine factors, growth factors, paracrine factors, hypothalamic release factors, neurotransmitter polypeptides, polypeptide agonists for a receptor expressed by a CNS cell, polypeptides involved in lysosomal storage disease or any combination thereof.
  • the payload comprises an IL-1 receptor antagonist (IL-IRa), dalargin, an interferon- ⁇ , Glial-derived neurotrophic factor (GDNF), tumor necrosis factor receptor (TNFR), nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-4/5, neurotrophin (NT)-3, a neurturin, neuregulin, a netrin, ciliary neurotrophic factor (CNTF), stem cell factor (SCF), a semaphorin, hepatocyte growth factor (HGF), epidermal growth factor (EGF), transforming growth factor (TGF)-cx, TGF-B, vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), heregulin, artemin, persephin, interleukins, granulocyte- colony stimulating factor (CSF), granulocyte-macrophage-CSF, cardiotrophin-1, hedgehogs, leukemia inhibitory factor
  • the payload is another antibody, or a heavy and/or light chain, or any other fragment thereof.
  • the payload comprises a heterologous antibody or fragment thereof, for example, a heterologous antibody or fragment thereof specifically binds to one or more of beta-secretase 1 (BACE1), CD20, CD25, CD52, CD33, CTLA-4, tenascin, alpha- 4 (a4) integrin, IL-12, IL-23, the p40 subunit of IL-12/IL-23, amyloid-13 (AI3), Huntingtin, nerve growth factor (NGF), epidermal growth factor receptor (EGFR/HER1), human epidermal growth factor receptor 2 (HER2/neu), vascular endothelial growth factor (VEGF), TrkA, TNF-a, TNF-13, a-synuclein Tau, apolipoprotein E4 (ApoE4), prion protein (PrP), leucine rich repeat (BACE1), CD20, CD25, CD
  • the payload comprises an immunomodulatory agent.
  • immunomodulatory agents include anti-hormones that block hormone action on tumors and immunosuppressive agents that suppress cytokine production, down-regulate self-antigen expression, or mask MHC antigens.
  • anti-hormones include anti-estrogens including, for example, tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4- hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone , and toremifene; and anti- androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and goserelin; and anti-adrenal agents.
  • anti-estrogens including, for example, tamoxifen, raloxifene, aromatase inhibiting 4(5)-imidazoles, 4- hydroxytamoxifen, trioxifene, keoxifene, LY 117018, onapristone , and toremifene
  • anti- androgens such as flutamide, nilutamide, bicalutamide, leuprolide, and go
  • Illustrative immunosuppressive agents include, but are not limited to 2-amino-6-aryl-5- substituted pyrimidines, azathioprine, cyclophosphamide, bromocryptine, danazol, dapsone, glutaraldehyde, anti-idiotypic antibodies for MHC antigens and MHC fragments, cyclosporin A, steroids such as glucocorticosteroids, streptokinase, or rapamycin.
  • the payload comprises an immune modulator.
  • immune modulators include, but are not limited to, gancyclovir, etanercept, tacrolimus, sirolimus, voclosporin, cyclosporine, rapamycin, cyclophosphamide, azathioprine, mycophenolate mofetil, methotrexate, glucocorticoid and its analogs, xanthines, stem cell growth factors, lymphotoxins, hematopoietic factors, tumor necrosis factor (TNF) (e.g., TNF ⁇ ), interleukins (e.g., interleukin-1 (IL-1), IL-2, IL-3, IL-6, IL-10, IL-12, IL-18, and IL-21), colony stimulating factors (e.g., granulocyte-colony stimulating factor (G-CSF) and granulocyte macrophage-colony stimulating factor (GM-CSF)), interferons (e.g., interferons-alpha, interferon
  • the payload comprises an immunotoxin.
  • Immunotoxins include, but are not limited to, ricin, radionuclides, pokeweed antiviral protein, Pseudomonas exotoxin A, diphtheria toxin, ricin A chain, fungal toxins such as restrictocin and phospholipase enzymes. See, generally, “Chimeric Toxins,” Olsnes and Pihl, Pharmac. Ther. 15:355-381 (1981); and “Monoclonal Antibodies for Cancer Detection and Therapy,” eds. Baldwin and Byers, pp. 159-179, 224-266, Academic Press (1985).
  • the payload comprises a nucleic acid polymer.
  • the nucleic acid polymer comprises short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), short hairpin RNA (shRNA), an antisense oligonucleotide.
  • the nucleic acid polymer comprises an mRNA, encoding, e.g., a cytotoxic protein or peptide or an apoptotic triggering protein or peptide.
  • Exemplary cytotoxic proteins or peptides include a bacterial cytotoxin such as an alpha-pore forming toxin (e.g., cytolysin A from E. coli), a beta-pore-forming toxin (e.g., ⁇ - Hemolysin, PVL—panton Valentine leukocidin, aerolysin, clostridial Epsilon-toxin, clostridium perfringens enterotoxin), binary toxins (anthrax toxin, edema toxin, C. botulinum C2 toxin, C spirofome toxin, C. perfringens iota toxin, C.
  • a bacterial cytotoxin such as an alpha-pore forming toxin (e.g., cytolysin A from E. coli), a beta-pore-forming toxin (e.g., ⁇ - Hemolysin, PVL—pa
  • cyto-lethal toxins A and B
  • prion parasporin, a cholesterol-dependent cytolysins (e.g., pneumolysin), a small pore-forming toxin (e.g., Gramicidin A), a cyanotoxin (e.g., microcystins, nodularins), a hemotoxin, a neurotoxin (e.g., botulinum neurotoxin), a cytotoxin, cholera toxin, diphtheria toxin, Pseudomonas exotoxin A, tetanus toxin, or an immunotoxin (idarubicin, ricin A, CRM9, Pokeweed antiviral protein, DT).
  • a cholesterol-dependent cytolysins e.g., pneumolysin
  • small pore-forming toxin e.g., Gramicidin A
  • cyanotoxin e.
  • Exemplary apoptotic triggering proteins or peptides include apoptotic protease activating factor-1 (Apaf-1), cytochrome-c, caspase initiator proteins (CASP2, CASP8, CASP9, CASP10), apoptosis inducing factor (AIF), p53, p73, p63, Bcl-2, Bax, granzyme B, poly-ADP ribose polymerase (PARP), and P 21-activated kinase 2 (PAK2).
  • the nucleic acid polymer comprises a nucleic acid decoy.
  • the nucleic acid decoy is a mimic of protein-binding nucleic acids such as RNA-based protein-binding mimics.
  • Exemplary nucleic acid decoys include transactivating region (TAR) decoy and Rev response element (RRE) decoy.
  • the payload is an aptamer.
  • Aptamers are small oligonucleotide or peptide molecules that bind to specific target molecules.
  • Exemplary nucleic acid aptamers include DNA aptamers, RNA aptamers, or XNA aptamers which are RNA and/or DNA aptamers comprising one or more unnatural nucleotides.
  • nucleic acid aptamers include ARC19499 (Archemix Corp.), REG1 (Regado Biosciences), and ARC1905 (Ophthotech).
  • Nucleic acids in accordance with the embodiments described herein optionally include naturally occurring nucleic acids, or one or more nucleotide analogs or have a structure that otherwise differs from that of a naturally occurring nucleic acid.
  • 2’- modifications include halo, alkoxy, and allyloxy groups.
  • the 2’-OH group is replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, NR2 or CN, wherein R is C1-C6 alkyl, alkenyl, or alkynyl, and halo is F, Cl, Br, or I.
  • modified linkages include phosphorothioate and 5’-N-phosphoramidite linkages.
  • nucleic acids include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine) or modified nucleosides.
  • natural nucleosides i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine
  • modified nucleotides include base modified nucleoside (e.g., aracytidine, inosine, isoguanosine, nebularine, pseudouridine, 2,6-diaminopurine, 2-aminopurine, 2-thiothymidine, 3-deaza-5-azacytidine, 2′- deoxyuridine, 3-nitorpyrrole, 4-methylindole, 4-thiouridine, 4-thiothymidine, 2-aminoadenosine, 2-thiothymidine, 2-thiouridine, 5-bromocytidine, 5-iodouridine, inosine, 6-azauridine, 6- chloropurine, 7-deazaadenosine, 7-deazaguanosine, 8-azaadenosine, 8-azidoadenosine, benzimidazole, M1-methyladenosine, pyrrolo-pyrimidine, 2-amino-6-chloropurine, M
  • nucleic acids Natural and modified nucleotide monomers for the chemical synthesis of nucleic acids are readily available.
  • nucleic acids comprising such modifications display enhanced properties relative to nucleic acids consisting only of naturally occurring nucleotides.
  • nucleic acid modifications described herein are utilized to reduce and/or prevent digestion by nucleases (e.g. exonucleases, endonucleases, etc.).
  • nucleases e.g. exonucleases, endonucleases, etc.
  • the structure of a nucleic acid may be stabilized by including nucleotide analogs at the 3′ end of one or both strands order to reduce digestion.
  • nucleotide modifications and/or backbone structures may exist at various positions in the nucleic acid.
  • any of the anti-Gal3 antibodies disclosed herein may be conjugated to one or more (e.g. 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10, or more) payloads described herein.
  • Conjugation Chemistry [0386] In some embodiments, the payload is conjugated to an anti-Gal3 antibody described herein by a native ligation.
  • the conjugation is as described in: Dawson, et al. “Synthesis of proteins by native chemical ligation,” Science 1994, 266, 776–779; Dawson, et al. “Modulation of Reactivity in Native Chemical Ligation through the Use of Thiol Additives,” J. Am. Chem. Soc.1997, 119, 4325–4329;hackeng, et al. “Protein synthesis by native chemical ligation: Expanded scope by using straightforward methodology.,” Proc. Natl. Acad. Sci. USA 1999, 96, 10068–10073; or Wu, et al. “Building complex glycopeptides: Development of a cysteine-free native chemical ligation protocol,” Angew. Chem.
  • the conjugation is as described in U.S. Patent No. 8,936,910.
  • the payload is conjugated to an anti-Gal3 antibody described herein by a site-directed method utilizing a “traceless” coupling technology (Philochem).
  • the “traceless” coupling technology utilizes an N-terminal 1,2-aminothiol group on the binding moiety which is then conjugated with a polynucleic acid molecule containing an aldehyde group.
  • the payload is conjugated to an anti-Gal3 antibody described herein by a site-directed method utilizing an unnatural amino acid incorporated into the binding moiety.
  • the unnatural amino acid comprises p-acetylphenylalanine (pAcPhe).
  • the keto group of pAcPhe is selectively coupled to an alkoxy- amine derivatived conjugating moiety to form an oxime bond.
  • the payload is conjugated to an anti-Gal3 antibody described herein by a site-directed method utilizing an enzyme-catalyzed process.
  • the site-directed method utilizes SMARTagTM technology (Redwood).
  • the SMARTagTM technology comprises generation of a formylglycine (FGly) residue from cysteine by formylglycine-generating enzyme (FGE) through an oxidation process under the presence of an aldehyde tag and the subsequent conjugation of FGly to an alkylhydraine- functionalized polynucleic acid molecule via hydrazino-Pictet-Spengler (HIPS) ligation.
  • FGE formylglycine residue from cysteine by formylglycine-generating enzyme
  • HIPS hydrazino-Pictet-Spengler
  • the enzyme-catalyzed process comprises microbial transglutaminase (mTG).
  • the payload is conjugated to the anti-Gal3 antibody utilizing a microbial transglutaminase catalyzed process.
  • mTG catalyzes the formation of a covalent bond between the amide side chain of a glutamine within the recognition sequence and a primary amine of a functionalized polynucleic acid molecule.
  • mTG is produced from Streptomyces mobarensis. (see Strop et al., “Location matters: site of conjugation modulates stability and pharmacokinetics of antibody drug conjugates,” Chemistry and Biology 20(2) 161-167 (2013)).
  • the payload is conjugated to an anti-Gal3 antibody by a method as described in PCT Publication No.
  • WO2014/140317 which utilizes a sequence-specific transpeptidase and is hereby expressly incorporated by reference in its entirety.
  • the payload is conjugated to an anti-Gal3 antibody described herein by a method as described in U.S. Patent Publication Nos. 2015/0105539 and 2015/0105540.
  • Linker [0393]
  • a linker described herein comprises a natural or synthetic polymer, consisting of long chains of branched or unbranched monomers, and/or cross-linked network of monomers in two or three dimensions.
  • the linker includes a polysaccharide, lignin, rubber, or polyalkylene oxide (e.g., polyethylene glycol).
  • the linker includes, but is not limited to, alpha-, omega- dihydroxylpolyethyleneglycol, biodegradable lactone-based polymer, e.g. polyacrylic acid, polylactide acid (PLA), poly(glycolic acid) (PGA), polypropylene, polystyrene, polyolefin, polyamide, polycyanoacrylate, polyimide, polyethylenterephthalat (PET, PETG), polyethylene terephthalate (PETE), polytetramethylene glycol (PTG), or polyurethane as well as mixtures thereof.
  • a mixture refers to the use of different polymers within the same compound as well as in reference to block copolymers.
  • block copolymers are polymers wherein at least one section of a polymer is built up from monomers of another polymer.
  • the linker comprises polyalkylene oxide.
  • the linker comprises PEG.
  • the linker comprises polyethylene imide (PEI) or hydroxy ethyl starch (HES).
  • the polyalkylene oxide e.g., PEG
  • polydisperse material comprises disperse distribution of different molecular weight of the material, characterized by mean weight (weight average) size and dispersity.
  • the monodisperse PEG comprises one size of molecules.
  • the linker is poly- or monodispersed polyalkylene oxide (e.g., PEG) and the indicated molecular weight represents an average of the molecular weight of the polyalkylene oxide, e.g., PEG, molecules.
  • the linker comprises a polyalkylene oxide (e.g., PEG) and the molecular weight of the polyalkylene oxide (e.g., PEG) is about 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, 1300, 1400, 1450, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3250, 3350, 3500, 3750, 4000, 4250, 4500, 4600, 4750, 5000, 5500, 6000, 6500, 7000, 7500, 8000, 10,000, 12,000, 20,000, 35,000, 40,000, 50,000, 60,000, or 100,000 Da.
  • PEG polyalkylene oxide
  • the polyalkylene oxide is a discrete PEG, in which the discrete PEG is a polymeric PEG comprising more than one repeating ethylene oxide unit.
  • a discrete PEG comprises from 2 to 60, from 2 to 50, or from 2 to 48 repeating ethylene oxide units.
  • a dPEG comprises about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 42, 48, 50 or more repeating ethylene oxide units.
  • a dPEG comprises about 2 or more repeating ethylene oxide units.
  • a dPEG is synthesized as a single molecular weight compound from pure (e.g., about 95%, 98%, 99%, or 99.5%) starting material in a step-wise fashion.
  • a dPEG has a specific molecular weight, rather than an average molecular weight.
  • the linker is a discrete PEG, optionally comprising from 2 to 60, from 2 to 50, or from 2 to 48 repeating ethylene oxide units.
  • the linker comprises a dPEG comprising about 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 24, 26, 28, 30, 35, 40, 42, 48, 50 or more repeating ethylene oxide units.
  • the linker is a polypeptide linker.
  • the polypeptide linker comprises at least 2, 3, 4, 5, 6, 7, 8, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, or more amino acid residues.
  • the polypeptide linker comprises at least 2, 3, 4, 5, 6, 7, 8, or more amino acid residues.
  • the polypeptide linker comprises at most 2, 3, 4, 5, 6, 7, 8, or less amino acid residues.
  • the polypeptide linker is a cleavable polypeptide linker (e.g., either enzymatically or chemically).
  • the polypeptide linker is a non-cleavable polypeptide linker.
  • the polypeptide linker comprises Val-Cit (valine-citrulline), Gly- Gly-Phe-Gly, Phe-Lys, Val-Lys, Gly-Phe-Lys, Phe-Phe-Lys, Ala-Lys, Val-Arg, Phe-Cit, Phe-Arg, Leu-Cit, Ile-Cit, Trp-Cit, Phe-Ala, Ala-Leu-Ala-Leu, or Gly-Phe-Leu-Gly.
  • the polypeptide linker comprises a peptide such as: Val-Cit (valine-citrulline), Gly-Gly-Phe-Gly, Phe-Lys, Val-Lys, Gly-Phe-Lys, Phe-Phe-Lys, Ala-Lys, Val-Arg, Phe-Cit, Phe-Arg, Leu-Cit, Ile- Cit, Trp-Cit, Phe-Ala, Ala-Leu-Ala-Leu, or Gly-Phe-Leu-Gly.
  • the polypeptide linker comprises L-amino acids, D-amino acids, or a mixture of both L- and D-amino acids.
  • the linker comprises a homobifunctional linker.
  • exemplary homobifunctional linkers include, but are not limited to, Lomant's reagent dithiobis (succinimidylpropionate) DSP, 3′3′-dithiobis(sulfosuccinimidyl proprionate (DTSSP), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl)suberate (BS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo DST), ethylene glycobis(succinimidylsuccinate) (EGS), disuccinimidyl glutarate (DSG), N,N′-disuccinimidyl carbonate (DSC), dimethyl adipimidate (DMA), dimethyl pimelimidate (DMP), dimethyl suberimidate (DMS), dimethyl-3,3′- di
  • DFDNPS 4,4′-difluoro-3,3′- dinitrophenylsulfone
  • BASED bis-[ ⁇ -(4-azidosalicylamido)ethyl]disulfide
  • formaldehyde glutaraldehyde
  • 1,4-butanediol diglycidyl ether 1,4-butanediol diglycidyl ether
  • adipic acid dihydrazide carbohydrazide, o-toluidine, 3,3′-dimethylbenzidine, benzidine, ⁇ , ⁇ ′-p-diaminodiphenyl, diiodo- p-xylene sulfonic acid, N,N′-ethylene-bis(iodoacetamide), or N,N′-hexamethylene- bis(iodoacetamide).
  • the linker comprises a heterobifunctional linker.
  • exemplary heterobifunctional linker include, but are not limited to, amine-reactive and sulfhydryl cross-linkers such as N-succinimidyl 3-(2-pyridyldithio)propionate (sPDP), long-chain N- succinimidyl 3-(2-pyridyldithio)propionate (LC-sPDP), water-soluble-long-chain N-succinimidyl 3-(2-pyridyldithio) propionate (sulfo-LC-sPDP), succinimidyloxycarbonyl- ⁇ -methyl- ⁇ -(2- pyridyldithio)toluene (sMPT), sulfosuccinimidyl-6-[ ⁇ -methyl- ⁇ -(2- pyridyldithio)toluamido]hexanoate (sulfo-
  • the linker comprises a benzoic acid group, or its derivatives thereof.
  • the benzoic acid group or its derivatives thereof comprise paraaminobenzoic acid (PABA).
  • the benzoic acid group or its derivatives thereof comprise gamma-aminobutyric acid (GABA).
  • the linker comprises one or more of a maleimide group, a peptide moiety, and/or a benzoic acid group, in any combination.
  • the linker comprises a combination of a maleimide group, a peptide moiety, and/or a benzoic acid group.
  • the maleimide group is maleimidocaproyl (mc).
  • the peptide group is val-cit.
  • the benzoic acid group is PABA.
  • the linker comprises a mc-val-cit group.
  • the linker comprises a val-cit-PABA group.
  • the linker comprises a mc-val-cit-PABA group.
  • the linker is a self-immolative linker or a self-elimination linker. In some embodiments, the linker is a self-immolative linker.
  • the linker is a self-elimination linker (e.g., a cyclization self-elimination linker).
  • the linker comprises a linker described in U.S. Patent No. 9,089,614 or PCT Publication No. WO2015038426.
  • the linker is a dendritic type linker.
  • the dendritic type linker comprises a branching, multifunctional linker moiety.
  • the dendritic type linker comprises PAMAM dendrimers.
  • the linker is a traceless linker or a linker in which after cleavage does not leave behind a linker moiety (e.g., an atom or a linker group) to the antibody or payload.
  • a linker moiety e.g., an atom or a linker group
  • Exemplary traceless linkers include, but are not limited to, germanium linkers, silicium linkers, sulfur linkers, selenium linkers, nitrogen linkers, phosphorus linkers, boron linkers, chromium linkers, or phenylhydrazide linker.
  • the linker is a traceless aryl- triazene linker as described in Hejesen, et al., “A traceless aryl-triazene linker for DNA-directed chemistry,” Org Biomol Chem 11(15): 2493-2497 (2013).
  • the linker is a traceless linker described in Blaney, et al., “Traceless solid-phase organic synthesis,” Chem. Rev. 102: 2607-2024 (2002).
  • a linker is a traceless linker as described in U.S. Patent No. 6,821,783.
  • the present disclosure provides host cells expressing any one of the anti-Gal3 antibodies or binding fragments thereof disclosed herein.
  • a subject host cell typically comprises a nucleic acid encoding any one of the anti-Gal3 antibodies or binding fragments thereof disclosed herein.
  • the disclosure provides host cells transfected with the polynucleotides, vectors, or a library of the vectors described above.
  • the vectors can be introduced into a suitable prokaryotic or eukaryotic cell by any of a number of appropriate means, including electroporation, microprojectile bombardment; lipofection, infection (where the vector is coupled to an infectious agent), transfection employing calcium chloride, rubidium chloride, calcium phosphate, DEAE- dextran, or other substances.
  • the choice of the means for introducing vectors will often depend on features of the host cell.
  • any of the above-mentioned methods is suitable for vector delivery.
  • Preferred animal cells are vertebrate cells, preferably mammalian cells, capable of expressing exogenously introduced gene products in large quantity, e.g. at the milligram level.
  • Non-limiting examples of preferred cells are NIH3T3 cells, COS, HeLa, and CHO cells.
  • expression of the anti-Gal3 antibodies or binding fragments thereof can be determined using any nucleic acid or protein assay known in the art.
  • the presence of transcribed mRNA of light chain CDRs or heavy chain CDRs, or the anti-Gal3 antibody or binding fragment thereof can be detected and/or quantified by conventional hybridization assays (e.g. Northern blot analysis), amplification procedures (e.g. RT- PCR), SAGE (U.S. Pat. No. 5,695,937), and array-based technologies (see e.g. U.S. Pat. Nos.
  • radioimmunoassays include but are not limited to radioimmunoassays, ELISA (enzyme linked immunoradiometric assays), “sandwich” immunoassays, immunoradiometric assays, in situ immunoassays (using e.g., colloidal gold, enzyme or radioisotope labels), western blot analysis, immunoprecipitation assays, immunofluorescent assays, and SDS-PAGE.
  • An anti-Gal3 antibody or binding fragment thereof comprising (1) a light chain variable region comprising a VL-CDR1, a VL-CDR2, and a VL-CDR3; and (2) a heavy chain variable region comprising a VH-CDR1, a VH-CDR2, and a VH-CDR3, wherein the V L -CDR1 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 170-220, the VL-CDR2 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 221-247, the VL-CDR3 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to
  • the anti-Gal3 antibody or binding fragment comprises a combination of a VL-CDR1, a VL-CDR2, a V L -CDR3, a V H -CDR1, a V H -CDR2, and a V H -CDR3 as illustrated in FIG. 14.
  • the anti-Gal3 antibody or binding fragment thereof of any one of arrangements 1-4 wherein the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 297-373, 822, 828. [0419] 6.
  • the anti-Gal3 antibody or binding fragment thereof of any one of arrangements 1-5 wherein the heavy chain variable region comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828. [0420] 7.
  • the anti-Gal3 antibody or binding fragment thereof of arrangement 9, wherein the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829. [0424] 11.
  • the anti-Gal3 antibody or binding fragment thereof of any one of arrangements 1-10 wherein the anti-Gal3 antibody or binding fragment is selected from the group consisting of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4,
  • a method of treating lung fibrosis in a subject in need thereof comprising: administering to the subject an effective amount of an anti-Gal3 antibody or binding fragment thereof; wherein the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a TGF-b receptor; and wherein the lung fibrosis is a sequela of a viral infection.
  • the method of arrangement 12 or 13 wherein the viral infection is a SARS- related coronavirus infection.
  • the viral infection is a SARS-CoV-2 coronavirus infection.
  • a method of disrupting an interaction between Gal3 and a SARS-CoV-2- associated host cell receptor comprising: contacting the SARS-CoV-2-associated host cell receptor with an anti-Gal3 antibody or binding fragment thereof; wherein the SARS-CoV-2-associated host cell receptor is ACE2 or CD147.
  • a method of disrupting an interaction between Gal3 and a SARS-CoV-2 S protein comprising: contacting the SARS-CoV-2 S protein with an anti-Gal3 antibody or binding fragment thereof.
  • a method of treating a SARS-CoV-2 infection in a subject in need thereof comprising: administering to the subject an effective amount of an anti-Gal3 antibody or binding fragment thereof; wherein the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a SARS-CoV-2-associated host cell receptor or a SAR-CoV-2 protein; and wherein the SARS-CoV-2 associated host cell receptor is ACE2 or CD147 or the SARS- CoV-2 protein is the SARS-CoV-2 S protein.
  • a method of treating a viral infection in a subject in need thereof comprising: administering to the subject an effective amount of an anti-Gal3 antibody or binding fragment thereof; wherein the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a viral protein.
  • a method of treating SARS-CoV-2 infection comprising: administering to a subject an effective amount of an anti-Gal3 antibody or binding fragment thereof, wherein the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and a SARS-CoV-2 S protein, and wherein the anti-Gal3 antibody is capable of binding to: (a) Gal3 on a SARS-CoV-2 virus, or (b) Gal3 associated with a cell.
  • a method of preventing and/or reducing a viral spread comprising: administering to a subject an effective amount of an anti-Gal3 antibody or binding fragment thereof, wherein the anti-Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and ACE2 and/or Gal3 and CD147.
  • a method of reducing a risk that a virus can invade a cell comprising: administering to a cell an anti-Gal3 antibody or binding fragment thereof, wherein the anti- Gal3 antibody or binding fragment thereof disrupts an interaction between Gal3 and ACE2 and/or Gal3 and CD147.
  • any one of arrangements 36-46, wherein the inflammation comprises lung inflammation.
  • SLE systemic lupus erythematosus
  • Graves’ disease rheumatoid arthritis
  • multiple sclerosis multiple sclerosis
  • Sjogren’s syndrome celiac disease, or any combination thereof.
  • a method of decreasing or inhibiting cleavage of CD62L, decreasing IL-8 production, and/or modulating expression of Gal3, MPO, GRO ⁇ /KC, Ly6c1, INOS, IL-6, TNF ⁇ , IL-1B, Col1A1, aSMA, TGF ⁇ , VEGFA, VEGFB, or any combination thereof, by a cell comprising contacting the cell with an anti-Gal3 antibody or binding fragment thereof, thereby decreasing or inhibiting cleavage of CD62L, decreasing IL-8 production, and/or modulating expression of Gal3, MPO, GRO ⁇ /KC, Ly6c1, INOS, IL-6, TNF ⁇ , IL-1B, Col1A1, aSMA, TGF ⁇ , VEGFA, VEGFB, or any combination thereof, by the cell.
  • the anti-Gal3 antibody or binding fragment thereof comprises (1) a light chain variable region comprising a V L - CDR1, a VL-CDR2, and a VL-CDR3; and (2) a heavy chain variable region comprising a VH- CDR1, a VH-CDR2, and a VH-CDR3, wherein the V L -CDR1 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 170-220, the V L -CDR2 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 221-247, the V L -CDR3 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 248-296,
  • the anti-Gal3 antibody or binding fragment comprises a combination of a VL-CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 as illustrated in FIG. 14.
  • the anti-Gal3 antibody or binding fragment comprises a combination of a VL-CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 as illustrated in FIG. 14.
  • 66 The method of any one of arrangements 12-64, wherein the anti-Gal3 antibody or binding fragment comprises a combination of a VL-CDR1, a VL-CDR2, a VL-CDR3, a VH-CDR1, a VH-CDR2, and a VH-CDR3 as illustrated in FIG. 14.
  • the method of arrangement 64 or 65, wherein the light chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 374-449. [0480] 67. The method of any one of arrangements 64-66, wherein the light chain variable region comprises the sequence selected from SEQ ID NOs: 374-449. [0481] 68.
  • the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 297-373, 822, 828. [0482] 69.
  • the method of any one of arrangements 64-68, wherein the heavy chain variable region comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828. [0483] 70.
  • the anti-Gal3 antibody or binding fragment thereof comprises a light chain
  • the light chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 495-538, 830.
  • 71 The method of arrangement 70, wherein the light chain comprises the sequence selected from SEQ ID NOs: 495-538, 830.
  • the anti-Gal3 antibody or binding fragment thereof comprises a heavy chain
  • the heavy chain comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 448-494, 829.
  • the method of arrangement 72, wherein the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829.
  • 74 is the sequence selected from SEQ ID NOs: 448-494, 829.
  • any one of arrangements 12-73 wherein the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16B5,
  • any one of arrangements 12-74 further comprising administering one or more antiviral or anti-inflammatory therapeutics selected from the group consisting of chloroquine, hydroxychloroquine, favipiravir, favilavir, remdesivir, tocilizumab, baricitinib, acalabrutinib, galidesivir, sarilumab, lopinavir, ritonavir, darunavir, ribavirin, dexamethasone, ciclesonide, convalescent plasma, interferon- ⁇ , pegylated interferon- ⁇ , and interferon alfa-2b, or any combination thereof.
  • one or more antiviral or anti-inflammatory therapeutics selected from the group consisting of chloroquine, hydroxychloroquine, favipiravir, favilavir, remdesivir, tocilizumab, baricitinib, acalabrutinib, galidesivir,
  • CRS an anti-Gal3 antibody or binding fragment thereof for the treatment of CRS.
  • arrangement 76 wherein the CRS is a result of a bacterial infection, viral infection, fungal infection, protozoan infection, graft-versus-host disease, cytomegalovirus, Epstein-Barr virus, hemophagocytic lymphohistiocystosis (HLH), Epstein-Barr virus-associated HLH, sporadic HLH, macrophage activation syndrome (MAS), chronic arthritis, systemic Juvenile idiopathic Arthritis (sJIA), Still’s Disease, Cryopyrin-associated Periodic Syndrome (CAPS), Familial Cold Auto-inflammatory Syndrome (FCAS), Familial Cold Urticaria (FCU), Muckle- Well Syndrome (MWS), Chronic Infantile Neurological Cutaneous and Articular (CINCA) Syndrome, cryopyrinopathy comprising inherited or de novo gain of function mutations in the NLRP
  • any one of arrangements 76-81, wherein the viral infection is a coronavirus infection.
  • 83 The use of any one of arrangements 76-82, wherein the viral infection is a SARS-related coronavirus infection.
  • 84 The use of any one of arrangements 76-83, wherein the viral infection is a SARS-CoV-2 coronavirus infection.
  • 85 The use of any one of arrangements 76-84, wherein the anti-Gal3 antibody or binding fragment thereof binds to the N-terminus of Gal3.
  • any one of arrangements 76-85, wherein the anti-Gal3 antibody or binding fragment thereof binds to the N-terminal domain of Gal3.
  • any one of arrangements 76-87, wherein the anti-Gal3 antibody or binding fragment thereof binds to Peptide 7 (AYPGAPGAYPGAPAPGVYPG; SEQ ID NO: 9).
  • the anti-Gal3 antibody or binding fragment thereof comprises (1) a light chain variable region comprising a VL-CDR1, a VL- CDR2, and a VL-CDR3; and (2) a heavy chain variable region comprising a VH-CDR1, a VH- CDR2, and a V H -CDR3, wherein the VL-CDR1 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 170-220, the VL-CDR2 comprises an amino acid sequence having at least 60%, at least 70%, at least 80%, at least 90%, or 100% sequence identity to any amino acid sequence according to SEQ ID NOs: 170-220, the VL-CDR2 comprises an amino acid sequence having at
  • arrangement 91 or 92 wherein the light chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 374-447, 823-825.
  • arrangement 91-93 wherein the light chain variable region comprises the sequence selected from SEQ ID NOs: 374-447, 823-825.
  • any one of arrangements 91-94, wherein the heavy chain variable region comprises a sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to the sequence selected from SEQ ID NOs: 297-373, 822, 828. [0509] 96. The use of any one of arrangements 91-95, wherein the heavy chain variable region comprises the sequence selected from SEQ ID NOs: 297-373, 822, 828. [0510] 97.
  • the use of arrangement 99, wherein the heavy chain comprises the sequence selected from SEQ ID NOs: 448-494, 829. [0514] 101.
  • any one of arrangements 76-100, wherein the anti-Gal3 antibody or binding fragment thereof is selected from the group consisting of: TB001, TB006, 12G5.D7, 13A12.2E5, 14H10.2C9, 15F10.2D6, 19B5.2E6, 20D11.2C6, 20H5.A3, 23H9.2E4, 2D10.2B2, 3B11.2G2, 7D8.2D8, mIMT001, 4A11.2B5, 4A11.H1L1, 4A11.H4L2, 4G2.2G6, 6B3.2D3, 6H6.2D6, 9H2.2H10, 13G4.2F8, 13H12.2F8, 15G7.2A7, 19D9.2E5, 23B10.2B12, 24D12.2H9, F846C.1B2, F846C.1F5, F846C.1H12, F846C.1H5, F846C.2H3, F846TC.14A2, F846TC.14E4, F846TC.16
  • a method of treating a disorder comprising: administering to a subject an effective amount of an anti-Gal3 antibody or binding fragment thereof, wherein the disorder is selected from at least one of: bacterial infection, viral infection, fungal infection, protozoan infection, graft-versus-host disease, cytomegalovirus, Epstein-Barr virus, hemophagocytic lymphohistiocystosis (HLH), Epstein-Barr virus-associated HLH, sporadic HLH, macrophage activation syndrome (MAS), chronic arthritis, systemic Juvenile idiopathic Arthritis (sJIA), Still’s Disease, Cryopyrin-associated Periodic Syndrome (CAPS), Familial Cold Auto-inflammatory Syndrome (FCAS), Familial Cold Urticaria (FCU), Muckle-Well Syndrome (MWS), Chronic Infantile Neurological Cutaneous and Articular (CINCA) Syndrome, cryopyrinopathy comprising inherited or de novo gain of function
  • the disorder is selected from at least
  • a pharmaceutical antibody formulation comprising: a therapeutically effective amount of the antibody of any one of arrangements 1-11; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • 104 A pharmaceutical antibody formulation comprising: a therapeutically effective amount of the antibody of any one of arrangements 1-11; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • the pharmaceutical antibody formulation of arrangement 103 wherein the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249.
  • 105 The pharmaceutical antibody formulation of arrangement 103 or 104, wherein the histidine is L-histidine.
  • the pharmaceutical antibody formulation of any one of arrangements 103- 123 wherein L-histidine is present at about 20 mM, methionine is present at about 5 mM, NaCl is present at about 100mM, polysorbate 80 is present at about 0.02%, sucrose is present at 2-5%, mannitol is present at 2-5%, the pH is about 5.8, and wherein the therapeutically effective amount of the antibody is one of: 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts. [0538] 125.
  • a pharmaceutical antibody formulation comprising: a therapeutically effective amount of an antibody, wherein the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH- CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249, and wherein the antibody is present at an amount as a unit dose of: 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg; L-histidine is present at 20 mM; methionine is present at 5 mM; NaCl is present at 100mM; polysorbate 80 is present at 0.02%; and the pH is about 5.8.
  • the pharmaceutical antibody formulation of arrangement 130 wherein the formulation configured for intravenous administration does not comprise sucrose or mannitol, or both.
  • 132 The pharmaceutical antibody formulation of any one of arrangements 103- 131, wherein the pharmaceutical antibody formulation is prepared at a concentration of antibody of 20 mg/mL or 50 mg/mL.
  • 133 The pharmaceutical antibody formulation of any one of arrangements 103- 132, wherein the pharmaceutical antibody formulation remains 60% stable over 3 months at either 5°C or 25°C/60% relative humidity (RH).
  • RH relative humidity
  • a sterile vial comprising a pharmaceutical antibody formulation, wherein the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, wherein the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a V H -CDR2 having the sequence of SEQ ID NO: 72, a V H -CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249. [0548] 135.
  • the sterile vial of arrangement 134 wherein the pharmaceutical antibody formation further comprises histidine, methionine, NaCl, and polysorbate, and wherein the formulation is at a pH between 5.3 and 6.3.
  • 136 The sterile vial of arrangement 134 or 135, wherein the sterile vial is a 5 mL or 10 mL sterile vial.
  • 137 The sterile vial of any one of arrangements 134-136, wherein the sterile vial contains 2, 3, 4, 5, 6, 7, 8, 9, or 10 mL of the pharmaceutical antibody formulation.
  • the sterile vial of arrangement 140 wherein the concentrated form of the pharmaceutical antibody formulation is at a concentration of 20, 30, 40, 50, 60, 70, 80, 90, or 100 mg/mL of antibody, or any concentration within a range defined by any two of the aforementioned concentrations.
  • 142 The sterile vial of arrangement 140 or 141, wherein the concentrated form of the pharmaceutical antibody formulation is at a concentration of 20 mg/mL or at least 20 mg/mL of antibody.
  • 143 The sterile vial of any one of arrangements 140-142, wherein the concentrated form of the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or at least 50 mg/mL of antibody.
  • 144 The sterile vial of any one of arrangements 140-142, wherein the concentrated form of the pharmaceutical antibody formulation is at a concentration of 50 mg/mL or at least 50 mg/mL of antibody.
  • the sterile vial of arrangement 149, wherein the pharmaceutical antibody formulation configured for subcutaneous administration comprises sucrose or mannitol, or both.
  • the sterile vial of arrangement 151 wherein the pharmaceutical antibody formulation configured for intravenous administration does not comprise sucrose or mannitol, or both.
  • the sterile vial of any one of arrangements 134-152 wherein the pharmaceutical antibody formulation remains 60% stable over 3 months at either 5°C or 25°C/60% relative humidity (RH).
  • RH relative humidity
  • 154 The pharmaceutical antibody formulation of any one of the preceding pharmaceutical antibody formulation arrangements or sterile vial arrangements, wherein the antibody comprises a heavy chain variable domain (VH) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 298.
  • VH heavy chain variable domain
  • the pharmaceutical antibody formulation of any one of the preceding pharmaceutical antibody formulation arrangements or sterile vial arrangements wherein the antibody comprises a light chain variable domain (VL) region having a sequence at least 80%, 85%, 90%, 95%, 99%, or 100% identical to that of SEQ ID NO: 375.
  • VL light chain variable domain
  • a method of treating a coronavirus infection comprising: administering the pharmaceutical antibody formulation of any one of the preceding pharmaceutical antibody formulation arrangements or sterile vial arrangements to a subject in need of treatment for a coronavirus infection.
  • the method of arrangement 172 wherein the pharmaceutical antibody formulation is administered daily, weekly, bi-weekly, or every 10 days.
  • 174 The method of arrangement 172 or 173, wherein the subject is administered 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg of antibody as a unit dose, or any amount of antibody as a unit dose within a range defined by any two of the aforementioned amounts.
  • any one of arrangements 172-174 wherein the subject is administered a pharmaceutical antibody formulation comprising: a therapeutically effective amount of the antibody, wherein the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a V H - CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, and wherein the antibody is present at an amount as a unit dose of: 1 mg, 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg; L-histidine is present at 20 mM; methionine is present at 5 mM; NaCl is present at 100mM; polysorbate 80 is present at 0.02%; and the pH is about 5.8.
  • the method of arrangement 178 wherein the step of identifying the subject in need of treatment for a coronavirus infection comprises one or more of identifying a positive coronavirus infection by PCR test or equivalent test, identifying the subject as having symptoms of fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, shortness of breath with excursion, respiratory rate ⁇ 20 breaths per minute, saturation of oxygen (SpO2) > 93% on room air at sea level, heart rate ⁇ 90 beats per minute, diabetes, hypertension, cancer, chronic kidney disease, body mass index (BMI) ⁇ 35, ⁇ 65 years of age, cardiovascular disease such as hypertension, chronic obstructive pulmonary disease or other chronic respiratory disease.
  • BMI body mass index
  • the method of one of arrangements 172-179, wherein the treating step is to a patient that already has symptoms of the coronavirus infection. [0594] 181. The method of one of arrangements 172-180, wherein the treating step is prophylactic. [0595] 182. The method of any one of arrangements 172-181, wherein the coronavirus infection is a SARS-CoV, MERS-CoV, or SARS-CoV-2 infection. [0596] 183. The method of any one of arrangements 172-182, wherein the pharmaceutical antibody formulation is administered for 10-18 months. [0597] 184. The method of any one of arrangements 172-183, wherein the pharmaceutical antibody formulation is administered intravenously. [0598] 185.
  • a pharmaceutical antibody formulation comprising: a therapeutically effective amount of an antibody, wherein the antibody comprises a V H - CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249, wherein each CDR can have up to 1, 2, 3, 4, or 5 amino acids changed from the recited sequence; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • a method of treating a coronavirus infection comprising: administering a pharmaceutical antibody formulation to a subject in need of treatment for a coronavirus infection, wherein the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, wherein the antibody comprises a VH-CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a V L -CDR1 having the sequence of SEQ ID NO: 171, a V L -CDR2 having the sequence of SEQ ID NO: 222; and a VL-CDR3 having the sequence of SEQ ID NO: 249; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • a method of decreasing or inhibiting inflammation in a subject in need thereof comprising: administering a pharmaceutical antibody formulation to the subject in need thereof, wherein the pharmaceutical antibody formulation comprises a therapeutically effective amount of an antibody, wherein the antibody comprises a V H -CDR1 having the sequence of SEQ ID NO: 31, a VH-CDR2 having the sequence of SEQ ID NO: 72, a VH-CDR3 having the sequence of SEQ ID NO: 113, a VL-CDR1 having the sequence of SEQ ID NO: 171, a VL-CDR2 having the sequence of SEQ ID NO: 222; and a V L -CDR3 having the sequence of SEQ ID NO: 249; histidine; methionine; NaCl; and polysorbate, wherein the formulation is at a pH between 5.3 and 6.3.
  • FIG. 1 shows a graphical representation of this relative Gal3 mRNA expression data as generated employing R software (available on the world wide web at r-project.org). Table 1. Gal3 expression profile in COVID-19 patients Example 2.
  • Gal3 binding to coronavirus host entry receptor proteins [0606] To evaluate the possibility that Gal3 could physically interact with human receptors mediating coronavirus entry into host cells, such as angiotensin-converting enzyme 2 (ACE2) and CD147 (EMMPRIN, basigin), ELISA assessments using purified Gal3 and purified ACE2 and CD147 were conducted.
  • ACE2 angiotensin-converting enzyme 2
  • CD147 EMMPRIN, basigin
  • human Gal3 protein (R&D Systems, 8259-GA; R&D Systems, 1154- GA/CF; or Acro Biosystems, GA3-H5129) was diluted in PBS (Corning, 21-030-CM) to a concentration of 4, 2, or 1 ⁇ g/ml and added to the wells of a 96-well ELISA plate (Thermo Fisher, 44-2404-21). After incubating the plate at 4°C overnight, the plate was washed three times with PBST (PBS with 0.05% Tween 20 [VWR, 0777]). The plate was then blocked for an hour with 2% BSA (EMD Millipore, 126609) in PBST at room temperature with gentle rocking.
  • PBS Corning, 21-030-CM
  • BSA EMD Millipore, 126609
  • the host entry receptor proteins used include recombinant human ACE2 (hACE2; LifeSpan Biosciences, LS-G97114-10, hIgG1 Fc-tagged; or Acro Biosystems, AC2-H82F9, biotinylated) and CD147 (hCD147; R&D Systems, 972-EMN, 6X His-tagged).
  • the plate was incubated for an hour at room temperature with gentle rocking. Thereafter, the plate was washed three times with PBST.
  • Peroxidase AffiniPure F(ab')2 Fragment Goat Anti-Human IgG (H+L) polyclonal antibody Jackson ImmunoResearch, 109-036-003; 1:4000 dilution; detects ACE2 from LifeSpan Biosciences), Avidin HRP (Biolegend, 405103; 1:2000 dilution, detects ACE2 from Acro Biosystems), or goat anti-6X His HRP antibody (Abcam, ab1269; 1:3000 dilution, detects CD147) was diluted in 2% BSA in PBST and added to the wells.. The plate was incubated at room temperature for an hour with gentle rocking and then washed three times with PBST.
  • TMB substrate (Thermo Scientific, 34029) was then added to each well. The reaction was stopped with 1M HCl (JT Baker, 5620-02) and read using a plate reader (Molecular Devices) at absorbance of 450 nm.
  • 1M HCl JT Baker, 5620-02
  • plate reader Molecular Devices
  • Gal3 binding to coronavirus spike protein [0609] To evaluate the possibility that human Gal3 could physically interact with SARS- CoV-2 spike protein (S protein), which mediates coronavirus entry into host cells, ELISA assessment with purified Gal3 and SARS-CoV-2 S protein was conducted. Briefly, human Gal3 protein (R&D Systems, 1154-GA/CF or Acro Biosystems, GA3-H5129) was diluted in PBS (Corning, 21-030-CM) to a concentration of 4, 2, or 1 ⁇ g/ml and added to the wells of a 96-well ELISA plate (Thermo Fisher, 44-2404-21).
  • PBST PBS with 0.05% Tween 20 [VWR, 0777]
  • BSA EMD Millipore, 126609
  • SARS-CoV-2 S protein Acro Biosystems, SPN-C52H4
  • EZ Link Sulfo-NHS-LC-Biotin ThermoFisher Scientific, A39257), following manufacturer’s instructions.
  • the protein was desalted using a Zeba Spin Desalting Column (ThermoFisher Scientific, 89882), following manufacturer’s instructions. Thereafter, the 2% BSA in PBST was discarded and 4, 2, or 1 ⁇ g/ml of non-biotinylated or biotinylated recombinant SARS-CoV-2 S protein in 2% BSA in PBST was added to the wells. The plate was incubated for an hour at room temperature with gentle rocking. Thereafter, the plate was washed three times with PBST.
  • Anti-6X His HRP antibody (Abcam, ab1269; 1:3000 dilution) or Avidin HRP (Biolegend, 405103; 1:2000 dilution) was diluted in 2% BSA in PBST and then added to the wells. The plate was incubated at room temperature for an hour with gentle rocking and then washed three times with PBST. TMB substrate (Thermo Scientific, 34029) was then added to each well. The reaction was stopped with 1M HCl (JT Baker, 5620-02) and read using a plate reader (Molecular Devices) at absorbance of 450 nm. [0610] As depicted in FIG. 4, no significant binding of the SARS-CoV-2 S protein was observed to plates without Gal3 coating.
  • human Gal3 protein (Acro Biosystems, GA3-H5129) was diluted in PBS to a concentration of 1.5 ⁇ g/ml and added to the wells of a 96-well ELISA plate. After incubating the plate at 4°C overnight, the plate was washed three times with PBST. The plate was then blocked for an hour with 2% BSA in PBST at room temperature with gentle rocking.
  • TMB substrate was then added to each well. The reaction was stopped with 1M HCl and read using a plate reader at absorbance of 450 nm.
  • antibodies targeted to the N-terminal domain or TRD of Gal3 exhibited a range of inhibitory activity against the binding of Gal3 to the host entry receptor protein ACE2.
  • Several antibody clones, 2D10.2B2, 6H6.2D6, murine IMT1 (mIMT1, mIMT001), and human IMT1 (hIMT1, IMT001) displayed over 95% blocking of GAL3 assembly with ACE2.
  • 24D12.2H9 antibody demonstrated only 55% of blocking activity.
  • Anti-Gal3 antibodies targeted to the N-terminal domain or TRD blocks binding of Gal3 to coronavirus spike protein
  • S protein SARS-CoV-2 spike protein
  • purified Gal3 and SARS-CoV-2 S protein were incubated in the presence of a panel of Gal3-targeted monoclonal antibodies, with non-specific control antibodies, or without antibody, and protein interaction was evaluated by ELISA.
  • Human Galectin-3 protein Human Galectin-3 protein (Immutics, HEK2936his-EK-hGal3 E1) was diluted in PBS to a concentration of 4 ⁇ g/ml and 40 ⁇ l was added to the wells of an ELISA plate.
  • Anti-Gal3 antibodies targeted to the N-terminal domain or TRD reduces coronavirus load in vivo
  • Patients present with an active SARS-CoV-2 infection One or more anti-Gal3 antibodies or binding fragments thereof are administered to the patients enterally, orally, intranasally, parenterally, subcutaneously, intramuscularly, intradermally, or intravenously.
  • the anti-Gal3 antibodies or binding fragments thereof are administered as doses at an amount of 1 ng as a unit dose (or in the alternative, an amount of 10, 100, 1000 ng, or 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 ⁇ g, or 1, 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts, or any other amount appropriate for optimal efficacy in humans).
  • the doses are administered every 1 day (or in the alternative, every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, or 48 days or weeks or any time within a range defined by any two of the aforementioned times).
  • a reduction in viral load or viral count in a nasal swab sample, saliva sample, or bronchoalveolar lavage sample is observed in the patients following administration of the anti- Gal3 antibodies or binding fragments thereof.
  • Administration of the anti-Gal3 antibodies or binding fragments may be performed in conjunction with another antiviral or anti-inflammatory therapy.
  • Potential antiviral or anti-inflammatory therapeutics may include but are not limited to chloroquine, hydroxychloroquine, favipiravir, favilavir, remdesivir, tocilizumab, baricitinib, acalabrutinib, galidesivir, sarilumab, lopinavir, ritonavir, darunavir, ribavirin, dexamethasone, ciclesonide, convalescent plasma, interferon- ⁇ , pegylated interferon- ⁇ , or interferon alfa-2b, or any combination thereof.
  • Anti-Gal3 antibodies targeted to the N-terminal domain or TRD reduces pulmonary fibrosis caused by a prior SARS-CoV-2 infection
  • One or more anti-Gal3 antibodies or binding fragments thereof are administered to the patients enterally, orally, intranasally, parenterally, subcutaneously, intramuscularly, intradermally, or intravenously.
  • the anti-Gal3 antibodies or binding fragments thereof are administered as doses at an amount of 1 ng as a unit dose (or in the alternative, an amount of 10, 100, 1000 ng, or 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 ⁇ g, or 1, 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts, or any other amount appropriate for optimal efficacy in humans.
  • the doses are administered every 1 day (or in the alternative, every 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, or 48 days or weeks or any time within a range defined by any two of the aforementioned times).
  • a reduction in fibrotic tissue is observed in the patients following administration of the anti-Gal3 antibodies or binding fragments thereof.
  • An improvement to other sequelae of the SARS-CoV-2 infection including but not limited to another fibrosis, pulmonary edema, cardiovascular disease, thrombosis, neurological disease, kidney disease, or liver disease may be also seen.
  • Administration of the anti-Gal3 antibodies or binding fragments may be performed in conjunction with another antiviral or anti-inflammatory therapy.
  • Potential antiviral or anti-inflammatory therapeutics may include but are not limited to chloroquine, hydroxychloroquine, favipiravir, favilavir, remdesivir, tocilizumab, baricitinib, acalabrutinib, galidesivir, sarilumab, lopinavir, ritonavir, darunavir, ribavirin, dexamethasone, ciclesonide, convalescent plasma, interferon- ⁇ , pegylated interferon- ⁇ , or interferon alfa-2b, or any combination thereof.
  • Anti-Gal3 antibodies targeted to the N-terminal domain or TRD reduces cytokine release syndrome
  • Patients present with cytokine release syndrome CRS, cytokine storm
  • other inflammatory symptoms including but not limited to fever, headache, myalgia, arthralgia, fatigue, nausea, diarrhea, dermatitis, tachycardia, hypotension, hypoxia, tachypnea, pulmonary edema, azotemia, transaminitis, hyperbilirubinemia, or organ failure.
  • the CRS is a result of another disease, infection or condition. In some alternatives, the CRS is a result of a bacterial infection. In some alternatives, the CRS is a result of sepsis. In some alternatives, the CRS is a result of CAR T therapy. In some alternatives, the CRS is a result of a viral infection. In some alternatives, the CRS is a result of a coronavirus infection. In some alternatives, the CRS is a result of a SARS-related coronavirus infection. In some alternatives, the CRS is a result of a SARS-CoV-2 virus infection. In some alternatives, the CRS is a result of sepsis caused by a viral infection.
  • the CRS is a result of sepsis caused by a coronavirus infection. In some alternatives, the CRS is a result of sepsis caused by a SARS-related coronavirus infection. In some alternatives, the CRS is a result of sepsis caused by a SARS-CoV-2 virus infection.
  • One or more anti-Gal3 antibodies or binding fragments thereof described herein are administered to the patients enterally, orally, intranasally, parenterally, subcutaneously, intramuscularly, intradermally, or intravenously.
  • the anti-Gal3 antibodies or binding fragments thereof are administered as doses at an amount of 1 ng as a unit dose (or in the alternative, an amount of 10, 100, 1000 ng, or 1, 10, 50, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 ⁇ g, or 1, 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000 mg as a unit dose, or any amount within a range defined by any two of the aforementioned amounts, or any other amount appropriate for optimal efficacy in humans.
  • the doses are administered every 1 day (or in the alternative, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 24, 36, or 48 days or weeks or any time within a range defined by any two of the aforementioned times).
  • hIMT001 human IMT001
  • hIMT001 antibody 10 mg/kg, i.p.
  • PBS vehicle control
  • Body weight, body temperature by rectal thermometer and clinical observation were monitored for forty-eight hours.
  • Mice treated with LPS and PBS experienced substantial hypothermia, agreeing with evidence that LPS can cause systemic inflammation and hypothermia to mice.
  • hIMT001 was able to significantly reverse the hypothermia compared to the PBS-treated group (FIG. 21). Multiple t- tests were used to compare PBS vs.
  • Potential antiviral or anti-inflammatory therapeutics may include but are not limited to chloroquine, hydroxychloroquine, favipiravir, favilavir, remdesivir, tocilizumab, baricitinib, acalabrutinib, galidesivir, sarilumab, lopinavir, ritonavir, darunavir, ribavirin, dexamethasone, ciclesonide, convalescent plasma, interferon- ⁇ , pegylated interferon- ⁇ , or interferon alfa-2b, anti-cytokine antibodies, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, corticosteroids, free radical scavengers, TNF- ⁇ blockers or any combination thereof.
  • Gal3-targeted antibodies bind to distinct epitopes of Gal3 [0629] To identify the epitopes to which Gal3 antibodies bound, a library of 20 amino acid peptides representing portions of Gal3, summarized in FIG. 7, was produced and the ability to bind Gal3 antibodies was evaluated by ELISA.
  • At least 2 ⁇ g/ml of hGal3 peptide in 50 ⁇ l of PBS or 0.1 ⁇ g/ml of full-length human Gal3 protein were diluted in PBS (Corning, 21-030-CM) to concentrations of at least 2 ⁇ g/ml or 0.1 ⁇ g/ml, respectively, and added to the wells of a 96-well ELISA plate (Thermo Fisher, 44-2404-21). After incubating the plate at 4°C overnight, the plate was washed three times with PBST (PBS with 0.05% Tween 20 [VWR, 0777]).
  • PBST PBS with 0.05% Tween 20 [VWR, 0777]
  • the plate was then blocked for an hour with 2% BSA (EMD Millipore, 126609) in PBST at room temperature with gentle rocking. Thereafter, the 2% BSA in PBST was discarded and human Gal3 hybridoma supernatants or antibodies were diluted in 2% BSA in PBST to concentrations of at least 0.1 ⁇ g/ml and added to the wells.
  • the plate was incubated for an hour at room temperature with gentle rocking and then washed three times with PBST.
  • Goat Anti-Mouse IgG- HRP Jackson ImmunoResearch,115-036-1461
  • Goat Anti-Rat IgG HRP Abcam, ab205720
  • Gal3-binding antibodies (IMT001, 846T.1H2, 13H12.2F8, 19D9.2E5, 14H10.2C9, 2D10.2B2, 4A11.2B5, 846.2H3, 846.1F5, 3B11.2D2, and 13A12.2E5) all bound peptide 6 of Gal3, corresponding to amino acids 51-70 of Gal3, GAYPGQAPPGAYPGAPGAYP (SEQ ID NO: 8).
  • Gal3-binding antibodies (6H6.2D6, 20H5.A3, 20D11.2C6, 13H12.2F8, 19B5.2E6, 23H9.2E4, 15G7.2A7, 19D9.2E5, 14H10.2C9, 7D8.2D8, 15F10.2D6 and 846.14A2) all bound peptide 7 of Gal3, corresponding to amino acids 61-80 of Gal3, AYPGAPGAYPGAPAPGVYPG (SEQ ID NO: 9).
  • peptides 4, 5, 6, and 7 share repeated amino acid sequences comprised of proline-glycine (PG) and tyrosine-proline-glycine (YPG), indicating a common feature that may explain the ability of Gal3-targeted antibodies to bind to multiple Gal3 peptides.
  • PG proline-glycine
  • YPG tyrosine-proline-glycine
  • GxYPG amino acid sequence glycine-x-tyrosine-proline-glycine
  • x may be the amino acids alanine (A), glycine (G), or valine (V)
  • the presence of two GxYPG sequences in close apposition is likely predictive of the ability to bind Gal3- targeted antibodies.
  • the Grantham distance of alanine, glycine, and valine is Ala- Val: 64, Ala-Gly: 60, Val-Gly: 109, thereby predicting that amino acids with similarly low Grantham distances may similarly be able to substitute at the variable region, including proline and threonine.
  • Humanized anti-Gal3 antibodies have high affinity for Gal3 of different species [0633] Humanized IMT001 and IMT006a, which were derived from mouse mAbs, both have high affinity for human (IMT001: 3.6 nM, IMT006a: 8.9 nM) and cynomolgus (IMT001: 8.9 nM, IMT006a: 5.1 nM) Gal3 (FIG. 20). IMT001 also has high affinity for mouse Gal3 (IMT001: 2.3 nM, IMT006a: 40000 nM) and rat Gal3 (IMT001: 14 nM, IMT006a: undetected). Example 11.
  • Gal3 The amino-terminal domain of Gal3 promotes activation of neutrophils
  • wild-type Gal3 (Gal3 WT) was compared to Gal3 with changes in the N-terminal domain: a truncation from residues 1-64 (Gal3 Cut; Gal3C) and a proline-to-histidine point mutation at residue 64 (P64H; Gal3 Mut).
  • HL60 promyelocytic cells ATCC, #CCL-240 were stimulated for three days with 1.3% DMSO to differentiate the cell line into neutrophils (as in Milius and Weiner, Meth. Mol.
  • the percent of cells that expressed CD62L was calculated as those with fluorescence greater than isotype control-stained cells.
  • cytokines supernatants were tested on a Human IL-8 Duoset ELISA kit (R&D #DY208), according to manufacturer’s instructions. The optical density was measured on a SpectraMax Machine and the concentration of cytokine was calculated using SoftMax Pro software. All data was graphed using GraphPad Prism software and shows mean ⁇ standard error.
  • Gal3 WT and Gal3 Mut decreased the percent of cells that were positive for CD62L in a dose-dependent manner, demonstrating that Gal3 can promote neutrophil infiltration into tissue.
  • Gal3 Cut did not affect CD62L, demonstrating that the amino-terminal domain of Gal3 is required for activity (FIG. 22A).
  • IL-8 is a cytokine that is up-regulated after activation and directs migration towards a source of injury or infection.
  • Gal3 WT and Gal3 Mut increased IL-8 in a dose-dependent manner, demonstrating that Gal3 can activate neutrophils and enhance their migration.
  • Gal3 Cut was less effective, demonstrating that the amino-terminal domain of Gal3 is required for activity (FIG. 22B).
  • Anti-Gal3 antibodies reduce activation of neutrophils
  • a neutrophil cell line was treated with Gal3 and readouts of neutrophil activation and migration were measured.
  • HL60 promyelocytic cells (ATCC #CCL-240) were stimulated for four days with 1.3% DMSO to differentiate the cell line into neutrophils. 2 x 10 5 cells were then plated in serum-free media on a 96 well plate in triplicate for each condition.
  • Recombinant human Gal3 (rhGal3) (TrueBinding #QC200361) at 1, 0.5, 0.25, 0.125, and 0.0625 or 0 ⁇ M was pre- incubated for 30 minutes with 1 ⁇ M of the anti-Gal3 antibody TB001 or media-only control, then added to the cells. Samples were collected four hours after the treatment for analysis by flow cytometry and ELISA. [0639] To stain for flow cytometry, cells were incubated for 15 minutes on ice with a 1:80 dilution of Human TruStain FcXTM (Biolegend #422302) in PBS.
  • CD62L-APC Biolegend #304810
  • cytokines supernatants were tested on a Human IL-8 Duoset ELISA kit (R&D #DY208), according to manufacturer’s instructions. The optical density was measured on a SpectraMax machine and the concentration of cytokine was calculated using SoftMax Pro software.
  • IL-8 is a cytokine that is up-regulated after activation and directs migration towards a source of injury or infection. rhGal3 increased IL-8 in a dose-dependent manner, demonstrating that Gal3 can activate neutrophils and enhance their migration.
  • the percent of cells that expressed CD62L was calculated as those with higher fluorescence than with isotype control-stained cells and the average of technical replicates was calculated (Table 2).
  • To measure cytokines supernatants were tested on a Human IL-8 Duoset ELISA kit (R&D #DY208), according to manufacturer’s instructions. The optical density was measured on a SpectraMax machine and the concentration of cytokine was calculated using SoftMax Pro software. All data was graphed using GraphPad Prism software and the average of technical replicates was calculated. The level of IL-8 induced by 1 ⁇ M rhGal with or without anti-Gal3 antibodies is shown in Table 2.
  • Antibodies that reduce CD62L cleavage by at least 75% and/or reduce IL-8 production by at least 33% are listed in Table 3.
  • the antibody 14D11.2D2 is an antibody specific for the C-terminal carbohydrate binding domain of Gal3 and has been previously described in PCT Publication WO 2019/152895, which is hereby expressly incorporated by reference in its entirety.
  • Table 2. Inhibition of CD62L shedding and IL-8 production by anti-Gal3 antibodies Table 3.
  • Anti-Gal3 antibodies reduce inflammation in a model of inflammatory lung disease
  • COPD chronic obstructive pulmonary disease
  • the ability of anti-Gal3 antibodies to reduce lung inflammation in vivo was tested in a mouse model of chronic obstructive pulmonary disease (COPD).
  • COPD chronic obstructive pulmonary disease
  • the animal experiment was performed in accordance with standard guidelines and regulations, and the protocol was approved by the Institutional Animal Care and Use Committee (IACUC) at TrueBinding.
  • Elastase is a proteolytic enzyme that is released by activated neutrophils in the lungs and leads to breakdown of alveolar tissue, inflammation and emphysema.
  • Five units of porcine pancreatic elastase (Elastin Products Company #EC134) was distilled intratracheally into C57BL/6 mice (Jackson Laboratory).
  • BALF samples were collected by perfusing lungs with 0.7 mL PBS.
  • ELISA was performed on plasma and BALF of healthy controls and MOPC21 treated animals using a Mouse Galectin-3 Duoset ELISA kit (R&D Systems #DY1197), according to manufacturer’s instructions.
  • the levels of transcripts involved in inflammation and fibrosis were quantified using qPCR. mRNA was isolated using the RNeasy Plus Mini Kit (Qiagen, #74134) according to manufacturer’s instructions.
  • the isolated mRNA was reverse transcribed to cDNA using iScriptTM Reverse Transcription Supermix (BioRad #1708841) with a CFX96 Touch Real-Time PCR Detection System thermocycler (BioRad) according to manufacturer’s instructions.
  • qRT-PCR was performed using SsoAdvancedTM Universal SYBR® Green Supermix (BioRad #1725174).
  • the forward primer and reference primers were purchased from GenScript and sequences are displayed in Table 4. Expression levels were expressed relative to the internal control GAPDH according to the comparative threshold cycle (Ct) method. Results were expressed as mean expression ⁇ SEM. Unpaired t-tests were used to determine statistical significance.
  • Thermo Fisher #VC2962251 After 30 minutes, the cells were washed and resuspended in PBS + DAPI (Thermo Fisher #VC2962251). Cells were analyzed on an Attune flow cytometer (Thermo Fisher) and analyzed with FlowJo software (TreeStar). Neutrophils were defined as DAPI-TCRb-F4/80- CD45+CD11b+Ly6G+ cells. Data was plotted with GraphPad Prism and one-way ANOVA was used to determine statistical significance. [0651] The levels of myeloperoxidase (MPO) and keratinocyte-derived chemokine (KC), two mediators associated with neutrophil number and function, were quantified by ELISA.
  • MPO myeloperoxidase
  • KC keratinocyte-derived chemokine
  • transcripts associated with inflammation and fibrosis were increased in the lungs of MOPC21-treated animals compared to healthy controls.
  • 2D10.2B2 (2D10) significantly reduced transcripts associated with neutrophil number and function (Ly6c1, Kc, Inos), inflammatory cytokines (Il6, Tnfa, Il1b), and fibrosis (Col1A1, ⁇ Sma, Tgfb, Vegfa, Vegfb).
  • mTB001 reduced a smaller subset of transcripts, including Tnfa, Inos, Vegfa, and Col1a1.
  • Gal3 antibodies are able to reduce inflammation and fibrosis in lungs.
  • Neutrophils are a major source of lung inflammation. As depicted in FIG. 24C, the percentage and absolute numbers of neutrophils were increased in the lungs of MOPC21- treated animals compared to healthy controls, consistent with induction of inflammatory disease. Treatment with 2D10.2B2 significantly reduced the percentage and number of neutrophils compared to MOPC21 controls. There was also a trend towards reduction in mTB001 treated animals. Hence, anti-Gal3 antibodies can suppress a cellular mediator of fibrosis.
  • Anti-DNA antibodies are amongst the most prevalent class of autoantibody in SLE.
  • An anti-Gal3 antibody was tested for its ability to block or attenuate the development of SLE in a mouse model. Spleens were removed from 10-12 week old DBA/2J mice (Jackson Laboratories #000671) and mashed through a 40 ⁇ M cell strainer into PBS to generate a single cell suspension. 6 x 10 6 spleen cells in 200 ⁇ L PBS were injected i.v. into B6D2F1/J (Jackson Laboratories #100006) host mice to induce anti-DNA autoantibody production.
  • plasma was tested for the development of anti-single-stranded (ss) or double-stranded (ds) DNA autoantibodies using ELISA.
  • ds-DNA (Thermo Fisher #15633- 019) was boiled at 95°C for 15 minutes to dissociate it into ss-DNA.
  • FIG. 25 demonstrates that hosts injected with DBA/2J cells developed anti-ss- DNA autoantibodies while no autoantibodies were detected in healthy controls.
  • mTB001 significantly decreased levels of anti-ss-DNA autoantibodies by two-fold on average. DBA/2J cells induced development of anti-ds-DNA autoantibodies compared to healthy controls. mTB001 decreases levels of auto-ds-DNA autoantibodies.
  • Example 15 Binning of anti-Gal3 antibodies [0660] Table 2 also depicts epitope binning of the tested exemplary anti-Gal3 antibodies. [0661] The epitope binning assay was done in a sandwich format on the high-throughput SPR-based Carterra LSA unit (CarterraBio, Salt Lake City, UT).
  • the purified antibodies were diluted to 10 ⁇ g/ml concentration in 10 mM NaOAc (pH 5.0) and then were covalently coupled via amine group to HC200M chip activated by EDC and S-NHS to immobilize antibodies to different positions of a 384-spot array.
  • One hundred thirty-eight binning cycles were run on the array of immobilized antibodies.
  • human Gal3 (AcroBio GA3-H5129) was injected over the entire array to bind to different antibodies (primary antibody), followed by one antibody (secondary antibody) selected among the panel of anti-GAL3 antibodies tested.
  • Antibodies 20H5.A3, 23H9.2E4, 2D10-VH0- VL0 and TB006 (4A11.H3L1) exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 3.
  • Antibodies 15G7.2A7 and 20D11.2C6 exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 5.
  • Antibodies 13A12.2E5 and 3B11.2G2 exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 7.
  • Antibodies 14H10.2C9, 15F10.2D6, 7D8.2D8, 846T.14E4, 846T.7F10, and 849.8D10 exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 8.
  • Antibody 849.2D7 defined bin 10.
  • Antibodies 24D12.2H9, 6B3.2D3, 849.1D2 exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 11.
  • Antibodies 13G4.2F8 and 9H2.2H10 exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 12.
  • Antibodies 846.1B2, 846.1F5, 846.1H12, 846.2H3, and 846T.16B5 exhibited mutual competitive binding for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin 17.
  • Antibody 849.5H1 defined bin 21.
  • Antibodies 847.12C4, 847.15D12, 847.15H11, 847.20H7, and 847.27B9 exhibited mutual competitive binding and competed with binding with the commercially available anti-Gal3 antibody B2C10 for hGAL3, but did not prevent binding of the rest of the clones, thus defining bin “B2C10”.
  • B2C10 has been epitope mapped to bind to the first 18 amino acids of Gal3.
  • Antibodies 847.10C9, 847.11D6, 847.13E2-mH0mL1, 847.13E2-mH0mL2, 847.16D10, 847.23F11, 847.28D1, and 847.3B3 exhibited mutual competitive binding to the C-terminal carbohydrate-recognition domain (CRD), but did not prevent binding of the rest of the clones, thus defining bin “CRD”.
  • Antibodies 847.10B9, 847.11B1, 847.4B10, 846.1H5, 847.14H4, 847.26F5, 849.2F12, 14D11.2D2, and MOPC21 were either not tested or not assigned to a bin.
  • Antibodies 846.2B11, 846T.4C9, 847.15F9, 847.21B11, 847.2B8, 847.4D3, 849.4F12, and 849.4B2 were determined to not bind to hGAL3 under the conditions tested.
  • Example 16 Anti-Gal3 antibodies reduces cytokine production by neutrophils under pro- inflammatory conditions.
  • Cytokines, such as TNF ⁇ and IL-6 released by neutrophils in response to pro- inflammatory conditions (e.g. infection or autoimmunity) can initiate and perpetuate disease symptoms in patients.
  • pro- inflammatory conditions e.g. infection or autoimmunity
  • HL60 promyelocytic cells ATCC, #CCL-240 were stimulated for four days with 1.3% DMSO to differentiate the cell line into neutrophils.2x10 5 cells were treated with a mixture of recombinant Gal3 and the pro-inflammatory stimulus lipopolysaccharide (LPS) with or without anti-Gal3 antibodies. The mixture was pre-incubated together before being added to cells. Conditions were assayed in duplicate or triplicate. [0666] To prepare the mixture without antibodies, different concentrations of recombinant human Gal3 (rhGal3) (TrueBinding, #QC200361) ranging from 0.015625 ⁇ M to 1 ⁇ M were pre-incubated with media.
  • rhGal3 recombinant human Gal3
  • TNF ⁇ was blocked with an IC50 of 0.3928 ⁇ M and 0.01106 ⁇ M for TB001 and TB006, respectively (FIG. 26).
  • IL-6 was blocked with an IC50 of 0.5095 ⁇ M and 0.03371 ⁇ M for TB001 and TB006, respectively (FIG.27).
  • Gal3 antibodies across various bins reduce cytokine secretion from neutrophils under pro-inflammatory conditions
  • HL60 promyelocytic cells ATCC, #CCL-240 were stimulated for four days with 1.3% DMSO to differentiate the cell line into neutrophils. 2x10 5 cells were then placed in serum-free media on a 96 well plate in triplicate for each condition. 1 ⁇ M recombinant human Gal3 (rhGal3) (TrueBinding, #QC200361) was pre-incubated for 30 minutes with 1 ⁇ M of a panel of anti-Gal3 antibodies or control media, then 0.1 ng/mL LPS was added for 30 minutes. Finally, the pre-incubated mixture of recombinant Gal3, anti-Gal3 antibodies, and LPS was added to the cells.
  • a number of antibodies that blocked TNF ⁇ secretion unexpectedly promoted IL-6 production.
  • this includes clones belonging to bins 7, 8, 17, and some antibodies binding to the C-terminal carbohydrate recognition domain of Gal3.
  • Table 5 Modulation of neutrophil TNF ⁇ and IL-6 secretion by exemplary anti-Gal3 antibodies Table 6.
  • Formulations of anti-Gal3 antibodies can be used to treat a coronavirus infection in humans [0672] A patient presents with a coronavirus infection, is experiencing initial symptoms of a coronavirus infection, or is at risk of developing a coronavirus infection.
  • the coronavirus infection is a SARS-CoV, MERS-CoV, or SARS-CoV-2 infection.
  • one or more of the pharmaceutical antibody formulations disclosed herein are administered.
  • the one or more pharmaceutical antibody formulations are administered to the patient enterally, orally, intranasally, parenterally, intracranially, subcutaneously, intramuscularly, intradermally, or intravenously.
  • the formulation is administered intravenously or subcutaneously.
  • the pharmaceutical antibody formulation comprises an anti-Gal3 antibody, and one or more excipients.
  • the pharmaceutical antibody formulation comprises an anti-Gal3 antibody and one or more of L-histidine, methionine, NaCl, polysorbate, and optionally sucrose and/or mannitol.
  • the pharmaceutical antibody formulation is administered to the patient such that 1 mg (or in the alternative: 5 mg, 10 mg, 20 mg, 40 mg, or 50 mg) as a unit dose is administered to the patient.
  • the formulation is administered daily (or in the alternative: weekly, bi-weekly, or every 10 days) for a duration of 10 months (or in the alternative: 11, 12, 13, 14, 15, 16, 17, or 18 months).
  • An improvement of the coronavirus infection or symptoms associated with the coronavirus infection is observed in the patient following administration of the pharmaceutical antibody formulation.
  • Example 19 An improvement of the coronavirus infection or symptoms associated with the coronavirus infection is observed in the patient following administration of the pharmaceutical antibody formulation.
  • each range discussed herein can be readily broken down into a lower third, middle third and upper third, etc.
  • all language such as “up to,” “at least,” “greater than,” “less than,” and the like include the number recited and refer to ranges which can be subsequently broken down into sub-ranges as discussed above.
  • a range includes each individual member.
  • a group having 1-3 articles refers to groups having 1, 2, or 3 articles.
  • a group having 1-5 articles refers to groups having 1, 2, 3, 4, or 5 articles, and so forth.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
PCT/US2021/034096 2020-05-26 2021-05-25 Methods of treating inflammatory diseases by blocking galectin-3 Ceased WO2021242776A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP21812182.0A EP4157338A4 (en) 2020-05-26 2021-05-25 METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CA3185040A CA3185040A1 (en) 2020-05-26 2021-05-25 Methods of treating inflammatory diseases by blocking galectin-3
CN202180059397.XA CN116157151A (zh) 2020-05-26 2021-05-25 通过阻断半乳凝素-3治疗炎性疾病的方法
JP2022572799A JP2023528797A (ja) 2020-05-26 2021-05-25 ガレクチン－３を遮断することにより炎症性疾患を処置する方法
AU2021278935A AU2021278935A1 (en) 2020-05-26 2021-05-25 Methods of treating inflammatory diseases by blocking Galectin-3
MX2022014786A MX2022014786A (es) 2020-05-26 2021-05-25 Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
KR1020227042763A KR20230016186A (ko) 2020-05-26 2021-05-25 갈렉틱-3 차단에 의한 염증성 질환의 치료 방법

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063030069P 2020-05-26 2020-05-26
US63/030,069 2020-05-26

Publications (2)

Publication Number Publication Date
WO2021242776A2 true WO2021242776A2 (en) 2021-12-02
WO2021242776A3 WO2021242776A3 (en) 2022-02-10

Family

ID=78706982

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2021/034096 Ceased WO2021242776A2 (en) 2020-05-26 2021-05-25 Methods of treating inflammatory diseases by blocking galectin-3

Country Status (9)

Country Link
US (2) US12281166B2 (https=)
EP (1) EP4157338A4 (https=)
JP (1) JP2023528797A (https=)
KR (1) KR20230016186A (https=)
CN (1) CN116157151A (https=)
AU (1) AU2021278935A1 (https=)
CA (1) CA3185040A1 (https=)
MX (1) MX2022014786A (https=)
WO (1) WO2021242776A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
WO2024073511A3 (en) * 2022-09-28 2024-05-10 Truebinding, Inc. Therapies with anti-gal3 antibodies
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US12497458B2 (en) 2019-01-30 2025-12-16 Truebinding, Inc. Anti-GAL3 antibodies and uses thereof

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7835441B2 (ja) * 2019-12-06 2026-03-25 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
US20220072210A1 (en) * 2020-09-10 2022-03-10 Eliaz Therapeutics, Inc. Treatment of viral infection by apheresis
JP2024515968A (ja) * 2021-04-26 2024-04-11 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体製剤およびその使用法
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
US20250215091A1 (en) * 2022-03-25 2025-07-03 Les Laboratoires Servier Anti-GAL3 Antibodies and Compositions
WO2025179086A1 (en) * 2024-02-23 2025-08-28 Children's National Medical Center Anti-ret antibodies as cancer therapeutics and diagnostic tools

Family Cites Families (729)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
JPH01207920A (ja) 1988-02-16 1989-08-21 Oki Electric Ind Co Ltd ＩｎＰ半導体薄膜の製造方法
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5270202A (en) 1989-11-03 1993-12-14 Syamal Raychaudhuri Anti-idiotypic antibodies to human melanoma-associated proteoglycan antigen
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
IE911869A1 (en) 1990-06-01 1991-12-04 Regeneron Pharma A family of map2 protein kinases
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5780587A (en) 1990-08-24 1998-07-14 President And Fellows Of Harvard College Compounds and methods for inhibiting β-protein filament formation and neurotoxicity
AU679167B2 (en) 1991-09-20 1997-06-26 Amgen, Inc. Glial derived neurotrophic factor
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
ATE207080T1 (de) 1991-11-25 2001-11-15 Enzon Inc Multivalente antigen-bindende proteine
DK0618968T3 (da) 1991-12-06 2000-04-10 Max Planck Gesellschaft Midler til diagnostisering og behandling af Alzheimer's sygdom
US5624807A (en) 1992-07-22 1997-04-29 The Mclean Hospital Corporation Methods for detecting Alzheimer's disease by measuring ratios of calcium-activated neutral protease isoforms
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AU6445894A (en) 1993-03-19 1994-10-11 Duke University Method of treatment of tumors with an antibody binding to tenascin
GB9316727D0 (en) 1993-08-12 1993-09-29 Inst Of Psychiatry Models of alzheimers's disease
AU683703B2 (en) 1993-10-20 1997-11-20 Duke University Method of binding material to the beta-amyloid peptide
US5985660A (en) 1994-06-15 1999-11-16 Systemix, Inc. Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation
CU22615A1 (es) 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
DE69534530T2 (de) 1994-08-12 2006-07-06 Immunomedics, Inc. Für b-zell-lymphom und leukämiezellen spezifische immunkonjugate und humane antikörper
WO1996006862A1 (en) 1994-08-26 1996-03-07 Human Genome Sciences, Inc. Gabaa receptor epsilon subunit
DE69535901D1 (de) 1994-10-28 2009-01-29 Max Planck Gesellschaft Proteinkinase npk-110
US6835555B1 (en) 1994-11-01 2004-12-28 Human Genome Sciences, Inc. Interleukin-1 β converting enzyme like apoptosis protease-3 and 4
US7427392B1 (en) 1994-11-14 2008-09-23 Elan Pharmaceuticals, Inc. Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
DE4447287C1 (de) 1994-12-30 1996-11-07 Cevc Gregor Präparat zum Wirkstofftransport durch Barrieren
US5650313A (en) 1995-06-05 1997-07-22 Human Genome Sciences, Inc. Ubiquitin conjugating enzymes 8 and 9
US5786180A (en) 1995-02-14 1998-07-28 Bayer Corporation Monoclonal antibody 369.2B specific for β A4 peptide
GB9506197D0 (en) 1995-03-27 1995-05-17 Hoffmann La Roche Inhibition of tau-tau association.
US6576607B1 (en) 1995-04-19 2003-06-10 Acorda Therapeutics Methods using CNS neurite outgrowth modulators
US5986054A (en) 1995-04-28 1999-11-16 The Hospital For Sick Children, Hsc Research And Development Limited Partnership Genetic sequences and proteins related to alzheimer's disease
US6221645B1 (en) 1995-06-07 2001-04-24 Elan Pharmaceuticals, Inc. β-secretase antibody
JP4073955B2 (ja) 1995-07-07 2008-04-09 ダーウィン モレキュラー コーポレイション アルツハイマー病に関連する第１染色体の遺伝子および遺伝子産物
US6156311A (en) 1995-07-27 2000-12-05 The American National Red Cross Modulators of expression and function of LRP in alzheimer's disease
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
FR2741892B1 (fr) 1995-12-04 1998-02-13 Pasteur Merieux Serums Vacc Procede de preparation d'une banque multicombinatoire de vecteurs d'expression de genes d'anticorps, banque et systemes d'expression d'anticorps "coliclonaux" obtenus
US5936078A (en) 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AUPN896596A0 (en) 1996-03-27 1996-04-26 Walter And Eliza Hall Institute Of Medical Research, The Therapeutic molecules
WO1997037228A1 (en) 1996-03-29 1997-10-09 The Trustees Of Boston University Methods for diagnosing and treating alzheimer's disease
US6455277B1 (en) 1996-04-22 2002-09-24 Amgen Inc. Polynucleotides encoding human glial cell line-derived neurotrophic factor receptor polypeptides
US5663059A (en) 1996-05-10 1997-09-02 Incyte Pharmaceuticals, Inc. Human phospholipase inhibitor
US6010878A (en) 1996-05-20 2000-01-04 Smithkline Beecham Corporation Interleukin-1 β converting enzyme like apoptotic protease-6
CA2183901A1 (en) 1996-08-22 1998-02-23 Johanna E. Bergmann Targets for therapy and diagnosis of alzheimer's disease and down syndrome in humans
US6413940B1 (en) 1997-02-07 2002-07-02 Nymox Corporation Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
PT966533E (pt) 1997-02-07 2010-01-26 Univ Ramot Factor neurotrófico iii dependente da actividade (adnf iii)
US6087153A (en) 1997-07-24 2000-07-11 The Trustees Of Columbia University In The City Of New York Sel-10 and uses thereof
IT1293511B1 (it) 1997-07-30 1999-03-01 Gentili Ist Spa Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
US7384910B2 (en) 1997-10-08 2008-06-10 Castillo Gerardo M Small peptides for the treatment of Alzheimer's disease and other beta-amyloid protein fibrillogenesis disorders
US6242421B1 (en) 1997-11-06 2001-06-05 Richard Lloyd Bowen Methods for preventing and treating Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7189703B2 (en) 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
GB9816575D0 (en) 1998-07-31 1998-09-30 Zeneca Ltd Novel compounds
DE69925133T2 (de) 1998-08-27 2006-01-19 Spirogen Ltd., Ryde Pyrrolobenzodiazepine
GB9818730D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Collections of compounds
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
WO2000017345A1 (en) 1998-09-17 2000-03-30 Otsuka Pharmaceutical Co., Ltd. Ly6h gene
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2000032805A1 (en) 1998-12-02 2000-06-08 The Trustees Of The University Of Pennsylvania Methods and compositions for determining lipid peroxidation levels in oxidant stress syndromes and diseases
US6982089B2 (en) 1999-02-24 2006-01-03 Tact Ip, Llc Cytokine antagonists for neurological and neuropsychiatric disorders
DE19909357A1 (de) 1999-03-03 2000-09-07 Gerd Multhaup Kupferagonist, der an die Kupferbindungsstelle von APP bindet und/oder eine hemmende Wirkung auf die Freisetzung des Amyloid-Aß-Peptids ausübt
DE19910108C2 (de) 1999-03-08 2001-02-22 Falk Fahrenholz Zellen, die ein Amyloidvorläuferprotein und eine alpha-Sekretase coexprimieren, ein Testverfahren zur Identifikation alpha-Sekretase-aktiver Substanzen sowie eines zur Identifikation weiterer Sekretasen, ein Testverfahren zur Bestimmung der Anfälligkeit gegenüber Morbus Alzheimer und Verwendung von Nukleinsäuren, die für eine alpha-Sekretase codieren, für die Gentherapie
US6303576B1 (en) 1999-04-21 2001-10-16 Adherex Technologies Inc. Compounds and methods for modulating β-catenin mediated gene expression
UA81216C2 (en) 1999-06-01 2007-12-25 Prevention and treatment of amyloid disease
EP1201754A4 (en) 1999-07-08 2005-02-09 Fujisawa Pharmaceutical Co FACTOR ASSOCIATED WITH APOPTOSIS
EP1074634B1 (en) 1999-07-09 2002-10-02 Institut Pasteur De Lille Method for the diagnosis or the prognosis of Alzheimer disease therapeutical composition for preventing or treating Alzheimer disease
AU783964B2 (en) 1999-08-06 2006-01-05 S.I.S.S.A. Scuola Internazionale Superiore Di Studi Avanzati Non-human transgenic animals for the study of neurodegenerative syndromes
AU784568B2 (en) 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6255054B1 (en) 1999-09-09 2001-07-03 Jacques Hugon Polymorphism of the human GluR-5 gene and risk factor for alzheimer disease
JP4969006B2 (ja) 1999-09-17 2012-07-04 学校法人慶應義塾 神経細胞死を抑制するポリペプチド、Ｈｕｍａｎｉｎ
US20020094335A1 (en) 1999-11-29 2002-07-18 Robert Chalifour Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
ATE490979T1 (de) 2000-02-14 2010-12-15 Takeshi Iwatsubo Neueskollagen-ähnliches protein clac, dessen vorläufer und dafür kodierende gene
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
CN1450908A (zh) 2000-06-28 2003-10-22 普拉纳生物技术有限公司 神经毒性寡聚体
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CA2414772C (en) 2000-07-07 2011-06-28 Jan Naslund Prevention and treatment of alzheimer's disease
US6825164B1 (en) 2000-08-14 2004-11-30 The Trustees Of Columbia University In The City Of New York Method to increase cerebral blood flow in amyloid angiopathy
WO2002026246A2 (en) 2000-09-29 2002-04-04 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Pharmaceutical compositions comprising polynucleotides encoding a raf protein
US7471798B2 (en) 2000-09-29 2008-12-30 Knowles Electronics, Llc Microphone array having a second order directional pattern
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
AT500379B8 (de) 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
AU2002254029A1 (en) 2001-02-27 2002-09-12 Daniel L. Alkon Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
DE10117281A1 (de) 2001-04-06 2002-10-24 Inst Molekulare Biotechnologie Peptid zur Diagnose und Therapie der Alzheimer-Demenz
ATE401576T1 (de) 2001-04-14 2008-08-15 Evotec Neurosciences Gmbh Verwendung eines zum kern beschränkten protein für die diagnose und therapie von alzheimer- krankheit und relatierte neurodegeneratiefe störungen
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
EP2165714B1 (en) 2001-04-30 2013-10-23 Eli Lilly And Company Humanized antibodies recognizing the beta-amyloid peptide
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
DE10130247A1 (de) 2001-06-22 2003-01-16 Elegene Ag I Ins Identifizierung von ses-3 sowie dessen Verwendungen
DE10130166A1 (de) 2001-06-22 2003-01-16 Elegene Ag I Ins Identifizierung von ses-1 sowie dessen Verwendungen
US6831699B2 (en) 2001-07-11 2004-12-14 Chang Industry, Inc. Deployable monitoring device having self-righting housing and associated method
DE60226036T9 (de) 2001-08-03 2016-09-29 Medical & Biological Laboratories Co., Ltd. ANTIKÖRPER, DER DAS GM1-GANGLIOSID-GEBUNDENE AMYLOID-b-PROTEIN ERKENNT, UND DNA, DIE FÜR DIESEN ANTIKÖRPER CODIERT
EP1423704B1 (en) 2001-09-07 2010-04-14 Takeda Pharmaceutical Company Limited Diagnostic and therapeutic use of f-box proteins for alzheimer's disease and related neurodegenerative disorders
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
DE60303360T2 (de) 2002-02-14 2006-09-21 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung des caps
WO2003074558A2 (en) 2002-03-04 2003-09-12 Nymox Corporation Spheron components useful in determining compounds capable of treating symptoms of alzheimer's disease, and treatments and animal models produced therefrom
WO2003076455A2 (en) 2002-03-05 2003-09-18 Ramot At Tel-Aviv University Ltd. Immunizing composition and method for inducing an immune response against the ss-secretase cleavage site of amyloid precursor protein
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
ATE365175T1 (de) 2002-03-21 2007-07-15 Evotec Neurosciences Gmbh Diagnostische und therapeutische verwendung von humanen maguinproteinen und nukleinsäuren bei neurodegenerativen krankheiten
ATE514707T1 (de) 2002-04-19 2011-07-15 Univ Toronto Immunologisches verfahren und zusammensetzungen für die behandlung der krankheit von alzheimer
EP1497661B1 (en) 2002-04-24 2009-11-25 EVOTEC Neurosciences GmbH Diagnostic use of ensadin-0477 gene and protein for neurodegenerative diseases
US20050032673A1 (en) 2002-06-10 2005-02-10 John Constance M. Sustained release N-terminally truncated galectin-3 and antibodies to galectin-3 carbohydrate ligands for use in treating disease
US7409040B2 (en) 2002-06-21 2008-08-05 Reuven Avrohom Cyrulnik System and method for noninvasive diagnostic imaging, detection, and identification of substances by microwave/RF modulation of x-rays and applications in treatment of diseases characterized by the presence of pathological macromolecules or by the need for regeneration of normal tissue
AU2003260301A1 (en) 2002-06-27 2004-01-19 Evotec Neurosciences Gmbh Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases
US7141137B2 (en) 2002-07-10 2006-11-28 University Of Maine System Board Of Trustees Method of making laminated wood beams with varying lamination thickness throughout the thickness of the beam
US20060167227A1 (en) 2002-07-12 2006-07-27 Axon Neuroscience Forschungs-Und Entwicklungs Gmbh Truncated tau proteins
EP2338510A1 (en) 2002-07-19 2011-06-29 Novartis Pharma AG Vaccine compositions containing amyloid beta1-6 antigen arrays
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
US20040146512A1 (en) 2002-10-09 2004-07-29 Arnon Rosenthal Methods of treating Alzheimer's disease using antibodies directed against amyloid beta peptide and compositions thereof
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
NZ567324A (en) 2003-02-01 2009-08-28 Wyeth Corp Active immunization to generate antibodies to soluble A-beta
EP1590673B1 (en) 2003-02-04 2009-04-15 EVOTEC Neurosciences GmbH Diagnostic use of scn2b for alzheimer's disease
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
US8663650B2 (en) 2003-02-21 2014-03-04 Ac Immune Sa Methods and compositions comprising supramolecular constructs
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
ES2246178B1 (es) 2003-05-08 2007-03-01 Universidad De Zaragoza. Uso de anticuerpos para el tratamiento de enfermedades amiloideas.
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
JP4888876B2 (ja) 2003-06-13 2012-02-29 田平 武 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
US7384523B2 (en) 2003-07-10 2008-06-10 Radiometer Medical Aps Chloride ion selective membrane and sensor
ES2284018T3 (es) 2003-07-28 2007-11-01 Sig Technology Ltd. Tapon vertedor con dispositivo cortador punzante para embases combinados o recipientes cerrados con meterial en laminas.
AR045219A1 (es) 2003-08-08 2005-10-19 Pharmacopeia Inc Aminas ciclicas inhibidoras de base - 1 que poseen un sustiuyente heterociclico
WO2005016876A2 (en) 2003-08-08 2005-02-24 Schering Corporation Cyclic amine bace-1 inhibitors having a benzamide substituent
US7625711B2 (en) 2003-09-05 2009-12-01 Hisamitsu Pharmaceutical Co., Inc. Screening method for the identification of a drug for the development of an agent for prevention and/or treatment of Alzheimer's disease
AT413336B (de) 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
EP1670943B1 (en) 2003-09-30 2013-11-13 Evotec International GmbH Diagnostic and therapeutic use of a sulfotransferase for alzheimer's disease
US7700823B2 (en) 2003-10-02 2010-04-20 Aventis Pharma S.A. Transgenic animals exhibiting major disorders related to Alzheimer's disease
CA2541006C (en) 2003-10-03 2015-02-17 Brigham And Women's Hospital Tim-3 polypeptides
GB0416511D0 (en) 2003-10-22 2004-08-25 Spirogen Ltd Pyrrolobenzodiazepines
EP1678505B1 (en) 2003-10-29 2014-08-06 Evotec International GmbH Diagnostic and therapeutic use of the human dax- 1 gene and protein for neurodegenerative diseases
US9296820B2 (en) 2003-11-05 2016-03-29 Roche Glycart Ag Polynucleotides encoding anti-CD20 antigen binding molecules with increased Fc receptor binding affinity and effector function
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
US20050158321A1 (en) 2003-12-17 2005-07-21 Entelos, Inc. Treatment of rheumatoid arthritis with galectin-3 antagonists
WO2005063761A1 (en) 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7807157B2 (en) 2004-02-20 2010-10-05 Intellect Neurosciences Inc. Monoclonal antibodies and use thereof
US8060179B1 (en) 2006-11-16 2011-11-15 Scientific Nanomedicine, Inc. Biomagnetic detection and treatment of Alzheimer's Disease
EP1721008B1 (en) 2004-03-03 2010-02-24 EVOTEC Neurosciences GmbH Diagnostic and therapeutic use of mal2 gene and protein for neurodegenerative diseases
WO2005085260A1 (en) 2004-03-09 2005-09-15 Spirogen Limited Pyrrolobenzodiazepines
JP2007528400A (ja) 2004-03-09 2007-10-11 エラン ファーマシューティカルズ，インコーポレイテッド 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
CA2564432A1 (en) 2004-04-27 2005-11-10 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Human anti-amyloid .beta. peptide antibody and fragment of said antibody
US7629443B2 (en) * 2004-06-02 2009-12-08 New York Blood Center, Inc. Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirus
EP1794313B1 (en) 2004-06-21 2013-05-15 Proteome Sciences Plc Screening methods using c-abl, fyn and syk in combination with tau protein
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
WO2006014638A2 (en) 2004-07-19 2006-02-09 The General Hospital Corporation ANTIBODIES TO CROSS-LINKED AMYLOID β OLIGOMERS
US20060024667A1 (en) 2004-07-29 2006-02-02 Karen Manucharyan Compositions and methods for Alzheimer's disease
CA2575340A1 (en) 2004-07-28 2006-02-09 Schering Corporation Macrocyclic beta-secretase inhibitors
GEP20105110B (en) 2004-08-03 2010-11-10 Transtech Pharma Inc Rage fusion proteins and their use
JP2008508893A (ja) 2004-08-11 2008-03-27 エボテツク・ニユーロサイエンシーズ・ゲー・エム・ベー・ハー 形質膜ａｔｐアーゼの診断及び治療への使用
CA2576405A1 (en) 2004-08-11 2006-02-16 Mitsubishi Chemical Corporation Antibody and utilization of the same
GB0421639D0 (en) 2004-09-29 2004-10-27 Proteome Sciences Plc Methods and compositions relating to alzheimer's disease
ATE459650T1 (de) 2004-10-08 2010-03-15 Univ Liege KOMPLEMENTÄRE PEPTIDE FÜR ß-AMYLOID 29-42-PEPTID
US9907485B2 (en) 2004-10-15 2018-03-06 Brainlab Ag Targeted immunization and plaque destruction against Alzheimer's disease
US7811563B2 (en) 2004-10-25 2010-10-12 Northwestern University Anti-addl antibodies and uses thereof
US8288352B2 (en) 2004-11-12 2012-10-16 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the N terminus
US7625560B2 (en) 2004-12-15 2009-12-01 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
WO2006067198A2 (en) 2004-12-22 2006-06-29 Direvo Biotech Ag Targeted use of engineered enzymes
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US20060257359A1 (en) 2005-02-28 2006-11-16 Cedric Francois Modifying macrophage phenotype for treatment of disease
WO2006112553A2 (en) 2005-04-20 2006-10-26 Dnavec Corporation Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
US7612062B2 (en) 2005-04-21 2009-11-03 Spirogen Limited Pyrrolobenzodiazepines
UY29504A1 (es) 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP1879613B1 (en) 2005-05-05 2011-11-30 Merck Sharp & Dohme Corp. Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease
DK2439273T3 (da) 2005-05-09 2019-06-03 Ono Pharmaceutical Co Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
US8114620B2 (en) 2005-05-30 2012-02-14 Takeda Pharmaceutical Company Limited Diagnostic and therapeutic target PRKX proteins for neurodegenerative diseases
EP1891234B1 (en) 2005-06-01 2014-12-10 Evotec International GmbH Use of slc39a12 proteins as target in diagnosis and drug screening in alzheimer's disease
WO2006138265A2 (en) 2005-06-14 2006-12-28 Schering Corporation Heterocyclic aspartyl protease inhibitors, preparation and use thereof
ATE489370T1 (de) 2005-06-14 2010-12-15 Schering Corp Herstellung und verwendung von verbindungen als aspartylproteasehemmer
WO2006134128A2 (en) 2005-06-16 2006-12-21 Evotec Neurosciences Gmbh Diagnostic and therapeutic target adarb2 proteins for neurodegenerative diseases
ATE439443T1 (de) 2005-06-17 2009-08-15 Ca Nat Research Council NEUES Aß-BINDUNGSPROTEIN UND DESSEN PEPTIDDERIVATE SOWIE VERWENDUNGEN DAVON
DE102005029729A1 (de) 2005-06-24 2006-12-28 Röchling Automotive AG & Co. KG Verkleidungs- oder Gehäuseteil eines Fahrzeugs und Verfahren zu seiner Herstellung
WO2007008848A2 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
US20070021282A1 (en) 2005-07-19 2007-01-25 Karp Shaun A Abdominal exercising and strength testing systems
EP1937720B1 (en) 2005-08-18 2014-04-09 Ramot at Tel-Aviv University Ltd. Single chain antibodies against beta-amyloid peptide
US8507439B2 (en) 2005-08-29 2013-08-13 Angela Shashoua Neuroprotective and neurorestorative method and compositions
US9133267B2 (en) 2005-11-22 2015-09-15 The Trustees Of The University Of Pennsylvania Antibody treatment of Alzheimer's and related diseases
JP2009518010A (ja) 2005-11-30 2009-05-07 アボット・ラボラトリーズ ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用
HRP20140240T4 (hr) 2005-11-30 2017-02-24 Abbvie Inc. Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US7977314B2 (en) 2005-12-02 2011-07-12 Amorfix Life Sciences Limited Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
RS52060B (sr) 2006-01-25 2012-04-30 Sanofi Citotoksični agensi koji sadrže nove derivate tomaimicina
US7750116B1 (en) 2006-02-18 2010-07-06 Seattle Genetics, Inc. Antibody drug conjugate metabolites
JP5097695B2 (ja) 2006-02-22 2012-12-12 株式会社林原 抗アミロイドβペプチド抗体産生誘導用のペプチドワクチン
RU2429244C2 (ru) 2006-03-23 2011-09-20 Байоарктик Ньюросайенс Аб Улучшенные селективные в отношении протофибрилл антитела и их применение
EP2005187A4 (en) 2006-03-23 2010-04-21 Life Technologies Corp METHOD AND REAGENTS FOR IN VIVO IMAGING CANCER CELL LINES
US8012936B2 (en) 2006-03-29 2011-09-06 New York University Tau fragments for immunotherapy
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
EP2011513B1 (en) 2006-04-25 2016-10-19 The University of Tokyo Therapeutic agents for alzheimer's disease and cancer
WO2008042024A2 (en) 2006-06-01 2008-04-10 Elan Pharmaceuticals, Inc. Neuroactive fragments of app
US8141022B2 (en) 2006-07-06 2012-03-20 Nec Corporation Method and apparatus for hierarchical design of semiconductor integrated circuit
US8759297B2 (en) 2006-08-18 2014-06-24 Armagen Technologies, Inc. Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns
WO2008029886A1 (en) 2006-09-06 2008-03-13 National University Corporation Tottori University Kit for diagnosis of alzheimer's disease, diagnostic marker, and method for detection of indicator for disease condition
WO2008036717A2 (en) 2006-09-19 2008-03-27 Emory University Use of soluble galectin-3 (gal-3) for cancer treatment
WO2008085564A2 (en) 2006-09-20 2008-07-17 The Board Of Regents Of The University Of Texas System Compositions and methods involving truncated recombinant seven g-protein coupled receptors
EP2094832B1 (en) 2006-11-15 2015-04-22 The J. David Gladstone Institutes Methods and compositions for reducing amyloid beta levels
EP2081961A2 (en) 2006-11-15 2009-07-29 The Brigham and Women's Hospital, Inc. Therapeutic uses of tim-3 modulators
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
RS60019B1 (sr) 2006-12-21 2020-04-30 H Lundbeck As Modulacija aktivnosti proneurotrofina
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
BRPI0806340B8 (pt) 2007-01-09 2021-05-25 Biogen Idec Inc anticorpo isolado que se liga especificamente a sp35, seu uso e composição farmacêutica
TW200844110A (en) 2007-01-11 2008-11-16 Univ Marburg Philipps Diagnosis and treatment of alzheimer's disease and other neurodementing diseases
DK2121754T3 (en) 2007-01-18 2015-02-23 Lilly Co Eli Pegylated amyloid BETA FAB
ES2655868T3 (es) 2007-04-20 2018-02-22 The Chemo-Sero-Therapeutic Research Institute Método para aumentar la respuesta inmunitaria con un péptido
EP2152744A4 (en) 2007-04-26 2012-02-15 Univ Yale PRION PROTEIN AS RECEPTOR FOR AMYLOID-BETA OLIGOMERS
WO2008141321A1 (en) 2007-05-14 2008-11-20 Medtronic, Inc. Methods and device to neutralize soluble toxic agents in the brain
WO2009008980A2 (en) 2007-07-05 2009-01-15 Schering Corporation Tetrahydropyranochromene gamma secretase inhibitors
EP2178882B1 (en) 2007-07-17 2013-04-17 Merck Sharp & Dohme Corp. Benzenesulfonyl-chromane, thiochromane, tetrahydronaphthalene and related gamma secretase inhibitors
SI2019104T1 (sl) 2007-07-19 2013-12-31 Sanofi Citotoksična sredstva, ki obsegajo nove tomaimicinske derivate, in njihova terapevtska uporaba
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
US8993833B2 (en) 2007-08-14 2015-03-31 Duke University Model of Alzheimer's Disease
WO2009027105A2 (en) 2007-08-31 2009-03-05 Neurimmune Therapeutics Ag Method of providing patient specific immune response in amyloidoses and protein aggregation disorders
US8518975B2 (en) 2007-09-06 2013-08-27 Merck Sharp + Dohme Corp. Gamma secretase modulators
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
MY155144A (en) 2007-10-29 2015-09-15 Inst Nat Sante Rech Med NEW ANTIBODIES SPECIFIC OF THE ß-AMYLOID PEPTIDES AND THEIR USES AS DIAGNOSTIC AGENTS OR DRUGS
EP2224000B1 (en) 2007-10-29 2020-05-13 TAO Health Life Pharma Co., Ltd. Antibody and use thereof
EP2207885B1 (en) 2007-11-01 2013-11-20 F. Hoffmann-La Roche AG Quadruple transgenic non-human animal
MX2010005028A (es) 2007-11-05 2010-05-27 Schering Corp Moduladores de gamma secretasa.
KR101397554B1 (ko) 2007-11-09 2014-05-21 재단법인서울대학교산학협력재단 치매(알츠하이머 병)의 진단, 예방, 치료제 및 이들의스크리닝 방법
UA104132C2 (en) 2007-11-13 2014-01-10 Тева Биофармасьютикалз Юесей, Инк. Humanized antibodies against tl1a
EP2207568B1 (en) 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
US8349579B2 (en) 2007-12-13 2013-01-08 Wayne State University Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer
US8883419B2 (en) 2008-01-07 2014-11-11 Council Of Scientific & Industrial Research Methods and kits useful for the identification of astrocytoma, it's grades and glioblastoma prognosis
ITNA20080006A1 (it) 2008-01-28 2009-07-29 Consiglio Nazionale Ricerche Proteine chimeriche capaci di formare particelle virus-like, che contengono sequenze peptidiche del beta-amiloide e la componente e2 della alfachetoacido deidrogenasi di "geobacillus stearothermophilus", utili per l'induzione di una risposta anticorp
CN102936287B (zh) 2008-02-08 2015-09-09 伊缪纳斯制药株式会社 能够特异性结合Aβ寡聚体的抗体及其应用
CA2716521A1 (en) 2008-02-29 2009-09-11 Baxter Healthcare S.A. Anti-amyloid .beta. activity of intravenous immunoglobulin (ivig) in vitro
FR2929292A1 (fr) 2008-03-28 2009-10-02 Exonhit Therapeutics S A Sa Procede et methodes de diagnostic de la maladie d'alzheimer
US9908943B2 (en) 2008-04-03 2018-03-06 Vib Vzw Single domain antibodies capable of modulating BACE activity
AU2009236699B2 (en) 2008-04-14 2013-09-05 Alzinova Ab Stable amyloid beta monomers and oligomers
EP2116556B1 (en) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
WO2009146301A1 (en) 2008-05-27 2009-12-03 Yale University TARGETING TGF-β AS A THERAPY FOR ALZHEIMER'S DISEASE
US8969023B2 (en) 2008-06-10 2015-03-03 Eleanore Bennett Charitable Trust #2 Methods and compositions for treating alzheimer's disease
WO2009155609A1 (en) 2008-06-20 2009-12-23 Oklahoma Medical Research Foundation IMMUNOGENIC MEMAPSIN 2 β-SECRETASE PEPTIDES AND METHODS OF USE
EP2303001A4 (en) 2008-06-20 2016-07-13 Janssen Biotech Inc METHOD FOR VERIFYING THE EFFECTIVENESS OF TREATMENT OF NEUROLOGICAL ILLNESSES
KR102050040B1 (ko) 2008-06-25 2019-11-28 에스바테크 - 어 노바티스 컴파니 엘엘씨 ＴＮＦα를 저해하는 안정한 가용성 항체
CN102112488A (zh) 2008-07-01 2011-06-29 由卫生福利和体育大臣代表的荷兰王国 抗淀粉样折叠中间体的疫苗
JP5465720B2 (ja) 2008-07-08 2014-04-09 インサイト・コーポレイション インドールアミン２，３−ジオキシゲナーゼの阻害剤としての１，２，５−オキサジアゾール
AU2009268808A1 (en) 2008-07-08 2010-01-14 Merck Sharp & Dohme Corp. Vaccine for the treatment of Alzheimer's disease
GB0813432D0 (en) 2008-07-22 2008-08-27 Spirogen Ltd Pyrrolobenzodiazepines
CA2735578C (en) 2008-08-12 2018-10-23 Zinfandel Pharmaceuticals, Inc. Method of identifying risk factors for alzheimer's disease comprising tomm40 gene variants
US8283322B2 (en) 2008-08-15 2012-10-09 Orthopeutics, Lp Formulations for nonsurgical exogenous crosslink therapy
AU2009340423B2 (en) 2008-10-29 2014-07-24 Bg Medicine, Inc. Galectin-3 immunoassay
JP2012508748A (ja) 2008-11-13 2012-04-12 シェーリング コーポレイション γ−セクレターゼ調節剤
MX2011005046A (es) 2008-11-13 2011-06-01 Schering Corp Moduladores de gamma secretasa.
DE102008037564A1 (de) 2008-11-19 2010-05-20 Forschungszentrum Jülich GmbH Zusammensetzung zur Herstellung von anti-Amyloid beta-Peptid-Antikörpern mit D-Peptiden
US8912145B2 (en) 2008-11-28 2014-12-16 Hokko Chemical Industry Co., Ltd. Vaccine composition for prophylaxis and/or therapy of Alzheimer's disease
EP2373338B1 (en) 2008-12-03 2017-02-15 The Johns Hopkins University Annexina2 as immunological target
EP2379563B1 (en) 2008-12-22 2014-07-16 Merck Sharp & Dohme Corp. Gamma secretase modulators
US20100196882A1 (en) 2009-02-04 2010-08-05 Avraham Raz GALECTIN-3 nsSNP MARKER FOR CANCER
RU2683325C2 (ru) 2009-02-05 2019-03-28 Иммьюноджен, Инк. Новые производные бензодиазепина
FR2942476B1 (fr) 2009-02-20 2013-03-15 Commissariat Energie Atomique Composes de type pyridocarbazole et leurs applications
HUE055739T2 (hu) 2009-03-18 2021-12-28 Ac Immune Sa Eljárás terápiás alkalmazásra
US9173928B2 (en) 2009-03-26 2015-11-03 Yoh Matsumoto DNA vaccine for Alzheimer's disease
JP2010268789A (ja) 2009-04-24 2010-12-02 Kumamoto Univ 細胞医薬の製造方法
FR2945538B1 (fr) 2009-05-12 2014-12-26 Sanofi Aventis Anticorps humanises specifiques de la forme protofibrillaire du peptide beta-amyloide.
EP2258398A1 (en) 2009-05-26 2010-12-08 Araclón Biotech, S. L. Albumin-amyloid peptide conjugates and uses thereof
CN106390107B (zh) 2009-06-10 2019-12-31 纽约大学 病理tau蛋白的免疫靶向
WO2010146058A1 (en) 2009-06-15 2010-12-23 Vib Vzw Bace1 inhibitory antibodies
WO2010147969A2 (en) 2009-06-16 2010-12-23 Schering Corporation Gamma secretase modulators
LT2448968T (lt) 2009-06-29 2021-05-10 Bioarctic Ab Antikūnai, atpažįstantys n gale sutrumpintas amiloido protofibriles/oligomerus
EP2273273A1 (en) 2009-07-11 2011-01-12 Rheinische Friedrich-Wilhelms-Universität Bonn Inhibitors of the nitration of amyloid ß peptides and their uses in the diagnosis and treatment of alzheimer's disease
US9312330B2 (en) 2009-07-15 2016-04-12 Fuji Electric Co., Ltd. Super-junction semiconductor device
WO2011016238A1 (en) 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
SG177679A1 (en) 2009-08-07 2012-02-28 Kyowa Hakko Kirin Co Ltd Humanized anti-amyloid-b oligomer antibody
AU2010286501B2 (en) 2009-08-28 2015-06-11 The Board Of Regents Of The University Of Texas System Antibodies that bind Tau oligomers
WO2011031720A1 (en) 2009-09-11 2011-03-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Bispecific nanobodies as a therapeutic for alzheimer's disease
DE102009043750A1 (de) 2009-09-30 2011-08-04 Carl Zeiss Meditec AG, 07745 Verfahren und Vorrichtung zur Detektion von Ablagerungen im Auge
EP2489675A4 (en) 2009-10-16 2013-06-05 Univ Kyoto ANTIBODIES WITH RECOGNITION OF THE INVERTED STRUCTURE IN AN AMYLOID ß
WO2011102901A1 (en) 2010-02-20 2011-08-25 Ebiotec (Euroespes Biotechnology) Prevention and treatment of alzheimer's disease by amyloid beta peptide and sphingosine-1-phosphate
JP6190113B2 (ja) 2010-03-03 2017-08-30 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア オリゴマー特異アミロイドベータエピトープおよび抗体
JP2013529181A (ja) 2010-03-25 2013-07-18 ザ ジェイ． デヴィッド グラッドストーン インスティテューツ 神経障害を治療するための組成物および方法
CN102946799A (zh) 2010-04-13 2013-02-27 巴克斯特国际公司 脑室增大率在阿尔茨海默病的静脉内免疫球蛋白治疗中的应用
CA2795349C (en) 2010-04-15 2016-11-29 Seattle Genetics, Inc. Targeted pyrrolobenzodiazepine conjugates
JP5875083B2 (ja) 2010-04-15 2016-03-02 メディミューン リミテッド 増殖性疾患治療用ピロロベンゾジアゼピン
AU2011263642B2 (en) 2010-06-11 2014-09-04 Isarna Therapeutics Gmbh Method for selective oligonucleotide modification
EP2593475B1 (en) 2010-07-14 2016-03-02 Merck Sharp & Dohme Corp. Anti-addl monoclonal antibody and uses thereof
US10420923B1 (en) 2010-08-10 2019-09-24 Amiram Katz Method and device for intrathecal administering of immunoglobulin
PL3042917T3 (pl) 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2012036786A1 (en) 2010-09-17 2012-03-22 University Of L'aquila Nanoparticles of cerium oxide targeted to an amyloid-beta antigen of alzheimer's disease
AU2011323316B2 (en) 2010-11-03 2016-02-25 Immunogen, Inc. Cytotoxic agents comprising new ansamitocin derivatives
WO2012066495A2 (en) 2010-11-17 2012-05-24 Ben Gurion University Of The Negev Research And Development Authority T-cell therapy to neurodegenerative diseases
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
EP2660600B1 (en) 2010-12-28 2018-08-08 Sumitomo Dainippon Pharma Co., Ltd. Diagnostic drug and diagnostic method for alzheimer's disease
US20120244174A1 (en) 2011-01-31 2012-09-27 Intellect Neurosciences Inc. Treatment of tauopathies
EP2508212A1 (en) 2011-04-05 2012-10-10 Universitätsklinikum Freiburg Biocompatible and biodegradable gradient layer system for regenerative medicine and for tissue support
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
KR101589135B1 (ko) 2011-04-20 2016-01-29 주식회사 셀앤바이오 인간화 항-ｅｍａｐｉｉ 항체 및 이의 용도
US20140086836A1 (en) 2011-05-03 2014-03-27 Mental Health Research Institute Method for detection of a neurological disease
GB201108490D0 (en) 2011-05-18 2011-07-06 Ucl Business Plc Methods and uses
EP2710024A4 (en) 2011-05-19 2015-04-29 Harvard College OSW-1 ANALOGA AND CONJUGATES AND ITS USE
AR086543A1 (es) 2011-05-25 2014-01-08 Bg Medicine Inc Inhibidores de galectina-3 y metodos de uso de los mismos, composicion farmaceutica
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
WO2013008402A1 (ja) 2011-07-08 2013-01-17 シャープ株式会社 薄膜トランジスタ基板及びそれを備えた表示装置
NO2748201T3 (https=) 2011-08-23 2018-05-12
ME03008B (me) 2011-09-19 2018-10-20 Axon Neuroscience Se Terapija na osnovu proteina i dijagnoza patologije u којој posreduje tau u alcнajмerovoj bolesti
WO2013042053A2 (en) 2011-09-19 2013-03-28 University Of The Witwatersrand, Johannesburg Compounds for use in the treatment of alzheimer's disease
WO2013044099A1 (en) 2011-09-23 2013-03-28 Siemens Healthcare Diagnostics Inc. Cell response assay for cancer and methods of producing and using same
CA2850373C (en) 2011-10-14 2019-07-16 Seattle Genetics, Inc. Pyrrolobenzodiazepines and targeted conjugates
US9549953B2 (en) 2011-12-08 2017-01-24 Eliaz Therapeutics, Inc. Galectin-3 plasmapheresis therapy
US20130164217A1 (en) 2011-12-21 2013-06-27 Meso Scale Technologies, Llc Method of diagnosing, preventing and/or treating dementia & related disorders
KR20140068105A (ko) 2011-12-29 2014-06-05 타오 헬스 라이프 파마 가부시키가이샤 아밀로스페로이드가 결합하여 성숙 신경 세포사를 유발하는 표적 분자, 아밀로스페로이드가 유도하는 신경 세포사를 억제하는 방법 및 물질, 및 그들의 이용
WO2013106572A1 (en) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
WO2013120497A1 (en) 2012-02-15 2013-08-22 Curevac Gmbh Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
WO2013127829A1 (en) 2012-02-27 2013-09-06 Universitat De Barcelona Protease-resistant compounds useful as shuttles through the blood-brain barrier and shuttle-cargo constructs
ITRM20120383A1 (it) 2012-03-20 2013-09-21 Uni Degli Studi Di Milano B Icocca Metodo e kit per la rivelazione di anticorpi.
WO2013144957A1 (en) 2012-03-26 2013-10-03 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression
RU2644242C2 (ru) 2012-04-05 2018-02-08 Ац Иммуне С.А. Гуманизированное тау-антитело
WO2013169890A1 (en) 2012-05-08 2013-11-14 Bg Medicine, Inc. Systems and methods for assessing disease risk, status, and prognosis
EP2847217B1 (en) 2012-05-10 2017-10-11 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin CONFORMATIONAL-SPECIFIC ANTIBODIES AGAINST OLIGOMERS of Amyloid beta
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
US9682143B2 (en) 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
FR2994803B1 (fr) 2012-08-30 2016-02-26 Oreal Modulation de la forme des fibres keratiniques
US9655977B2 (en) 2012-08-31 2017-05-23 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
HK1212240A1 (en) 2012-09-07 2016-06-10 吉宁特有限公司 Combination therapy of a type ii anti-cd20 antibody with a selective bcl-2 inhibitor
AU2013315019B2 (en) 2012-09-17 2017-06-01 Galectin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
DK3456734T3 (da) 2012-10-04 2022-04-19 Res Found Dev Serinproteasemolekyler og behandlinger
SMT202000340T1 (it) 2012-10-15 2020-07-08 Medimmune Ltd Anticorpi contro il beta amiloide
WO2014082083A1 (en) 2012-11-26 2014-05-30 Caris Science, Inc. Biomarker compositions and methods
US9066928B1 (en) 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9089614B2 (en) 2012-12-21 2015-07-28 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9433665B2 (en) 2013-01-11 2016-09-06 Cyvax, Inc. Vaccines for protection from and treatment of alzheimer's disease
JP6372040B2 (ja) 2013-02-06 2018-08-15 公立大学法人横浜市立大学 抗セマフォリン３ａ抗体、並びにこれを用いたアルツハイマー病及び免疫・炎症性疾患の治療
SI2961426T1 (sl) 2013-02-26 2020-01-31 Baxalta GmbH Zdravljanje motenj centralnega živčnega sistema z intranazalnim dajanjem imunoglobulina G
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
EP3666795A1 (en) 2013-03-12 2020-06-17 Molecular Templates, Inc. Cytotoxic proteins comprising cell-targeting binding regions and shiga toxin a subunit regions for selective killing of specific cell types
TWI680766B (zh) 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
WO2014151747A1 (en) 2013-03-15 2014-09-25 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
US9937231B2 (en) 2013-03-27 2018-04-10 The General Hospital Corporation Methods and agents for treating Alzheimer's disease
HUE044737T2 (hu) 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
WO2014194166A1 (en) 2013-05-31 2014-12-04 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat alzheimer's disease
EP3013355B1 (en) 2013-06-25 2019-08-07 ICM - Institut du Cerveau et da la Moelle Epinière Il-2 for use in treating alzheimer disease and related disorders
US9645155B2 (en) 2013-08-28 2017-05-09 University Of South Florida Methods of synthesizing γ-aapeptides, γ-aapeptide building blocks, γ-aapeptide libraries, and γ-aapeptide inhibitors of Aβ40 aggregates
WO2015038446A1 (en) 2013-09-13 2015-03-19 Merck Sharp & Dohme Corp. C5-spiro iminothiazine dioxides as bace inhibitors, compositions, and their use
WO2015038426A1 (en) 2013-09-13 2015-03-19 Asana Biosciences, Llc Self-immolative linkers containing mandelic acid derivatives, drug-ligand conjugates for targeted therapies and uses thereof
AU2014337317A1 (en) 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
GB201319761D0 (en) 2013-11-08 2013-12-25 Nordic Bioscience As Biomarkers of disease progression
AU2014368696A1 (en) 2013-12-20 2016-06-02 F. Hoffmann-La Roche Ag Humanized anti-Tau(pS422) antibodies and methods of use
WO2015100353A1 (en) 2013-12-27 2015-07-02 Dignity Health Diagnosing and treating alzheimer's disease
US10272083B2 (en) 2014-01-21 2019-04-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
CN112851769A (zh) 2014-01-27 2021-05-28 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
HUE045065T2 (hu) 2014-01-31 2019-12-30 Novartis Ag TIM-3 antitest molekulák és felhasználásaik
WO2015120058A2 (en) 2014-02-05 2015-08-13 Molecular Templates, Inc. Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity
EP3102230B1 (en) 2014-02-08 2021-04-28 F. Hoffmann-La Roche AG Methods of treating alzheimer's disease
AR099707A1 (es) 2014-03-10 2016-08-10 La Jolla Pharma Co Composiciones y métodos para tratar trastornos renales
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
CA2942245C (en) 2014-03-12 2021-11-02 Yeda Research And Development Co. Ltd. Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN106459088A (zh) 2014-04-10 2017-02-22 辉瑞公司 2‑氨基‑6‑甲基‑4，4a，5，6‑四氢吡喃并[3，4‑d][1，3]噻嗪‑8a(8H)‑基‑1，3‑噻唑‑4‑基酰胺
ES2921180T3 (es) 2014-04-16 2022-08-19 Kyowa Kirin Co Ltd Método para medir la toxicidad del CSF humano
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
AU2015258814B2 (en) 2014-05-16 2018-04-05 Synaptec Development Llc Clearance of amyloid ss
CN106604934A (zh) 2014-06-11 2017-04-26 分子模板公司 耐受蛋白酶切割的志贺毒素a亚基效应子多肽和包含其的细胞靶向分子
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
KR102177190B1 (ko) 2014-06-30 2020-11-10 마이크로소프트 테크놀로지 라이센싱, 엘엘씨 유연한 스키마를 사용한 데이터 관리
WO2016004093A2 (en) 2014-07-01 2016-01-07 Stealth Biotherapeutics Corp Therapeutic compositions including galectin-3 inhibitors and uses thereof
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
GB2528098B (en) 2014-07-09 2018-11-21 Jaguar Land Rover Ltd Vehicle camera system
WO2016005466A2 (en) 2014-07-10 2016-01-14 Bioarctic Neuroscience Ab IMPROVED Aß PROTOFIBRIL BINDING ANTIBODIES
EP3177643B1 (en) 2014-08-04 2019-05-08 F.Hoffmann-La Roche Ag Bispecific t cell activating antigen binding molecules
PL3179991T3 (pl) 2014-08-11 2022-02-14 Acerta Pharma B.V. Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CN106794247B (zh) 2014-09-15 2022-12-02 豪夫迈·罗氏有限公司 抗体配制剂
TWI599358B (zh) 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
US10328051B2 (en) 2014-09-22 2019-06-25 Zoser B. Salama Proline or proline derivatives for the treatment of dementia
WO2016059453A1 (en) 2014-10-16 2016-04-21 Fundacion Fraunhofer Chile Research Biomarkers and therapeutic targets for alzheimer's disease
CN107428820B (zh) 2014-11-19 2022-03-22 阿克松神经系统科学公司 在阿尔茨海默氏病中的人源化tau抗体
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
US10464999B2 (en) 2015-01-28 2019-11-05 Prothena Biosciences Limited Anti-transthyretin antibodies
US10654917B2 (en) 2015-01-29 2020-05-19 Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders
US11867696B2 (en) 2015-02-06 2024-01-09 Cell Idx, Inc. Antigen-coupled immunoreagents
TWI669314B (zh) 2015-02-26 2019-08-21 美國禮來大藥廠 針對ｔａｕ之抗體及其用途
GB201504432D0 (en) 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
GB201505239D0 (en) 2015-03-27 2015-05-13 Neuro Bio Ltd Antibody
CN115925932A (zh) 2015-04-15 2023-04-07 安奈普泰斯生物有限公司 针对白细胞介素36受体（il-36r）的抗体
IL292798A (en) 2015-05-04 2022-07-01 Cytomx Therapeutics Inc Anti-cd166 antibodies, activatable anti-cd166 antibodies, preparations containing them and their uses
HK1248577A1 (zh) 2015-05-11 2018-10-19 F. Hoffmann-La Roche Ag 治疗狼疮性肾炎的组合物和方法
GB201508276D0 (en) 2015-05-14 2015-06-24 Electrophoretics Ltd A casein kinase 1 delta inhibitor
CN107810198B (zh) 2015-05-29 2021-09-03 艾伯维公司 抗cd40抗体及其用途
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
EP3302561A4 (en) 2015-06-08 2019-02-06 Debiopharm International SA COMBINATIONS OF ANTI-CD37 IMMUNOCONJUGATE AND ANTI-CD20 ANTIBODIES
US10203342B2 (en) 2015-06-11 2019-02-12 Nanosomix, Inc. Biomarkers and differential diagnosis of alzheimer's disease and other neurodegenerative disorders
WO2016207245A1 (en) 2015-06-24 2016-12-29 F. Hoffmann-La Roche Ag Humanized anti-tau(ps422) antibodies and methods of use
HUE057952T2 (hu) 2015-06-24 2022-06-28 Hoffmann La Roche Anti-transzferrin receptor antitestek testreszabott affinitással
CN114129737A (zh) 2015-06-30 2022-03-04 纳米提克斯有限责任公司 与清除颗粒相关的组合物和方法
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
WO2017027685A2 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules specific for the truncated asp421 epitope of tau and their uses in the diagnosis and treatment of tauopathy
WO2017027691A1 (en) 2015-08-13 2017-02-16 New York University Antibody-based molecules selective for the {p}ser404 epitope of tau and their uses in the diagnosis and treatment of tauopathy
US11154620B2 (en) 2015-08-18 2021-10-26 Rakuten Medical, Inc. Compositions, combinations and related methods for photoimmunotherapy
US10282349B2 (en) 2015-08-26 2019-05-07 International Business Machines Corporation Method for storing data elements in a database
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
US20180360959A1 (en) 2015-09-25 2018-12-20 Universität Duisburg-Essen Agents inhibiting kallikrein-8 for use in the prevention or treatment of alzheimer's disease
EP3356415B1 (en) 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI873952B (zh) 2015-10-02 2025-02-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
CN108779167A (zh) 2015-10-28 2018-11-09 宾夕法尼亚州大学信托人 鞘内施用腺伴随病毒载体用于基因治疗
CA3000924A1 (en) 2015-11-09 2017-05-18 Galecto Biotech Ab Novel galactoside inhibitors of galectins
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
EP3397645B1 (en) 2015-12-28 2026-03-25 Innate Pharma Variable regions for nkp46 binding proteins
CN108779182A (zh) 2015-12-28 2018-11-09 麻省理工学院 具有恒定区突变的双特异性抗体及其用途
CN109069539A (zh) 2016-02-18 2018-12-21 恩立夫克治疗有限责任公司 用于癌症治疗的联合免疫疗法和细胞因子控制疗法
EP3423491A1 (en) 2016-03-01 2019-01-09 H. Hoffnabb-La Roche Ag Obinutuzumab variants having altered cell death induction
JP7251981B2 (ja) 2016-03-24 2023-04-04 バイエル ファーマ アクチエンゲゼルシャフト 酵素開裂基を有する細胞毒性活性剤のプロドラッグ
WO2017172757A1 (en) 2016-03-29 2017-10-05 Acadia Pharmaceuticals Inc. 5-ht2a serotonin receptor inverse agonists or antagonists for use in reducing amyloid-beta peptides and accumulation of amyloid plaques
US11768203B2 (en) 2016-03-31 2023-09-26 University Of Southern California Highly sensitive and specific luciferase based reporter assay for antigen detection
US11446398B2 (en) 2016-04-11 2022-09-20 Obsidian Therapeutics, Inc. Regulated biocircuit systems
EP3448427A1 (en) 2016-04-29 2019-03-06 CureVac AG Rna encoding an antibody
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US9933440B2 (en) 2016-05-31 2018-04-03 Edward J. Goetzl Drug efficacy test method for dementias utilizing astrocyte-derived exosomes
AU2017290703B2 (en) 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
PH12018502613B1 (en) 2016-07-12 2023-02-01 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018017604A1 (en) 2016-07-18 2018-01-25 Cell Idx, Inc. Reagent compounds, compositions, kits, and methods for amplified assays
CA3030754C (en) 2016-07-20 2022-04-26 Anahit Ghochikyan Humanized anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
US10076552B2 (en) 2016-08-09 2018-09-18 DATT MEDIPRODUCTS LIMITED and DATT LIFE SCIENCE PVT. LTD. Multifunctional formulation comprised of natural ingredients and method of preparation/manufacturing thereof
WO2018030405A1 (ja) 2016-08-09 2018-02-15 国立大学法人東京医科歯科大学 Ｈｍｇｂ１に対する抗体、及びそれを含有するアルツハイマー病を治療又は予防するための組成物
WO2018058098A1 (en) 2016-09-26 2018-03-29 Yale University Compounds and methods for treating or preventing alzheimer's disease
KR102546471B1 (ko) * 2016-09-27 2023-06-21 프레제니우스 카비 도이치란트 게엠베하 액상의 약학 조성물
US10662226B2 (en) 2016-10-28 2020-05-26 The Regents of the University of Caiifomia Synthetic beta-amyloid peptides capable of forming stable antigenic oligomers
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
ES2834484T3 (es) 2016-11-21 2021-06-17 Univ Ruhr Bochum Método para la preselección de fármacos para enfermedades de plegamiento incorrecto de proteínas
EP3548055A4 (en) 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
WO2018106895A1 (en) 2016-12-07 2018-06-14 Molecular Templates, Inc. Shiga toxin a subunit effector polypeptides, shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
US20200347143A1 (en) 2016-12-19 2020-11-05 Glenmark Pharmaceuticals S.A. Novel tnfr agonists and uses thereof
KR102692708B1 (ko) 2016-12-20 2024-08-07 에프. 호프만-라 로슈 아게 항-cd20/항-cd3 이중특이성 항체 및 4-1bb(cd137) 작용물질의 병용 요법
CN110312534B (zh) 2016-12-21 2023-04-04 拜耳制药股份公司 具有酶促可裂解基团的抗体-药物-缀合物(adc)
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
CA3048224A1 (en) 2016-12-23 2018-06-28 Bluefin Biomedicine, Inc. Anti-sez6l2 antibodies and antibody drug conjugates
WO2018129188A1 (en) 2017-01-04 2018-07-12 Nanotics, Llc Methods for assembling scavenging particles
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
WO2018138709A1 (en) 2017-01-30 2018-08-02 National Research Council Of Canada Blood-brain barrier transmigrating compounds and uses thereof
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
US10473672B2 (en) 2017-02-09 2019-11-12 Kaohsiung Chang Gung Memorial Hospital Methods for diagnosing and treating Alzheimers disease using G72 protein and SLC7A11 mRNA as biomarkers
JP7165995B2 (ja) 2017-02-21 2022-11-07 アールイーエムディー バイオセラピューティクス，インコーポレイテッド 細胞傷害性ｔリンパ球抗原－４（ｃｔｌａ－４）に結合する抗体を使用した癌治療
WO2018156617A2 (en) 2017-02-22 2018-08-30 The Regents Of The University Of Michigan Compositions and methods for delivery of polymer / biomacromolecule conjugates
ES3010117T3 (en) 2017-03-27 2025-04-01 Hoffmann La Roche Improved antigen binding receptors
US20230399414A1 (en) 2017-03-31 2023-12-14 Genmab Holding B.V, Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP7330942B2 (ja) 2017-03-31 2023-08-22 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体、モノクローナル抗ｃｄ３７抗体、およびそれらの使用方法
SG11201909160WA (en) 2017-04-11 2019-10-30 Inhibrx Inc Multispecific polypeptide constructs having constrained cd3 binding and methods of using the same
CN108728465A (zh) 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
JP7382232B2 (ja) 2017-05-02 2023-11-16 メルク・シャープ・アンド・ドーム・エルエルシー 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤
CN113831417B (zh) 2017-05-08 2024-10-01 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
KR20200015528A (ko) 2017-05-12 2020-02-12 갈랙틴 사이언시즈, 엘엘씨 전신 인슐린 내성 질환의 치료용 화합물 및 그의 용도
WO2018210898A1 (en) 2017-05-18 2018-11-22 F. Hoffmann-La Roche Ag Reduction of application-related side reaction of a therapeutic antibody
CR20190550A (es) 2017-06-05 2020-04-05 Janssen Biotech Inc Anticuerpos que se unen específicamente a pd-1 y métodos de uso
US11214835B1 (en) 2017-06-06 2022-01-04 University Of South Florida Methods and compositions for diagnosis and management of neurodegerative diseases
WO2018231759A1 (en) 2017-06-12 2018-12-20 Obsidian Therapeutics, Inc. Pde5 compositions and methods for immunotherapy
JP2020530280A (ja) 2017-07-03 2020-10-22 トルク セラピューティクス， インコーポレイテッド 免疫刺激性融合分子およびその使用
US10662246B2 (en) 2017-07-10 2020-05-26 New York University Monoclonal antibody to treat alzheimer's disease, prion disease, frontotemporal dementias and traumatic brain injury/chronic traumatic encephalopathy
CN111133006A (zh) 2017-07-14 2020-05-08 西托姆克斯治疗公司 抗cd166抗体及其用途
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US20190029970A1 (en) 2017-07-31 2019-01-31 The Chinese University Of Hong Kong Fatty acid conjugated nanoparticles and uses thereof
BR112020001698A2 (pt) 2017-08-03 2020-07-21 Galectin Sciences, Llc compostos para prevenção e tratamento de distúrbios médicos e usos dos mesmos
IL272418B2 (en) 2017-08-08 2024-09-01 Hoffmann La Roche Abinotuzumab treatment of a new subgroup of DLBCL patients
CN107881160A (zh) 2017-08-11 2018-04-06 百奥泰生物科技(广州)有限公司 一种由基因组被编辑的cho宿主细胞产生的具有独特糖谱的重组抗体及其制备方法
WO2019067805A1 (en) 2017-09-27 2019-04-04 University Of Southern California NEW PLATFORMS FOR CO-STIMULATION, NEW CAR DESIGNS AND OTHER IMPROVEMENTS FOR ADOPTIVE CELL THERAPY
EP3466975A1 (en) * 2017-10-05 2019-04-10 Laboratoire Français du Fractionnement et des Biotechnologies A specific binding molecule directed against galectin-3 protein
US20200330592A1 (en) 2017-10-09 2020-10-22 Keith Black Compositions and methods of treating alzheimer's and other amyloid related diseases
MX2020003888A (es) 2017-10-18 2020-11-06 Regenxbio Inc Anticuerpos terapeuticos postraduccionalmente modificados completamente humanos.
CN111770761B (zh) 2017-10-25 2024-07-09 爱兰细胞技术公司 H1.0k180me2抗体、其制造方法和用途
CA3080128A1 (en) 2017-10-31 2019-05-09 Galectin Sciences, Llc Selenogalactoside compounds for the treatment of systemic insulin resistance disorders and the use thereof
WO2019094679A1 (en) 2017-11-10 2019-05-16 The Regents Of The University Of California BRAIN DELIVERY OF THE BACE INHIBITOR SAPPALPHA, ANTIBODIES, OR INHIBITORY RNA's USING SYNTHETIC EXOSOMES (DEFORMABLE NANOVESICLES, DNVs)
PE20211453A1 (es) 2017-11-29 2021-08-05 Prothena Biosciences Ltd Formulacion liofilizada de un anticuerpo monoclonal contra transtirretina
EP3729081B1 (en) 2017-12-21 2025-02-19 F. Hoffmann-La Roche AG Car-t cell assay for specificity test of novel antigen binding moieties
CN109985231A (zh) 2018-01-02 2019-07-09 上海清流生物医药科技有限公司 一种蛋白在制备预防和治疗痴呆症的药物中的应用
EP3737472A1 (en) 2018-01-09 2020-11-18 Leibniz-Institut für Naturstoff-Forschung und Infektionsbiologie Modulators of c1q, in particular of the interaction of apoe with c1q, and uses of the modulators in the therapy of neuronal diseases and inflammation
KR101868343B1 (ko) 2018-01-16 2018-06-18 재단법인대구경북과학기술원 콧물 시료의 베타 아밀로이드 올리고머를 이용한 알츠하이머 질환의 진행 단계 스크리닝용 조성물 및 이를 이용한 알츠하이머 질환의 진행 단계 스크리닝 방법
AU2019215202B2 (en) * 2018-02-01 2025-11-13 Memorial Sloan Kettering Cancer Center Antibodies to Galectin-3 and methods of use thereof
US12398201B2 (en) 2018-02-19 2025-08-26 New York University Tau single domain antibodies
EP3755350A4 (en) 2018-02-23 2021-11-03 TrueBinding, Inc. TREATING CANCER BY BLOCKING THE INTERACTION OF VISTA AND HIS ASSOCIATION PARTNER
WO2019165240A1 (en) 2018-02-23 2019-08-29 Rhnanopharma Nanosuspensions of salsalate and methods of using the same
EP3759145A4 (en) 2018-02-26 2022-03-09 Minerva Biotechnologies Corporation DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
SG11202008098TA (en) 2018-03-28 2020-10-29 Axon Neuroscience Se Antibody-based methods of detecting and treating alzheimer's disease
CN116173238A (zh) 2018-03-29 2023-05-30 微脉管治疗有限公司 用于检测和治疗阿尔茨海默病的组合物及方法
CN112584901A (zh) 2018-04-04 2021-03-30 真和制药有限公司 用于阻断非糖基化的pd-1多肽之间的相互作用的方法和组合物
KR20260046525A (ko) 2018-04-11 2026-04-07 인히브릭스 바이오사이언스, 인크. 제한된 cd3 결합을 갖는 다중특이적 폴리펩티드 컨스트럭트 및 관련된 방법 및 용도
JP7318948B2 (ja) 2018-04-13 2023-08-01 国立大学法人京都大学 微生物由来化合物を用いたアルツハイマー病の予防、治療、または診断薬
TWI874314B (zh) 2018-04-16 2025-03-01 瑞士商赫孚孟拉羅股份公司 螯合型放射核種之抗體
US20210230255A1 (en) 2018-04-27 2021-07-29 Fondazione Ebri Rita Levi-Montalcini Antibody directed against a tau-derived neurotoxic peptide and uses thereof
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
US20210207167A1 (en) 2018-05-16 2021-07-08 Voyager Therapeutics, Inc. Aav serotypes for brain specific payload delivery
WO2019231957A1 (en) 2018-05-30 2019-12-05 National Health Research Institutes Anti-abeta antibodies and uses thereof
WO2019241315A1 (en) 2018-06-12 2019-12-19 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
WO2019243453A1 (en) 2018-06-19 2019-12-26 Universidad Pablo De Olavide Compositions for treating and/or preventing protein-aggregation diseases
US12280063B2 (en) 2018-06-20 2025-04-22 Sanford Burnham Prebys Medical Discovery Institute Anti-retroviral therapies and reverse transcriptase inhibitors for treatment of Alzheimer's disease
CA3106212A1 (en) 2018-07-11 2020-01-16 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc-antigen binding domain constructs
US20210324056A1 (en) 2018-07-24 2021-10-21 Eisai R&D Management Co., Ltd. Methods of treatment and prevention of alzheimer's disease
CN121248772A (zh) 2018-08-17 2026-01-02 Ab工作室有限公司 催化抗体和其使用方法
JP7525160B2 (ja) 2018-08-31 2024-07-30 Ｂｌｏｏｍ Ｔｅｃｈｎｏｌｏｇｙ 株式会社 終末糖化産物に対する抗体およびその使用
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
EP3854875B1 (en) 2018-09-21 2026-01-14 Institute of Science Tokyo Human monoclonal antibody binding specifically to human hmgb1, and pharmaceutical composition for treating or preventing alzheimer's disease containing said human monoclonal antibody
CN113508300A (zh) 2018-10-04 2021-10-15 曼尼托巴大学 用于人类阿尔茨海默病的新型生物标记物
BR112021006153A2 (pt) 2018-10-04 2021-06-29 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin anticorpo monoclonal beta amiloide anti-n-truncado humanizado
CN120623346A (zh) 2018-10-11 2025-09-12 因荷布瑞克斯生物科学公司 Pd-1单结构域抗体及其治疗组合物
EP3867267A1 (en) 2018-10-18 2021-08-25 FundaMental Pharma GmbH Novel means to modulate nmda receptor-mediated toxicity
EP3643319A1 (en) 2018-10-25 2020-04-29 Grifols Worldwide Operations Limited Use of low volume plasma exchange for the treatment of alzheimer's disease in early and middle stages
US20220089704A1 (en) 2018-10-29 2022-03-24 Biogen Ma Inc. Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport
BR112021008139A2 (pt) 2018-10-29 2021-08-03 Cyclo Therapeutics, Inc. métodos para tratar doença de alzheimer
US12534526B2 (en) 2018-11-07 2026-01-27 Shanghai Hyamab Biotech Co., Ltd. NKG2A antibody, preparation method therefor and application thereof
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
JP2022510218A (ja) 2018-11-30 2022-01-26 メモリアル スローン ケタリング キャンサー センター ヘテロ二量体四価特異性抗体およびこれらの使用
CN121714327A (zh) 2018-12-04 2026-03-24 脑部保护私人有限公司 包括用于治疗病症的可植入阻尼装置和治疗剂的组合疗法及相关系统和使用方法
US12365724B2 (en) 2018-12-10 2025-07-22 New York University Antibodies binding to phospho-tau comprising phosphorylated Ser396 and Ser404 and methods of detecting thereof
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
JP2022037257A (ja) 2018-12-27 2022-03-09 クリニジェン株式会社 アルツハイマー病を治療又は予防する為の抗ウイルス剤及びその使用
CA3122321A1 (en) 2018-12-27 2020-07-02 Glycomimetics, Inc. Galectin-3 inhibiting c-glycosides
EP3911371A4 (en) 2019-01-18 2023-04-26 University of Southern California METHODS AND COMPOSITIONS FOR IMPROVING THE SAFETY AND EFFICACY OF CELL THERAPY
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
CN111518205B (zh) 2019-02-01 2022-03-29 长春金赛药业有限责任公司 人源化抗Aβ单克隆抗体及其应用
WO2020163817A1 (en) 2019-02-08 2020-08-13 Prothena Biosciences Limited Antibodies recognizing tau
MY206596A (en) 2019-02-08 2024-12-25 Janssen Pharmaceuticals Inc Method of safe administration of phosphorylated tau peptide vaccine
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
CA3131019A1 (en) 2019-02-22 2020-08-27 Memorial Sloan Kettering Cancer Center Cd33 antibodies and methods of using the same to treat cancer
WO2020176672A1 (en) 2019-02-26 2020-09-03 Cytomx Therapeutics, Inc. Combined therapies of activatable immune checkpoint inhibitors and conjugated activatable antibodies
US20220160710A1 (en) 2019-03-08 2022-05-26 University Of Virginia Patent Foundation Compositions and methods for treating or preventing alzheimer's disease
KR20220022112A (ko) 2019-03-21 2022-02-24 이뮤노젠 아이엔씨 세포-결합 제제-약물 콘쥬게이트를 준비하는 방법
JOP20210265A1 (ar) 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
SG11202110810WA (en) 2019-03-29 2021-10-28 Torque Therapeutics Inc Immunotherapeutic compositions and use thereof
CN113661172A (zh) 2019-03-29 2021-11-16 伊缪诺金公司 用于抑制异常细胞生长或治疗增生性疾病的细胞毒性双苯并二氮杂䓬衍生物及其与细胞结合剂的缀合物
CN113795262A (zh) 2019-04-08 2021-12-14 东莞凡恩世生物医药有限公司 人源化抗dll3嵌合抗原受体及其用途
WO2020219868A1 (en) 2019-04-24 2020-10-29 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
JOP20210284A1 (ar) 2019-04-24 2023-01-30 Janssen Pharmaceuticals Inc الإعطاء غير المتجانس للقاحات تاو
SG11202110922QA (en) 2019-04-26 2021-10-28 Immunogen Inc Camptothecin derivatives
DE202020006093U1 (de) 2019-05-06 2025-04-09 The Regents Of The University Of California Nicht-HLA-Marker der Transplantatabstoßung
US20230212250A1 (en) 2019-05-09 2023-07-06 University Of The Witwatersrand, Johannesburg A method of decreasing concentration of tau (t) protein and/or phosphorylated tau (t) protein
AU2020275415B2 (en) 2019-05-14 2026-01-15 Genentech, Inc. Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
US20220226514A1 (en) 2019-05-17 2022-07-21 Cytomx Therapeutics, Inc. Methods and compositions for determining the biodistribution of activatable anti-cd166 antibody conjugates
CA3141334A1 (en) 2019-06-04 2020-12-10 Verseau Therapeutics, Inc. Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof
CN116987197A (zh) 2019-06-20 2023-11-03 成都恩沐生物科技有限公司 共价多特异性抗体
JP2022544640A (ja) 2019-06-21 2022-10-20 ユニバーシティ オブ カンザス 脳疾患の治療に有用な組成物および方法
CA3143519A1 (en) 2019-06-26 2020-12-30 Volker Schellenberger Cd3 antigen binding fragments and compositions comprising same
WO2020264211A1 (en) 2019-06-26 2020-12-30 Memorial Sloan Kettering Cancer Center Anti-cd33 antibodies for treating cancer
KR20220027993A (ko) 2019-06-28 2022-03-08 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 알츠하이머 질환을 치료하기 위한 방법 및 조성물
AR119303A1 (es) 2019-07-01 2021-12-09 Eisai R&D Man Co Ltd Anticuerpo anti-epha4 humano
EP3994159A4 (en) 2019-07-05 2023-08-09 University of Florida Research Foundation, Incorporated METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN
JP7194085B2 (ja) 2019-07-09 2022-12-21 日立Astemo株式会社 操舵制御装置、操舵制御方法、及び操舵制御システム
WO2021009646A1 (en) 2019-07-15 2021-01-21 Cochlear Limited Transcutaneous power and data communication link
CN115175932B (zh) 2019-07-16 2025-10-31 赛诺菲 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
EP4002490A4 (en) 2019-07-17 2023-04-05 Kabushiki Kaisha Toshiba SOLAR BATTERY MODULE AND TANDEM SOLAR BATTERY
US20220275037A1 (en) 2019-07-19 2022-09-01 Dingding MO ß-AMYLOID CYCLIC RIBONUCLEIC ACID, POLYPEPTIDE, AND APPLICATION THEREOF
CA3147020A1 (en) 2019-08-07 2021-02-11 Joe G.N. Garcia Anti-nampt antibodies and uses thereof
WO2021028590A1 (en) 2019-08-14 2021-02-18 Boehringer Ingelheim Rcv Gmbh & Co Kg Caspase-2 variants
WO2021041678A1 (en) 2019-08-30 2021-03-04 Qilu Puget Sound Biotherapeutics Corporation Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
US20220332757A1 (en) 2019-09-09 2022-10-20 Wuhan Yzy Biopharma Co., Ltd. Split intein and preparation method for recombinant polypeptide using the same
JP2022547513A (ja) 2019-09-09 2022-11-14 アクソン ニューロサイエンス エスエー アルツハイマー病及び軽度認知障害のバイオマーカー及び治療
WO2021050601A1 (en) 2019-09-09 2021-03-18 Scribe Therapeutics Inc. Compositions and methods for use in immunotherapy
CN114340675A (zh) 2019-09-12 2022-04-12 豪夫迈·罗氏有限公司 治疗狼疮性肾炎的组合物和方法
BR112022005044A2 (pt) 2019-09-17 2022-07-05 Ohio State Innovation Foundation Peptídeo quimérico, peptídeo sintético, composição farmacêutica, anticorpo, método de tratamento
AU2020351205A1 (en) 2019-09-19 2022-04-14 Igm Biosciences, Inc. Multimeric antibodies with enhanced selectivity for cells with high target density
US20230340157A1 (en) 2019-09-27 2023-10-26 Beijing Starmab Biomed Technology Ltd Monospecific and multi-specific antibodies
AR122307A1 (es) 2019-10-04 2022-08-31 Chugai Pharmaceutical Co Ltd Agente de supresión de la proliferación celular de cáncer cd20 positivo tolerante a obinutuzumab, y composición farmacéutica, medicamento, fabricación, procedimiento de supresión de la proliferación celular, procedimiento de tratamiento, anticuerpo anti-cd20 de tipo ii, compuesto, sus combinaciones, y agente potenciador y agente inductor, relacionados con estos
WO2021071830A1 (en) 2019-10-07 2021-04-15 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
CN112641953A (zh) 2019-10-10 2021-04-13 复旦大学 一种靶向功能分子修饰的抗体复合物
KR20220084095A (ko) 2019-10-22 2022-06-21 바이오젠 엠에이 인코포레이티드 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체
ES2821599A1 (es) 2019-10-24 2021-04-26 Univ Del Pais Vasco / Euskal Herriko Unibertsitatea Compuestos y metodos para el tratamiento de la enfermedad de alzheimer
CN115427439A (zh) 2019-10-30 2022-12-02 德克萨斯A&M大学系统 用于双靶标嵌合抗原受体t细胞疗法的蛋白酶开关
GB201915855D0 (en) 2019-10-31 2019-12-18 Univ Oxford Innovation Ltd An extracellular vesicle
EP4065600A1 (en) 2019-11-25 2022-10-05 Cornell University Apoe gene therapy
AU2020390448A1 (en) 2019-11-28 2022-07-14 Mcmaster University Recombinant polypeptides for programming extracellular vesicles
JP7835441B2 (ja) 2019-12-06 2026-03-25 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
US20230046007A1 (en) 2019-12-17 2023-02-16 Cirlo Gmbh Tubular shaped elongated catheter device assemblies for interacting with components of bodily fluids, method for recovering cells, cell aggregates and exosomes from a tubular shaped elongated catheter device and smart tubular shaped elongated catheter device assemblies for monitoring interaction with components of bodily fluids
EP4085251B1 (en) 2020-01-02 2024-07-31 F. Hoffmann-La Roche AG Method for determining the amount of a therapeutic antibody in the brain
BR112022013892A2 (pt) 2020-01-13 2022-10-04 Truebinding Inc Anticorpos anti-gal3 e métodos de uso
EP4095159A4 (en) 2020-01-21 2024-03-20 Shanghai Henlius Biotech, Inc. MONOCLONAL ANTI-LAG3 ANTIBODY AND METHOD FOR THE PRODUCTION THEREOF AND ITS USE
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
CN115066610A (zh) 2020-02-05 2022-09-16 住友制药株式会社 用于tau病变和痴呆相关疾病的确定试剂和确定方法
JP2023514972A (ja) 2020-02-12 2023-04-12 ザ スクリプス リサーチ インスティテュート 長時間作用型ｇｍ－ｃｓｆおよび使用方法
WO2021163681A2 (en) 2020-02-14 2021-08-19 The Trustees Of Columbia University In The City Of New York Combination of retromer pharmacological chaperones and exogenous retromer for the treatment of alzheimer's disease and other neurodegenerative diseases and disorders
EP4107177A4 (en) 2020-02-17 2024-06-19 Board of Regents, The University of Texas System CHIMERIC SCAVENGER RECEPTORS TARGETED TO PHOSPHORYLATED TAU (PTHO) AND USES THEREOF
US12595311B2 (en) 2020-03-02 2026-04-07 The Regents Of The University Of California Chimeric antigen receptors and related methods and compositions for the treatment of cancer
GB202003428D0 (en) 2020-03-10 2020-04-22 Univ Dundee IL-10 mutiens
CN113384710A (zh) 2020-03-14 2021-09-14 杭州星鳌生物科技有限公司 新型免疫激动剂复合物的组成及其在抗多种疾病药物中的应用
CA3171906A1 (en) 2020-03-16 2021-09-23 University Of Southern California Novel antigen binding domains and synthetic antigen receptors incorporating the same
US20230104705A1 (en) 2020-03-17 2023-04-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and application thereof
CN113402612A (zh) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
US20230212255A1 (en) 2020-03-17 2023-07-06 Cellular Biomedicine Group Inc. Combined chimeric antigen receptor targeting cd19 and cd20 and applications thereof
US20230143984A1 (en) 2020-03-20 2023-05-11 Heidelberg University Colloidal carrier systems for transfer of agents to a desired site of action
WO2021195020A1 (en) 2020-03-23 2021-09-30 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating fibrosis resulting from a coronavirus infection
EP4122489A4 (en) 2020-03-24 2023-04-12 Talengen International Limited METHODS AND MEDICATIONS FOR PROMOTING THE BREAKDOWN OF MISFOLDED PROTEIN AND AGGREGATE THEREOF
US20230173039A1 (en) 2020-03-24 2023-06-08 Talengen International Limited Method and drug for treating alzheimer disease
CA3174188A1 (en) 2020-03-31 2021-10-07 Neil R. Cashman Antibodies to misfolded amyloid beta
WO2021207312A1 (en) 2020-04-07 2021-10-14 G3 Pharmaceuticals, Inc. Methods and compositions for preventing and treating retinal nerve damage
WO2021207273A1 (en) 2020-04-07 2021-10-14 The Regents Of The University Of California Manufacturing of synthetic exosomes for cns and non-cns delivery of therapeutics
US20230265204A1 (en) 2020-04-24 2023-08-24 Hoffmann-La Roche Inc. Enzyme and pathway modulation with sulfhydryl compounds and their derivatives
CN115916822A (zh) 2020-04-24 2023-04-04 基因泰克公司 使用抗CD79b免疫缀合物的方法
BR112022023366A2 (pt) 2020-05-19 2023-05-02 Othair Prothena Ltd Vacina com múltiplos epítopos para o tratamento de mal de alzheimer
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
EP4157241A4 (en) 2020-05-29 2025-01-08 The Regents of the University of California AGENTS AND METHODS FOR THE TREATMENT OF TAUOPATHIES
EP4157462A1 (en) 2020-06-02 2023-04-05 Dynamicure Biotechnology LLC Anti-cd93 constructs and uses thereof
CN116529260A (zh) 2020-06-02 2023-08-01 当康生物技术有限责任公司 抗cd93构建体及其用途
WO2021248081A1 (en) 2020-06-05 2021-12-09 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Acvr1 (alk2) receptor inhibition to treat neurological diseases
KR102225447B1 (ko) 2020-06-16 2021-03-08 부산대학교 산학협력단 구강 세균의 군집을 이용한 알츠하이머 진단용 바이오마커 및 이의 용도
PE20230470A1 (es) 2020-06-19 2023-03-14 Hoffmann La Roche Moleculas de union al dominio fc de activacion inmunitaria
WO2021260193A1 (en) 2020-06-25 2021-12-30 Medimmune Limited Prevention of axonal damage using antibody binding to amyloid beta 1-42
US20210403644A1 (en) 2020-06-29 2021-12-30 University Of South Carolina Method For The Degradation Of Endogenous Protein
WO2022004760A1 (ja) 2020-06-30 2022-01-06 塩野義製薬株式会社 抗ｃｃｒ８抗体と化学療法剤の併用
TW202216777A (zh) 2020-07-10 2022-05-01 美商生質分子控股有限責任公司 四面體抗體
IL299950A (en) 2020-07-20 2023-03-01 Neotx Therapeutics Ltd Superantigen conjugate for use in methods and compositions for the treatment of cancer
WO2022020232A1 (en) 2020-07-20 2022-01-27 Genentech, Inc. Methods for middle down antibody characterization
EP4185705A4 (en) 2020-07-21 2025-01-22 Amunix Pharmaceuticals, Inc. COMPOSITIONS AND METHODS RELATED TO ACTIVATED THERAPEUTIC AGENTS
US20230322935A1 (en) 2020-07-29 2023-10-12 Dynamicure Biotechnology Llc Anti-cd93 constructs and uses thereof
EP4188441A1 (en) 2020-07-30 2023-06-07 AnaptysBio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for ichthyosis
EP4188408A1 (en) 2020-07-30 2023-06-07 Unigen, Inc. A standardized bioflavonoid composition for regulation of homeostasis of host defense mechanism
WO2022029051A1 (en) 2020-08-03 2022-02-10 F. Hoffmann-La Roche Ag Improved antigen binding receptors
JP2023536602A (ja) 2020-08-03 2023-08-28 ジェネンテック， インコーポレイテッド リンパ腫のための診断及び治療方法
MX2023001501A (es) 2020-08-07 2023-03-08 Prothena Biosciences Ltd Vacuna tau para tratamiento de enfermedad de alzheimer.
WO2022032166A1 (en) 2020-08-07 2022-02-10 Othair Prothena Limited Multiepitope vaccine for the treatment of alzheimer's disease
IL300534A (en) 2020-08-11 2023-04-01 Kanaph Therapeutics Inc A fusion protein containing 12-il and an anti-fap antibody, and its use
EP4186926A4 (en) 2020-08-28 2024-06-05 Harbour Biomed US, Inc. ANTI-CCR8 ANTIBODIES AND CORRESPONDING APPLICATION
EP4129335A4 (en) 2020-09-01 2024-04-24 RemeGen Co., Ltd. ANTI C-MET DRUG-ANTIBODY CONJUGATE AND ITS APPLICATIONS
US20230364210A1 (en) 2020-09-17 2023-11-16 Othair Prothena Limited ß-AMYLOID VACCINE FOR THE TREATMENT OF ALZHEIMER’S DISEASE
CN116438191A (zh) 2020-09-18 2023-07-14 欧萨尔普罗席纳有限公司 治疗阿尔茨海默病之多表位疫苗
JP2023541482A (ja) 2020-09-18 2023-10-02 ピエリス ファーマシューティカルズ ゲーエムベーハー バイオマーカー法および使用法
KR20230074146A (ko) 2020-09-24 2023-05-26 에프. 호프만-라 로슈 아게 T 세포 이중특이성 항체 관련 역효과의 예방 또는 완화
WO2022072538A1 (en) 2020-09-30 2022-04-07 Biotheryx, Inc. Antibody-drug conjugates, pharmaceutical compositions thereof, and their therapeutic applications
CA3198102A1 (en) 2020-10-07 2022-04-14 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
EP4010378B1 (en) 2020-10-16 2026-05-06 LaNova Medicines Limited Anti-ccr8 monoclonal antibodies and uses thereof
JP2023547447A (ja) 2020-10-28 2023-11-10 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 改良型抗原結合受容体
WO2022101120A1 (en) 2020-11-10 2022-05-19 F. Hoffmann-La Roche Ag Prevention or mitigation of t-cell engaging agent-related adverse effects
WO2022125482A1 (en) 2020-12-08 2022-06-16 Memorial Sloan Kettering Cancer Center Antibodies to galectin-3 and methods of use thereof
CN114656562B (zh) 2020-12-23 2023-11-03 北京天广实生物技术股份有限公司 结合人和猴cd3的抗体及其应用
JP2024503826A (ja) 2021-01-06 2024-01-29 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１－ｌａｇ３二重特異性抗体及びｃｄ２０ ｔ細胞二重特異性抗体を用いる併用療法
WO2022150644A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for acne
WO2022150642A1 (en) 2021-01-08 2022-07-14 Anaptysbio, Inc. Anti-interleukin 36 receptor (il-36r) therapy for hidradenitis suppurativa
EP4284824A4 (en) 2021-01-27 2025-03-12 AbelZeta Inc. CHIMERIC ANTIGEN RECEPTORS TARGETING CD20
EP4286406A4 (en) 2021-01-29 2025-07-23 Illimis Therapeutics Inc FUSION MOLECULE WITH NON-INFLAMMATORY PHAGOCYTOSIS-INDUCING ACTIVITY
KR20230153529A (ko) 2021-02-19 2023-11-06 프리트 엠. 쇼드하리 다양한 면역세포를 위한 단일사슬 및 다중사슬 합성 항원 수용체
AU2022238526A1 (en) 2021-03-15 2023-09-07 F. Hoffmann-La Roche Ag Compositions and methods of treating lupus nephritis
BR112023018676A2 (pt) 2021-03-18 2023-10-10 Seagen Inc Conjugado anticorpo-fármaco, composição farmacêutica, métodos de tratamento de uma doença ou condição e de um câncer, e, composição de conjugado ligante-fármaco
CA3213625A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
AU2022241940A1 (en) 2021-03-23 2023-10-26 Pieris Pharmaceuticals Gmbh Her2/4-1bb bispecific fusion proteins for the treatment of cancer
WO2022204282A1 (en) 2021-03-24 2022-09-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
WO2022200478A1 (en) 2021-03-24 2022-09-29 Pieris Pharmaceuticals Gmbh Tumor treatment with a 4-1bb/her2-bispecific agent and a her2-targeted tyrosine kinase inhibitor
WO2022200525A1 (en) 2021-03-26 2022-09-29 Innate Pharma Multispecific proteins comprising an nkp46-binding site, a cancer antgienge binding site fused to a cytokine for nk cell engaging
WO2022212918A1 (en) 2021-04-02 2022-10-06 The Board Of Trustees Of The Leland Stanford Junior University Bispecific molecules and related compositions and methods
CN117597150A (zh) 2021-04-20 2024-02-23 思进公司 抗体依赖性细胞毒性的调节
WO2022223651A1 (en) 2021-04-23 2022-10-27 F. Hoffmann-La Roche Ag Prevention or mitigation of nk cell engaging agent-related adverse effects
JP2024515968A (ja) 2021-04-26 2024-04-11 トゥルーバインディング，インコーポレイテッド 抗ｇａｌ３抗体製剤およびその使用法
TW202244059A (zh) 2021-04-30 2022-11-16 瑞士商赫孚孟拉羅股份公司 用抗ｃｄ２０／抗ｃｄ３雙特異性抗體進行治療之給藥
CA3213632A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
WO2022235622A2 (en) 2021-05-04 2022-11-10 Biocove Llc Cd20 targeting fusion proteins and methods of use thereof
JP2024518536A (ja) 2021-05-12 2024-05-01 アナプティスバイオ インコーポレイティッド 抗体組成物
EP4337694A1 (en) 2021-05-12 2024-03-20 Dana-Farber Cancer Institute, Inc. Lag3 and gal3 inhibitory agents, xbp1, cs1, and cd138 peptides, and methods of use thereof
IL308351A (en) 2021-05-12 2024-01-01 Genentech Inc Methods for using anti-CD79B immunoconjugates to treat diffuse large B-cell lymphoma
US11951986B2 (en) 2021-05-14 2024-04-09 Toyota Motor Engineering & Manufacturing North America, Inc. EHC warmup notification
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
AR126009A1 (es) 2021-06-02 2023-08-30 Hoffmann La Roche Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
EP4347042A1 (en) 2021-06-04 2024-04-10 Xencor, Inc. Dosing of a bispecific antibody that binds cd20 and cd3
US20220411514A1 (en) 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
KR20240019786A (ko) 2021-06-09 2024-02-14 이나뜨 파르마 에스.에이. Cd20, nkp46, cd16에 결합하고 il-2에 접합된 다중특이적 항체
BR112023025331A2 (pt) 2021-06-09 2024-02-27 Innate Pharma Proteína multiespecífica, composição farmacêutica, célula recombinante, ácido nucleico ou conjunto de ácidos nucleicos, uso de uma proteína ou composição, métodos ou uso
WO2022258691A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkg2d, a cytokine receptor, a tumour antigen and cd16a
WO2022258678A1 (en) 2021-06-09 2022-12-15 Innate Pharma Multispecific proteins binding to nkp30, a cytokine receptor, a tumour antigen and cd16a
IL308918A (en) 2021-06-09 2024-01-01 Shanghai Epimab Biotherapeutics Co Ltd Antibodies and bispecific binding proteins that bind OX40 and/or PD-L1
US20240279321A1 (en) 2021-06-18 2024-08-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN yC DOMAIN AND METHODS OF USE
WO2022266539A2 (en) 2021-06-18 2022-12-22 Therini Bio, Inc. ANTIBODIES WHICH BIND HUMAN FIBRIN OR FIBRINOGEN γC DOMAIN AND METHODS OF USE
US20240189341A1 (en) 2021-06-22 2024-06-13 Remegen Co., Ltd. Pharmaceutical combination and use thereof
KR20240025013A (ko) 2021-06-25 2024-02-26 난징 이뮤노파지 바이오테크 코., 엘티디. 항-ccr8 항체 및 이의 용도
US20230201364A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Antibody conjugates and manufacture thereof
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
JP7826449B2 (ja) 2021-07-13 2026-03-09 ジェネンテック， インコーポレイテッド サイトカイン放出症候群を予測する多変量モデル
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
JP2024525727A (ja) 2021-07-14 2024-07-12 ２セブンティ バイオ インコーポレイテッド 抗体由来の結合ドメインに融合した操作されたｔ細胞受容体
EP4373859A1 (en) 2021-07-22 2024-05-29 F. Hoffmann-La Roche AG Heterodimeric fc domain antibodies
US20240336697A1 (en) 2021-08-07 2024-10-10 Genentech, Inc. Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
WO2023019216A2 (en) 2021-08-13 2023-02-16 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and treating ischemic eye disease
TW202330594A (zh) 2021-09-29 2023-08-01 美商莫德斯醫療公司 抗原結合多肽、抗原結合多肽複合物及其使用方法
CN118251411A (zh) 2021-09-29 2024-06-25 摩德斯医疗股份有限公司 抗原结合多肽、抗原结合多肽复合物及其使用方法
WO2023051727A1 (zh) 2021-09-30 2023-04-06 上海君实生物医药科技股份有限公司 结合cd3的抗体及其用途
AR127271A1 (es) 2021-10-09 2024-01-03 Hutchmed Ltd Anticuerpos biespecíficos que se unen específicamente a cd47 y cd20, y usos de los mismos
CN115746134A (zh) 2021-10-15 2023-03-07 深圳市睿盟创新生物科技有限公司 半乳糖凝集素-3的免疫测定
KR20230060546A (ko) 2021-10-22 2023-05-04 상트네어바이오사이언스 주식회사 두개의 Fc 도메인을 포함하는 항원 결합 단백질 및 이의 용도
US20250011418A1 (en) 2021-10-29 2025-01-09 Zielbio, Inc. Cancer specific plectin-1 specific antibodies and methods of use thereof
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
IL312652A (en) 2021-11-25 2024-07-01 Hoffmann La Roche Enhanced receptors for antigen binding
CN118524854A (zh) 2021-12-17 2024-08-20 北京加科思新药研发有限公司 包含可用作sting激动剂的新型化合物的化合物-连接基构建体及其用途
WO2023116880A1 (en) 2021-12-23 2023-06-29 Concept To Medicine Biotech Co., Ltd. Anti-ccr8 antibodies and uses thereof
EP4458861A1 (en) 2021-12-29 2024-11-06 Sichuan Huiyu Pharmaceutical Co., Ltd. Antibody targeting cd3, multispecific antibody, and uses thereof
US20230220115A1 (en) 2022-01-12 2023-07-13 Biomolecular Holdings Llc Tetrahedral antibodies
MX2024008641A (es) 2022-01-12 2024-07-24 Biomolecular Holdings Llc Anticuerpos tetraedricos.
CN116462765A (zh) 2022-01-20 2023-07-21 上海君实生物医药科技股份有限公司 抗cd3和抗cd20双特异性抗体及其用途
US20250388669A1 (en) 2022-01-21 2025-12-25 Jieyi Wang Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation
KR20230119859A (ko) 2022-02-08 2023-08-16 연세대학교 산학협력단 신규 이중타겟 융합항체를 유효성분으로 포함하는 암의 예방 또는 치료용 조성물
TW202400643A (zh) 2022-02-28 2024-01-01 日商帝人製藥股份有限公司 神經退化性疾病之治療劑
GB202203070D0 (en) 2022-03-04 2022-04-20 Iksuda Therapeutics Ltd Anti-canag antibody conjugate
WO2023178289A2 (en) 2022-03-17 2023-09-21 Seagen Inc. Camptothecin conjugates
CN116789820A (zh) 2022-03-18 2023-09-22 北京天诺健成医药科技有限公司 一种新型免疫调节剂的开发和应用
MX2024011468A (es) 2022-03-23 2024-09-25 Hoffmann La Roche Tratamiento conjunto de un anticuerpo biespecifico anti-cd20/anti-cd3 y quimioterapia.
US20250215091A1 (en) 2022-03-25 2025-07-03 Les Laboratoires Servier Anti-GAL3 Antibodies and Compositions
JP2025512798A (ja) 2022-03-25 2025-04-22 サイトムエックス セラピューティクス，インク． 活性化可能な二重アンカー型マスク化分子及びその使用方法
US20250223364A1 (en) 2022-04-04 2025-07-10 Dren Bio, Inc. Multispecific binding proteins that bind dectin-1 and cd20 and methods of use thereof
EP4504794A1 (en) 2022-04-04 2025-02-12 Dren Bio, Inc. Anti-dectin-1 antibodies and methods of use thereof
CA3255500A1 (en) 2022-04-08 2023-10-12 Regeneron Pharmaceuticals, Inc. MULTI-PART RECEIVERS AND SIGNALING COMPLEXES
US20250346681A1 (en) 2022-04-11 2025-11-13 Astrazeneca Ab T cell binding proteins
WO2023198727A1 (en) 2022-04-13 2023-10-19 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023201299A1 (en) 2022-04-13 2023-10-19 Genentech, Inc. Pharmaceutical compositions of therapeutic proteins and methods of use
AU2023253036A1 (en) 2022-04-15 2024-10-17 Mabsoft Therapeutics Conjugate comprising toll-like receptor agonist
CN117003872A (zh) 2022-04-28 2023-11-07 北京天广实生物技术股份有限公司 含有突变轻链可变区骨架的单链抗体片段
AU2023264582A1 (en) 2022-05-03 2024-11-21 Incyte Corporation Methods for treating lymphoma
EP4518905A1 (en) 2022-05-06 2025-03-12 Seagen Inc. Immunomodulatory antibody-drug conjugates
JP2025517476A (ja) 2022-05-25 2025-06-05 イナート・ファルマ・ソシエテ・アノニム ネクチン－４結合剤
US20230416412A1 (en) 2022-05-31 2023-12-28 Hoffmann-La Roche Inc. Prevention or mitigation of t-cell engaging agent-related adverse effects
CN117323429A (zh) 2022-07-01 2024-01-02 广东克冠达医药科技有限公司 Cd101的抗体及其用途
JP2025524628A (ja) 2022-07-12 2025-07-30 シートムエックス セラピューティクス，インコーポレイテッド Ｅｐｃａｍイムノコンジュゲート及びその使用
EP4562058A1 (en) 2022-07-28 2025-06-04 The Board of Regents of the University of Oklahoma Biomarkers, diagnostic methods, treatments, and therapeutics for autoimmune disorders and diseases
JP2025525904A (ja) 2022-08-03 2025-08-07 シージェン インコーポレイテッド 免疫刺激性抗ｐｄ－ｌ１－薬物コンジュゲート
WO2024036148A1 (en) 2022-08-08 2024-02-15 A2 Biotherapeutics, Inc. Compositions and methods for treating blood cancers
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN117051537A (zh) 2023-07-03 2023-11-14 五邑大学 一种乙酰化葡甘聚糖静电纺丝膜及其制备方法与应用

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12227567B2 (en) 2017-07-25 2025-02-18 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
US12497458B2 (en) 2019-01-30 2025-12-16 Truebinding, Inc. Anti-GAL3 antibodies and uses thereof
US12281166B2 (en) 2020-05-26 2025-04-22 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
US20220411514A1 (en) * 2021-06-08 2022-12-29 Truebinding, Inc. Anti-gal3 antibodies and methods of use for insulin resistance
WO2024073511A3 (en) * 2022-09-28 2024-05-10 Truebinding, Inc. Therapies with anti-gal3 antibodies

Also Published As

Publication number Publication date
JP2023528797A (ja) 2023-07-06
MX2022014786A (es) 2023-01-16
CA3185040A1 (en) 2021-12-02
US12281166B2 (en) 2025-04-22
EP4157338A4 (en) 2024-11-13
US20250243282A1 (en) 2025-07-31
KR20230016186A (ko) 2023-02-01
WO2021242776A3 (en) 2022-02-10
US20210371533A1 (en) 2021-12-02
EP4157338A2 (en) 2023-04-05
AU2021278935A1 (en) 2022-12-08
CN116157151A (zh) 2023-05-23

Similar Documents

Publication Publication Date Title
US12281166B2 (en) Methods of treating inflammatory diseases by blocking Galectin-3
CN116063505B (zh) 抗gal3抗体及其用途
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
US20250145722A1 (en) Anti-gal3 antibodies and methods of use
US20230279120A1 (en) Methods of treating or inhibiting cardiovascular diseases
US20220411514A1 (en) Anti-gal3 antibodies and methods of use for insulin resistance
US20240158512A1 (en) Anti-gal3 antibody formulations and methods of use thereof
JP7835441B2 (ja) Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
US20220281973A1 (en) Antibodies and blocking the interaction of vista and its binding partner
HK40078860A (en) Anti-gal3 antibodies and methods of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21812182

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2022572799

Country of ref document: JP

Kind code of ref document: A

Ref document number: 3185040

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 202217068382

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20227042763

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2021278935

Country of ref document: AU

Date of ref document: 20210525

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 21812182

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2021812182

Country of ref document: EP

Effective date: 20230102